WO2007006688A1 - Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists - Google Patents

Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists Download PDF

Info

Publication number
WO2007006688A1
WO2007006688A1 PCT/EP2006/063846 EP2006063846W WO2007006688A1 WO 2007006688 A1 WO2007006688 A1 WO 2007006688A1 EP 2006063846 W EP2006063846 W EP 2006063846W WO 2007006688 A1 WO2007006688 A1 WO 2007006688A1
Authority
WO
WIPO (PCT)
Prior art keywords
indol
spiro
benzofuran
chloro
carbonyl
Prior art date
Application number
PCT/EP2006/063846
Other languages
French (fr)
Inventor
Caterina Bissantz
Christophe Grundschober
Hasane Ratni
Mark Rogers-Evans
Patrick Schnider
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE602006004997T priority Critical patent/DE602006004997D1/en
Priority to AU2006268724A priority patent/AU2006268724B2/en
Priority to CA2615726A priority patent/CA2615726C/en
Priority to BRPI0612988-9A priority patent/BRPI0612988A2/en
Priority to DK06764048T priority patent/DK1904477T3/en
Priority to MX2008000585A priority patent/MX2008000585A/en
Priority to JP2008520842A priority patent/JP4927079B2/en
Priority to CN2006800321491A priority patent/CN101253164B/en
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to PL06764048T priority patent/PL1904477T3/en
Priority to EP06764048A priority patent/EP1904477B1/en
Publication of WO2007006688A1 publication Critical patent/WO2007006688A1/en
Priority to IL188478A priority patent/IL188478A/en
Priority to NO20080059A priority patent/NO20080059L/en
Priority to HK09101245.2A priority patent/HK1123554A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Definitions

  • the present invention relates to compounds of the general formula (I)
  • R 1 is H, or is Ci- ⁇ -alkyl optionally substituted by CN, or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl which are optionally substituted by one or more B, or is -(CH 2 ) m -R a
  • R a is: CN, OR 1 , NR 1 R 11 , C 3 _ 6 -cycloalkyl, 3 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH 2 ) n - (CO) -R b or -(CH 2 ) n - (SO 2 ) -R b , wherein R b is: Ci_ 6 -alkyl, Ci- 6 - alkoxy, C 3 - 6 -cycloalkyl,
  • R 2 is one or more of H, OH, halo, CN, nitro, C 1-6 - alkyl optionally substituted by -
  • R 3 is H, or is halo, or is -(CO)-R C , wherein R c is: C 1 ⁇ - alkyl,
  • R d is C ⁇ -alky! optionally substituted by halo or nitro, or R d is aryl or a 5 or 6 membered heteroaryl, which are optionally substituted by halo, nitro, C ⁇ -alky! or Q- ⁇ -haloalkyl;
  • R is one or more of H, halo, Q-o-alkyl or Q- ⁇ -alkoxy optionally substituted by OH, or two R 4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
  • R 5 is H, Ci_ 6 - alkyl or aryl;
  • R 6 is H or Q- ⁇ -alkyl
  • R 7 is H or -SO 2 -R 6 wherein R e is Ci_ 6 -alkyl or aryl; R 8 is H or C 1-6 - alkyl;
  • B is halo, CN, NR 1 R 11 , Ci_ 6 -alkyl optionally substituted by CN, halo or Ci_ 6 -alkoxy,
  • R 1 and R 11 are H, C 1-6 -alkyl, Ci_ 6 -alkyl-NR m R lv , -(CO)O-C 1-6 -alkyl, -C(O)-NR m R lv , -C(O)-
  • R 111 and R 1V are H or C 1-6 -alkyl;
  • m is 1 to 6;
  • n is O to 4; as well as pharmaceutically acceptable salts thereof.
  • the compounds of formula (I) may contain some asymmetric carbon atoms. Accordingly, the present invention includes all stereioisomeric forms of the compounds of formula (I), including each of the individual enantiomers and mixtures thereof.
  • the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of medicaments for the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.
  • Vasopressin is a 9 amino acid peptide mainly produced by the paraventricular nucleus of the hypothalamus.
  • Three vasopressin receptors, all belonging to the class I G- protein coupled receptors, are known.
  • the Via receptor is expressed in the brain, liver, vascular smooth muscle, lung, uterus and testis, the VIb or V3 receptor is expressed in the brain and pituitary gland, the V2 receptor is expressed in the kidney where it regulates water excretion and mediates the antidiuretic effects of vasopressin.
  • vasopressin acts as a neurohormone and stimulates vasoconstriction, glycogenolysis and antidiuresis.
  • vasopressin acts as a neuromodulator and is elevated in the amygdala during stress ( Ebner, K, C. T. Wotjak, et al. (2002). "Forced swimming triggers vasopressin release within the amygdala to modulate stress-coping strategies in rats.” Eur J Neurosci 15(2): 384-8).
  • the Via receptor is extensively expressed in the brain and particularly in limbic areas like the amygdala, lateral septum and hippocampus which are playing an important role in the regulation of anxiety.
  • the Via receptor is also mediating the cardiovascular effects of vasopressin in the brain by centrally regulating blood pressure and heart rate in the solitary tract nucleus (Michelini, L. C. and M. Morris (1999). "Endogenous vasopressin modulates the cardiovascular responses to exercise.” Ann N Y Acad Sci 897: 198-211). In the periphery it induces the contraction of vascular smooth muscles and chronic inhibition of the Via receptor improves hemodynamic parameters in myocardial infarcted rats ( Van Kerckhoven, R., I. Lankhuizen, et al. (2002). "Chronic vasopressin V(IA) but not V(2) receptor antagonism prevents heart failure in chronically infarcted rats.” Eur J Pharmacol 449(1-2): 135-41).
  • vasopressin receptor antagonists are useful as therapeutics in the conditions of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.
  • aryl means a monovalent cyclic aromatic hydrocarbon moiety consisting of a mono-, bi- or tricyclic aromatic ring.
  • aryl moieties include, but are not limited to, optionally substituted phenyl, naphthyl, phenanthryl, fluorenyl, indenyl, pentalenyl, azulenyl, oxydiphenyl, biphenyl, methylenediphenyl, aminodiphenyl, diphenylsulfidyl, diphenylsulfonyl, diphenylisopropylidenyl, benzodioxanyl, benzofuranyl, benzodioxylyl, benzopyranyl, benzoxazinyl, benzoxazinonyl, benzopiperadinyl, benzopiperazinyl, benzopyrrolidiny
  • aryl include but are not limited to halogen, C 1-6 - alkyl, Q- ⁇ -alkoxy as well as those specifically listed and illustrated by the description and examples herein below.
  • Preferred aryl are phenyl and naphthyl and still preferably phenyl.
  • C 1-6 - alkyl denotes a saturated straight- or branched-chain group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n- butyl, i-butyl, 2-butyl, t-butyl and the like.
  • Preferred C 1-6 - alkyl groups are Ci- 4 -groups, i.e. with 1 - 4 carbon atoms.
  • Ci- ⁇ -alkoxy denotes a group wherein the alkyl residues are as defined above, and which is attached via an oxygen atom.
  • Preferred Q- ⁇ -alkoxy groups are methoxy and ethoxy as well as those specifically illustrated by the examples herein below.
  • C 2 _ 6 -alkenyl denotes a carbon chain of 2 to 6 carbon atoms comprising a double bond in its chain.
  • C 2 _ 6 -alkenyl groups include ethenyl, propen- 1-yl, propen-2-yl, buten-1-yl, buten-3-yl, penten-1-yl, penten-2-yl, penten-3-yl, penten-4-yl, hexen-1-yl, hexen-2-yl, hexen-3-yl, hexen-4-yl and hexen-5-yl, as well as those specifically illustrated by the examples herein below.
  • benzyloxy denotes a benzyl group attached via an oxygen atom.
  • halogen or "halo” denotes chlorine (Cl), iodine (I), fluorine (F) and bromine (Br). - D -
  • Ci- ⁇ -haloalkyl denotes a Ci- ⁇ -alkyl group as defined above which is substituted by one or more halogen.
  • Examples of Ci- ⁇ -haloalkyl include but are not limited to methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n- hexyl substituted by one or more Cl, F, Br or I atom(s) as well as those groups specifically illustrated by the examples herein below.
  • Preferred Ci- ⁇ -haloalkyl are difluoro- or trifluoro- methyl or ethyl.
  • Ci- ⁇ -haloalkoxy denotes a Q- ⁇ -alkoxy group as defined above which is substituted by one or more halogen.
  • Q- ⁇ -haloalkoxy include but are not limited to methoxy or ethoxy, substituted by one or more Cl, F, Br or I atom(s) as well as those groups specifically illustrated by the examples herein below.
  • Preferred Q- ⁇ -haloalkoxy are difluoro- or trifluoro-methoxy or ethoxy.
  • C3- 6 -cycloalkyl denotes a monovalent or divalent saturated carbocyclic moiety consisting of a monocyclic ring.
  • Cycloalkyl can optionally be substituted with one, two, three or four substituents, wherein each substituent is independently hydroxy, Ci_ 6 - alkyl, Q- ⁇ -alkoxy, halogen, amino, unless otherwise specifically indicated.
  • Examples of cycloalkyl moieties include optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl and optionally substituted cyclohexyl as well as those specifically illustrated by the examples herein below.
  • 3 to 7 membered heterocycloalkyl means a monovalent saturated moiety, consisting of one ring of 3 to 7 atoms as ring members, including one, two, or three heteroatoms chosen from nitrogen, oxygen or sulfur, the rest being carbon atoms.
  • 3 to 7 membered heterocycloalkyl can optionally be substituted with one, two, three or four substituents, wherein each substituent is independently hydroxy, C 1-6 - alkyl, Q- ⁇ -alkoxy, Ci- ⁇ -thioalkyl, halo, Q- ⁇ -haloalkyl, Ci- ⁇ -hydroxyalkyl, alkoxycarbonyl, amino, C 1-6 - alkylamino, di(C 1 _ 6 )alkylamino, aminocarbonyl, or carbonylamino, unless otherwise specifically indicated.
  • heterocyclic moieties include, but are not limited to, oxirane, optionally substituted oxetane, optionally substituted tetrahydro-furanyl, optionally substituted piperidinyl, optionally substituted pyrrolidinyl, optionally substituted morpholinyl, optionally substituted piperazinyl, optionally substituted azepane or homopiperazine, and the like or those which are specifically exemplified herein.
  • Substituents can be selected from Ci- 6 -alkyl, Ci- 6 -alkoxy, Ci- 6 -haloalkyl, halo, CN, OH, NH 2 , as well as those substituents which are are specifically illustrated in the examples hereinafter.
  • the term "5 or 6 membered heteroaryl” means an aromatic ring of 5 or 6 ring atoms as ring members containing one, two, or three ring heteroatoms selected from N, O, or S, the rest being carbon atoms.
  • heteroaryl can optionally be substituted with one, two, three or four substituents, wherein each substituent is independently hydroxy, C 1-6 - alkyl, Q- ⁇ -alkoxy, Ci- ⁇ -thioalkyl, halo, Ci- ⁇ -haloalkyl, Ci- ⁇ -hydroxyalkyl, alkoxycarbonyl, amino, Ci- ⁇ -alkylamino, di(C 1 _ 6 )alkylamino, aminocarbonyl, or carbonylamino, unless otherwise specifically indicated.
  • heteroaryl moieties include, but are not limited to, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted thiazolyl, optionally substituted pyrazinyl, optionally substituted pyrrolyl, optionally substituted pyrazinyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted furanyl, and those which are specifically exemplified herein.
  • sulfonylaryl denotes an aryl group as defined hereinabove which is attached via a sulfonyl group.
  • pharmaceutically acceptable acid addition salts embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic - o - acid, tartaric acid, methane- sulfonic acid, p-toluenesulfonic acid, as well as those specifically illustrated by the examples herein below.
  • the compounds of formula (I) are those compounds wherein: A is selected from (a), (b), (c), (d), (e), (f), (g) or (h) and wherein
  • R 1 is H, or is Ci- ⁇ -alkyl optionally substituted by CN, or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl which are optionally substituted by one or more B, or is -(CH 2 ) m -R a wherein R a is:
  • R 2 is one or more of H, OH, halo, C 1-6 - alkyl optionally substituted by -NR m R lv , C 1-6 - alkoxy;
  • R 3 is H, or is halo or is -(CO)-R C , wherein R c is:
  • R 4 is is one or more of H, halo, or Ci_ 6 - alkoxy optionally substituted by OH, or two R 4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
  • R 5 is H or aryl
  • R 6 is H
  • R 7 is H or -SO 2 -R 6 wherein R e is Ci_ 6 -alkyl or aryl;
  • R 8 is H or Q- ⁇ -alkyl
  • B is halo, CN, NH 2 , Ci- ⁇ -alkyl optionally substituted by CN or Q- ⁇ -alkoxy, C 1-6 - alkoxy, Ci-e-haloalkoxy, C 3 - 6 -cycloalkyl, -C(O)O-C 1 _ 6 -alkyl, -(CR m R lv ) n -phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci- ⁇ -alkyl optionally substituted by CN or halo, Q- ⁇ -alkoxy; R 1 and R 11 are H, C 1-6 -alkyl, Ci_ 6 -alkyl-NR m R lv , -(CO)O-C 1-6 -alkyl, -C(O)-NR m R lv , -C(O)- Q- ⁇ -
  • R 111 and R 1V are H or C 1-6 -alkyl; m is 1 to 6; n is O to 4; as well as pharmaceutically acceptable salts thereof.
  • the compounds of formula (I) are those compounds wherein: A is selected from (a), (b), (c), (d) or (e), and wherein R 1 is H, or is Ci- ⁇ -alkyl optionally substituted by CN, or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl which are optionally substituted by one or more B, or is -(CH 2 ) m -R a wherein R a is: CN, OR 1 , NR 1 R 11 ,
  • R 2 is one or more of H, OH, halo, CN, nitro, C 1-6 - alkyl optionally substituted by -
  • R 3 is H, or is halo, or is -(CO)-R C , wherein R c is: C 1-6 - alkyl,
  • Ci- ⁇ -alkyl optionally substituted by Ci- ⁇ -alkyl, or is Ci- ⁇ -alkyl or aryl, which are optionally substituted by halo,
  • R d is Ci- ⁇ -alkyl optionally substituted by halo or nitro, or R d is aryl or a 5 or 6 membered heteroaryl, which are optionally substituted by halo, nitro, Ci- ⁇ -alkyl or Q- ⁇ -haloalkyl;
  • R 4 is one or more of H, halo, C 1-6 - alkyl or Q- ⁇ -alkoxy or two R 4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
  • R 5 is H, Ci_ 6 - alkyl or aryl;
  • R 6 is H or Ci_ 6 -alkyl
  • R 7 is H or -SO 2 -R 6 wherein R e is Ci_ 6 -alkyl or aryl; B is halo, CN, NR 1 R 11 , Ci_ 6 -alkyl optionally substituted by CN, halo or Ci_ 6 -alkoxy,
  • R 1 and R 11 are H, C 1-6 -alkyl, Ci_ 6 -alkyl-NR m R lv , -(CO)O-C 1-6 -alkyl, -C(O)-NR m R lv , -C(O)- Ci_ 6 -alkyl, -S(O) 2 -Ci_ 6 -alkyl or -S(O) 2 - NR 1U R 1V ;
  • R 111 and R 1V are H or C 1-6 -alkyl; m is 1 to 6; n is O to 4; as well as pharmaceutically acceptable salts thereof.
  • the compounds of formula (I) are those compounds wherein:
  • A is selected from (a), (b), (c), (d) or (e), and wherein R 1 is H, or is Ci- 6 - alkyl, or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl which are optionally substituted by one or more B, or is -(CH 2 ) m -R a wherein R a is: CN, NR 1 R 11 , C 3 - 6 -cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH 2 V (CO) -R b or -(CH 2 ),,- (SO 2 ) -R b , wherein R b is: C 1 -O- alkoxy, NR 1 R 11 , 4 to 7 membered-heterocycloalkyl, aryl, which are optionally substituted by one or more
  • R 2 is one or more of H, OH, halo, C 1-6 - alkyl optionally substituted by -NR m R lv , C 1-6 - alkoxy;
  • R 3 is H, or is -(CO)-R C , wherein R c is: -(CH 2 VNR 1 R 11 , -(CH 2 ) n -NR m R lv , 5 or 6 membered heterocycloalkyl optionally substituted by C 1-6 - alkyl, or is Ci- ⁇ -alkyl or aryl, which are optionally substituted by halo, R 4 , R 5 and R 6 are H;
  • R 7 is H or -SO 2 -R 6 wherein R e is Ci- ⁇ -alkyl or aryl;
  • B is halo, NH 2 , Q-o-alkyl optionally substituted by CN or Q- ⁇ -alkoxy, Q- ⁇ -alkoxy, Ci-e-haloalkoxy, C 3 - 6 -cycloalkyl, -C(O)O-C 1 _ 6 -alkyl, -(CR m R lv ) n -phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci- ⁇ -alkyl optionally substituted by CN or halo, Q- ⁇ -alkoxy;
  • R 1 and R 11 are H, Ci_ 6 -alkyl, Ci_ 6 -alkyl-NR m R lv , -(CO)O-Ci_ 6 -alkyl, -C(O)-NR m R lv , -C(O)- Ci_ 6 -alkyl, -S(O) 2 -Ci_ 6 -alkyl or -S(O) 2 - NR 1U R 1V ;
  • R 111 and R 1V are H or Ci_ 6 -alkyl; m is 1 to 6; n is O to 4; as well as pharmaceutically acceptable salts thereof.
  • the compound of formula (I) are those compounds wherein:
  • A is selected from (a), (b), (c), (d) or (e), and wherein R 1 is H or,
  • Ci- ⁇ -alkyl optionally substituted by CN or, Ci- 6 - alkoxy or, aryl or,
  • R a is C 3 _ 6 -cycloalkyl, 5 or 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more substituents selected from the group consisting of: halo, CN, Ci_ 6 -alkyl, Q- ⁇ -alkoxy, Q- ⁇ -haloalkoxy, -C(O)O-C 1 _ 6 -alkyl and phenyl optionally substituted by halo, Q-o-alkyl, Ci- ⁇ -haloalkyl or C 1 -O- alkoxy, -(CH 2 ) I11 -NR 1 R 11 or,
  • R b is aryl or 5 or 6 membered-heterocycloalkyl
  • R 2 is one or more of H, halo, CN, nitro, C ⁇ -allcyl, C 1-6 - alkoxy, -O-CH 2 -C 2 _ 6 -alkenyl, benzyloxy, or two R 2 may form an oxo or dioxo bridge together with the indole ring to which they are attached
  • R 3 is H or, - - halo or,
  • R c is C 1-6 - alkyl, 5 or 6 membered heterocycloalkyl optionally substituted by C 1-6 -alkyl, or R c is -(CH 2 VNR 1 R 11 or, Ci- ⁇ -alkyl or aryl, which are optionally substituted by: -O(CO)-C 1 _ 6 -alkyl, or by-NH(CO)R d , wherein R d is C ⁇ -alky!
  • R d is aryl or a 5 or 6 membered heteroaryl, which are optionally substituted by halo, nitro, C ⁇ -allcyl or Q- ⁇ -haloalkyl;
  • R 4 is one or more of H, halo, Ci_ 6 - alkyl or Q- ⁇ -alkoxy or two R 4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
  • R 5 is H, Ci_ 6 - alkyl or aryl
  • R 6 is H or Q- ⁇ -alkyl
  • R 7 is H or -SO 2 -R 6 wherein R e is Ci_ 6 -alkyl or aryl;
  • R 1 and R 11 are independently selected from H, C ⁇ -alky! or -(CO)O-C 1 _ 6 -alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
  • said compounds of formula (I) encompass the compounds of formulae (I- a), (I-b), (I-c), (I- d) , (I-e) , (I-f) , (I-g) and (I-h) as follows:
  • the compounds of the invention are those compounds of formula (I- a):
  • R 1 is H, or is Ci- ⁇ -alkyl optionally substituted by CN, or is sulfonylaryl, or is -(CH 2 ) m -R a wherein R a is:
  • R 2 is one or more of H, halo, C 1-6 - alkyl
  • R 3 is H, or is Ci- 6 - alkyl, or is -(CO)-R C , wherein R c is: Ci_ 6 -alkyl -(CHz) n -NR 1 R 11 , R 4 is is one or more of H, halo, or Q- ⁇ -alkoxy optionally substituted by OH, or two R 4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
  • R 5 is H;
  • R 6 is H;
  • B is halo, CN, Q-o-alkyl optionally substituted by CN or Q- ⁇ -alkoxy, Q- ⁇ -alkoxy, C 1- 6 -haloalkoxy, C 3 - 6 -cycloalky
  • the compounds of the invention are those compounds of formula (I- a) as described above, wherein R 1 is H or,
  • R a is aryl which is optionally substituted by one or more substituents selected from the group consisting of: halo, CN, C 1-6 -a]kyl, Ci_ 6 -alkoxy, Ci-e-haloalkoxy, -C(O)O-C 1 _ 6 -alkyl and phenyl optionally substituted by halo, C 1-6 - alkyl, Ci- ⁇ -haloalkyl or C 1 -O- alkoxy; R 2 is H or halo; R 3 is H or Q-6-alkyl; and R 4 , R 5 and R 6 are H; - - m is 1 to 6; as well as pharmaceutically acceptable salts thereof.
  • the compounds of the invention are those compounds of formula (I-b):
  • R 1 is H, or is Ci- ⁇ -alkyl optionally substituted by CN, or is sulfonylaryl, or is -(CH 2 ) m -R a wherein R a is:
  • NR 1 R 11 5 or 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B;
  • R 2 is one or more of H, halo, C 1-6 - alkyl;
  • R 3 is H, or is Ci- 6 - alkyl, or is -(CO)-R C , wherein R c is: Ci_ 6 -alkyl -(CHz) n -NR 1 R 11 ,
  • R 4 is is one or more of H, halo, or Q- ⁇ -alkoxy optionally substituted by OH, or two R 4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
  • R 6 is H;
  • R 7 is H or -SO 2 -R 6 wherein R e is Ci_ 6 -alkyl or aryl;
  • B is halo, CN, Ci- ⁇ -alkyl optionally substituted by CN or Q- ⁇ -alkoxy, Q- ⁇ -alkoxy, C 1- 6 -haloalkoxy, C 3-6 -cycloalkyl, -C(O)O-C 1 _ 6 -alkyl, -(CR m R lv ) n -phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, C 1-6 - alkyl optionally substituted by CN or halo, C 1-6 - alkoxy;
  • R 1 and R 11 are H, C 1-6 -alkyl, Ci_ 6 -alkyl-NR m R lv , -C(O)-C 1-6 -alkyl, -S(O) 2 -Ci_ 6 -alkyl or OH;
  • R 111 and R 1V are H or C 1-6 -alkyl;
  • m is 1 to 6;
  • n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
  • the compounds of the invention are those compounds of formula (I-b) as described above, wherein R 1 is H, or is -(CH 2 ) m -R a wherein R a is aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more subsituents selected from the group consisting of: halo, CN, C 1-6 - alkyl, C 1-6 - alkoxy, C 1-6 -haloalkoxy, -C(O)O-C 1-6 -alkyl and phenyl optionally substituted by halo, Ci- ⁇ -haloalkyl or C 1-6 - alkoxy, or is -(CH 2 )I 11 -NR 1 R 11 , or is -(CH 2 ) n -(CO)-R b , wherein R b is aryl or 5 or 6 membered-heterocycloalkyl which are optionally substituted by one or more B
  • R 3 is H or C 1-6 - alkyl;
  • R 4 is H or halo;
  • R 6 is H;
  • R 7 is H or -SO 2 -R 6 wherein R e is Ci_ 6 -alkyl or aryl;
  • B is halo, NH 2 , Q-o-alkyl optionally substituted by CN or Q- ⁇ -alkoxy, Q- ⁇ -alkoxy, Ci-e-haloalkoxy, C 3 - 6 -cycloalkyl, -C(O)O-C 1 _ 6 -alkyl, -(CR m R lv ) n -phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci- ⁇ -alkyl optionally substituted by CN or halo, Q- ⁇ -alkoxy; R 1 , R 11 are independently selected from H or C 1-6 - alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
  • R 1 is H or
  • R a is aryl which is optionally substituted by one or more sub situ ents selected from the group consisting of: halo, CN, Q-6-alkyl, Ci_ 6 -alkoxy, Ci-e-haloalkoxy, -C(O)O-C 1 _ 6 -alkyl and phenyl optionally substituted by halo, Ci- ⁇ -haloalkyl or Q- ⁇ -alkoxy;
  • R 2 is H or halo
  • R 3 is H or C 1-6 - alkyl
  • R 4 is H or halo;
  • R 6 is H;
  • R 7 is H or -SO 2 -R 6 wherein R e is C 1-6 -alkyl; m is 1 to 6; as well as pharmaceutically acceptable salts thereof.
  • the compounds of the invention are those compounds of formula (I-c):
  • R 1 is H, or is C 1-6 - alkyl optionally substituted by CN, or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl which are optionally substituted by one or more B, or is -(CH 2 ) m -R a wherein R a is: OR 1 , CN, NR 1 R 11 , C 3 - 6 -cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH 2 V (CO) -R b wherein R b is: Ci- 6 - alkoxy, NR 1 R 11 , 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or R 1 and R 3 together with the indole ring to which they are attached form
  • R 2 is one or more of H, halo, C ⁇ -alky! optionally substituted by-NR m R lv , C 1-6 - alkoxy;
  • R 3 is H, or is Ci- 6 - alkyl, or is halo, or is -(CO)-R C , wherein R c is: C 1-6 - alkyl, -(CHz) n -NR 1 R 11 , -(CH 2 ) n -NR m R lv ,
  • R 4 is one or more of H, halo, or Q- ⁇ -alkoxy optionally substituted by OH, or two R 4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
  • B is halo, NH 2 , Q-o-alkyl optionally substituted by CN or Q- ⁇ -alkoxy, Q- ⁇ -alkoxy, Ci-e-haloalkoxy, C 3 - 6 -cycloalkyl, -C(O)O-C 1 _ 6 -alkyl, -(CR m R lv ) n -phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci- ⁇ -alkyl optionally substituted by CN or halo, Q- ⁇ -alkoxy; R 1 and R 11 are H, C 1-6 -alkyl, Ci_ 6 -alkyl-NR m R lv , -(CO)O-C 1-6 -alkyl, -C(O)-NR m R lv , -C(O)-
  • R 111 and R 1V are H or C 1-6 -alkyl; m is 1 to 6; n is O to 4; as well as pharmaceutically acceptable salts thereof.
  • R 1 is H or
  • R a is aryl which is optionally substituted by one or more sub situ ents selected from the group consisting of: halo, CN, C 1-6 - alkyl, C 1-6 - alkoxy, C 1-6 -haloalkoxy, -C(O)O-C 1-6 -alkyl and phenyl optionally substituted by halo, Ci- ⁇ -haloalkyl or Q- ⁇ -alkoxy;
  • R 2 is H or halo
  • R 3 is H, C 1-6 - alkyl or,
  • R c is 5 or 6 membered heterocycloalkyl optionally substituted by Q-6-alkyl, or R c is - (CH 2 VNR 1 R 11 ; R 4 is H, halo, Ci_ 6 - alkoxy or two R 4 may form a dioxo bridge together with the phenyl ring to which they are attached;
  • R 1 and R 11 are independently selected from H, Ci- ⁇ -alkyl and -(CO)O-C 1 _ 6 -alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
  • the compounds of the invention are those compounds of formula (I- d):
  • R 1 is H, or is Ci- ⁇ -alkyl optionally substituted by CN, or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl which are optionally substituted by one or more B, or is -(CH 2 ) m -R a wherein R a is: OR 1 ,
  • CN NR 1 R 11 , C 3 _ 6 -cycloalkyl, 3 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH 2 ) n - (CO) -R b wherein R b is:
  • R 2 is one or more of H, halo, Ci_ 6 - alkyl, Q- ⁇ -alkoxy
  • R 3 is H, or is Ci- 6 - alkyl, or is -(CO)-R C , wherein R c is C 1-6 -alkyl, or -(CH 2 )D-NR 1 R 11
  • R 4 is one or more of H, halo, or Q- ⁇ -alkoxy optionally substituted by OH, or two R 4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
  • R 5 is H or aryl
  • B is halo, NH 2 , Ci- ⁇ -alkyl optionally substituted by CN or Q- ⁇ -alkoxy, Q- ⁇ -alkoxy, Ci-e-haloalkoxy, C 3 - 6 -cycloalkyl, -C(O)O-C 1-6 -alkyl, -(CR m R lv ) n -phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, C 1-6 - alkyl optionally substituted by CN or halo, Q- ⁇ -alkoxy;
  • R 1 and R 11 are H, C 1-6 -alkyl, Ci_ 6 -alkyl-NR m R lv , -(CO)O-C 1-6 -alkyl, -C(O)-NR m R lv , -C(O)- Ci_ 6 -alky
  • R 111 and R 1V are H or C 1-6 -alkyl; m is 1 to 6; n is O to 4; as well as pharmaceutically acceptable salts thereof.
  • R 1 is H or
  • Ci- ⁇ -alkyl optionally substituted by CN or,
  • R a is C 3 _ 6 -cycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more substituents selected from the group consisting of: halo, CN, C 1-6 - alkyl, C 1-6 - alkoxy, -C(O)O-C 1-6 -alkyl and phenyl optionally substituted by halo, C 1-6 - alkyl Ci- ⁇ -haloalkyl or C 1-6 - alkoxy, -(CH 2 ) I11 -NR 1 R 11 or, -(CH 2 V (CO) -R b , wherein R b is aryl;
  • R 2 is H, halo or C 1-6 - alkoxy
  • R 3 is H or
  • R c is Ci_ 6 -alkyl or
  • R 4 is H or halo
  • R 5 is H or aryl; R 1 and R 11 are C 1-6 -alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
  • the compounds of the invention are those compounds of formula (I-e):
  • R 1 is H, or is Ci- ⁇ -alkyl optionally substituted by CN, or is sulfonylaryl, or is -(CH 2 ) m -R a wherein R a is:
  • R 11 5 or 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B;
  • R 2 is one or more of H, halo, C 1-6 - alkyl;
  • R 3 is H, or is Ci- 6 - alkyl, or is -(CO)-R C , wherein R' ; is:
  • R 4 is is one or more of H. halo. or may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
  • R 6 is H;
  • B is halo, CN, Q-o-alkyl optionally substituted by CN or Q- ⁇ -alkoxy, Q- ⁇ -alkoxy, C 1- 6 -haloalkoxy, C 3 - 6 -cycloalkyl, -C(O)O-C 1 - 6 -alkyl, -(CR m R lv ) n -phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci- ⁇ -alkyl optionally substituted by CN or halo, Q- ⁇ -alkoxy;
  • R 1 and R 11 are H, C 1-6 -alkyl, Ci- 6 -alkyl-NR m R lv , -C(O)-C 1-6 -alkyl, -S(O) 2 -Ci- 6 -alkyl or OH;
  • R 111 and R 1V are H or C 1-6 -alkyl;
  • m is 1 to 6;
  • n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
  • the compounds of the invention are those compounds of formula (I-e), wherein R 1 is H or,
  • R a is 5 or 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl or, -(CH 2 ) I11 -NR 1 R 11 or, -(CH 2 ) n -(CO)-R b , wherein R b is 5 or 6 membered-heterocycloalkyl;
  • R 2 is one or more of H or halo;
  • R 3 is H, or is Ci- 6 - alkyl
  • R 4 is one or more of H or halo ;
  • R 6 is H;
  • R 1 and R 11 are C 1-6 -alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
  • the following compounds are examples according to the invention: r-fC ⁇ -chloro-lH-indol-S-y ⁇ carbonyy spirof l-benzofuran-S ⁇ '-piperidine] ; r-fCl-benzyl-l-methyl-lH-indol-S-y ⁇ carbonyy spirof l-benzofuran-S ⁇ '-piperidine] ; r-(lH-indol-3-ylcarbonyl)spiro[l-benzofuran-3,4'-piperidine] ; r-[(6-chloro-5-fluoro-lH-indol-3-yl)carbonyl] spiro[l-benzofuran-3,4'-piperidine] ; 2- [6-chloro-3
  • the compounds of the invention are those compounds of formula (I-f): - -
  • R 1 is H, or is Ci- ⁇ -alkyl optionally substituted by CN, or is sulfonylaryl, or is -(CH 2 ) m -R a
  • R a is: OR 1 , CN, NR 1 R 11 , C 3 _ 6 -cycloalkyl, 3 to 6 membered-heterocycloalkyl, aryl or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH 2 V (CO) -R b
  • R b is: Ci- 6 - alkoxy, NR 1 R 11 , 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B
  • R 2 is one or more of H, halo, C 1-6 - alkyl
  • R 3 is H, or is C 1 - O - alkyl, or is - (CO)
  • R 4 is is one or more of H, halo, or Q- ⁇ -alkoxy optionally substituted by OH, or two R 4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
  • B is halo, CN, Ci- ⁇ -alkyl optionally substituted by CN or Q- ⁇ -alkoxy, Q- ⁇ -alkoxy, C 1- 6 -haloalkoxy, C 3 - 6 -cycloalkyl, -C(O)O-C 1 - 6 -alkyl, -(CR m R lv ) n -phenyl, wherein the - - phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci- ⁇ -alkyl optionally substituted by CN or halo, Q- ⁇ -alkoxy;
  • R 1 and R 11 are H, C 1-6 -alkyl, Ci_ 6 -alkyl-NR m R lv , -C(O)-C 1-6 -alkyl, -S(O) 2 -Ci_ 6 -alkyl or OH;
  • R 111 and R 1V are H or C 1-6 -alkyl;
  • m is 1 to 6;
  • n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
  • the compounds of the invention are those compounds of formula (I-f) , wherein
  • R 1 is H
  • R 2 is one or more of H or halo
  • R 3 is H
  • R 4 is one or more of H or halo ; as well as pharmaceutically acceptable salts thereof.
  • the compounds of the invention are those compounds of formula (I-g):
  • R 1 is H, or is Ci- ⁇ -alkyl optionally substituted by CN, or is sulfonylaryl, or is -(CH 2 ) m -R a wherein R a is: OR 1 , CN, 5 NR 1 R 11 ,
  • R 2 is one or more of H, halo, C 1-6 - alkyl
  • R 3 is H, 5 or is Ci- 6 - alkyl, or is -(CO)-R C , wherein R c is: Ci- 6 -alkyl -(CHz) n -NR 1 R 11 ,
  • R 4 is is one or more of H, halo, or Q- ⁇ -alkoxy optionally substituted by OH, or two R 4 0 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
  • B is halo, CN, Ci- ⁇ -alkyl optionally substituted by CN or Q- ⁇ -alkoxy, Q- ⁇ -alkoxy, C 1- 6 -haloalkoxy, C 3 - 6 -cycloalkyl, -C(O)O-C 1 - 6 -alkyl, -(CR m R lv ) n -phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the 5 group consisting of: halo, Ci- ⁇ -alkyl optionally substituted by CN or halo, Q- ⁇ -alkoxy;
  • R 1 and R 11 are H, C 1-6 -alkyl, Ci- 6 -alkyl-NR m R lv , -C(O)-C 1-6 -alkyl, -S(O) 2 -Ci- 6 -alkyl or OH;
  • R 111 and R 1V are H or C 1-6 -alkyl; m is 1 to 6; O n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
  • the compounds of the invention are those compounds of formula (I-g), wherein 5 R 1 is H or, - -
  • R a is aryl
  • R 2 is one or more of H or halo
  • R 3 is H, or is Ci- 6 - alkyl
  • R 4 is H
  • R 6 is H; as well as pharmaceutically acceptable salts thereof.
  • the compounds of the invention are those compounds of formula (I-h) :
  • R 1 is H, or is Ci- ⁇ -alkyl optionally substituted by CN, or is sulfonylaryl, or is -(CH 2 ) m -R a wherein R a is:
  • R 2 is one or more of H, halo, C 1 - O - alkyl;
  • R 3 is H, or is Ci- 6 - alkyl, or is -(CO)-R C , wherein R c is:
  • R 4 is is one or more of H, halo, or Q- ⁇ -alkoxy optionally substituted by OH, or two R 4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
  • B is halo, CN, C ⁇ -alky! optionally substituted by CN or Q- ⁇ -alkoxy, Q- ⁇ -alkoxy, C 1 . 6 -haloalkoxy, C 3 - 6 -cycloalkyl, -C(O)O-C 1 - 6 -alkyl, -(CR m R lv ) n -phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci- ⁇ -alkyl optionally substituted by CN or halo, Q- ⁇ -alkoxy;
  • R 1 and R 11 are H, Q-e-alkyl, Q-e-alkyl-NR 111 ⁇ , -C(O)-C 1 - 6 -alkyl, -S(O) 2 -C 1 - 6 -alkyl or OH;
  • R 111 and R 1V are H or Ci- 6 -alkyl;
  • m is 1 to 6;
  • n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
  • the compounds of the invention are those compounds of formula (I-h), wherein R 1 is H, or is -(CH 2 V (CO) -R b , wherein R b is NR 1 R 11 ; - -
  • R 2 is one or more of H or halo
  • R 3 is H
  • R 4 is H
  • R 8 is H or C 1-6 - alkyl
  • R 1 and R 11 are H or Ci- 6 - alkyl; as well as pharmaceutically acceptable salts thereof.
  • the invention also encompasses the compounds of formula (I), (I- a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h) for a use in the prevention or treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.
  • the invention also encompasses a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), (I- a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h), which pharmaceutical composition is useful against dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.
  • the invention further encompasses the use of a compound of formula (I), (I- a), (I- b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h) for the preparation of a medicament which is useful against dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.
  • a compound of formula (I), (I- a), (I- b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h) for the preparation of a medicament which is useful against dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.
  • the compounds of the invention can be manufactured according to a process comprising the step of reacting a compound of formula (II): with a compound of formula A-H in order to obtain the compound of formula (I), wherein A, R 1 , R 2 and R 3 are as defined hereinabove.
  • the compounds of the invention can be manufactured according to a process comprising the step of reacting a compound of formula (III) :
  • the compounds of the invention can be manufactured according to a process comprising the step of reacting a compound of formula (IV):
  • Compounds of formula (I) can be prepared via an amide coupling between an indole 3-carboxylic acid (II) and a spiropiperidine (A-H).
  • Indole 3-carboxylic acids (II) are either commercially available or readily prepared using a procedure described in J.Med.Chem. 1991, 34, 140. Alternatively, they can be prepared following the general scheme D as described hereinafter.
  • the spiropiperidine derivatives A-H are either commercially available or can be prepared using commercially available starting materials and conventional methods.
  • Spiropiperidines A-H of group (h) can be prepared as described in general scheme E.
  • General scheme A is hereinafter further illustrated with general scheme and procedure I to which, e.g., examples 1 to 24, 34, 39-43, 66-70, 77-80 and 123-126 refer.
  • Compounds of formula (I) with R 1 different from H can be prepared by N- deprotonation of an indole derivative (III) (a compound of formula (I) wherein R 1 is H) followed by treatment with an electrophilic reactant R 1 - Y (wherein Y is a leaving group) which is either commercially available or easily prepared according to methods well known in the art and commercially available starting materials.
  • compounds (I) can be prepared by coupling of an indole derivative (III) with a boronic acid R 1 - - -
  • examples 104-115, 117, 204-212 VI (e.g. examples 155-157, 222, 223, 225, 226), VII (e.g. examples 88-92, 128-132, 137-141, 145- 149, 158, 214-218, 221) and VIII.
  • intermediate (VI) which can be hydrolysed with an aqueous sodium hydroxide solution to give the 3-carboxylic acid indole derivative (Ha).
  • (VI) can react with an electrophilic reactant R 1 - Y to give (VII), which is then converted to the corresponding carboxylic acid derivative (lib) with NaH/H 2 O in DMF (see J. Org Chem., 1993, 10, 2862).
  • Intermediate (VII) can alternatively be obtained by treatment of an indole derivative (Vb) with triflu or o acetic anhydride in DMF, dichloromethane or 1,2- dichloroethane. Addition of a suitable base may be advantageous.
  • lactam (XI) can be N- alkylated to give lactam (XV). Both, lactam (XI) and (XV), are reduced using standard conditions to afford spiropiperidines (XIV) and (XVI) after N-deprotection, respectively. - -
  • the human Via receptor was cloned by RT-PCR from total human liver RNA
  • the coding sequence was subcloned in an expression vector after sequencing to confirm the identity of the amplified sequence.
  • Cell membranes were prepared from HEK293 cells transiently transfected with the expression vector and grown in 20 liter fermenters with the following protocol.
  • the pellet is resuspended in 12.5 ml Lysis buffer+ 12.5ml Sucrose 20% and homogenized using a Polytron for 1-2 min.
  • the protein concentration is determined by the Bradford method and aliquots are stored at -8O 0 C until use.
  • 60mg Yttrium silicate SPA beads (Amersham) are mixed with an aliquot of membrane in binding buffer (50 mM Tris, 12OmM NaCl, 5 mM KCl, 2 mM CaC12, 10 mM MgC12) for 15 minutes with mixing.
  • Non-specific binding counts are subtracted from each well and data is normalized to the maximum specific binding set at 100%.
  • the compounds of formula (I) as well as their pharmaceutically usable acid addition salts can be used as medicaments, e.g. in the form of pharmaceutical preparations.
  • the pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions.
  • the administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
  • the compounds of formula (I) and their pharmaceutically usable acid addition salts can be processed with pharmaceutically inert, inorganic or organic excipients for the production of tablets, coated tablets, dragees and hard gelatine capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc can be used as such excipients e.g. for tablets, dragees and hard gelatine capsules.
  • Suitable excipients for soft gelatine capsules are e.g. vegetable oils, waxes, fats, semisolid and liquid polyols etc.
  • Suitable excipients for the manufacture of solutions and syrups are e.g. water, polyols, saccharose, invert sugar, glucose etc. - D -
  • Suitable excipients for injection solutions are e.g. water, alcohols, polyols, glycerol, vegetable oils etc.
  • Suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats, semi- liquid or liquid polyols etc.
  • the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • the dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case.
  • a daily dosage of about 10 to 1000 mg per person of a compound of general formula (I) should be appropriate, although the above upper limit can also be exceeded when necessary.
  • the active substance, lactose and corn starch are firstly mixed in a mixer and then in a comminuting machine.
  • the mixture is returned to the mixer, the talc is added thereto and mixed thoroughly.
  • the mixture is filled by machine into hard gelatine capsules.
  • the suppository mass is melted in a glass or steel vessel, mixed thoroughly and cooled to 45 0 C. Thereupon, the finely powdered active substance is added thereto and stirred until it has dispersed completely. The mixture is poured into suppository moulds of suitable size, left to cool; the suppositories are then removed from the moulds and packed individually in wax paper or metal foil.
  • 6-chloro- lH-indole was prepared 5.80 g (64%) of 6-chloro- lH-indole-3-carboxylic acid as a light brown solid.
  • ES-MS m/e (%): 194 (M-H + ). - -
  • This intermediate compound methyl ⁇ 6-chloro-3-[(5-fluoro-3-oxo-l ⁇ ,3H-spiro[2- benzofuran-l,4'-piperidin]-l'-yl)carbonyl]-lH-indol-l-yl ⁇ acetate, was then hydrolysed using standard conditions (aq.NaOH IM, MeOH, room temperature) to give ⁇ 6-chloro- 3-[(5-fluoro-3-oxo-l ⁇ ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-yl)carbonyl]-lH- indol-l-yl ⁇ acetic acid as a white solid.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

This invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as Via receptor antagonists and which are represented by Formula (I): wherein the spiro-piperidine head group A and the residues R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, their use in medicaments against dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders, and methods of preparation thereof.

Description

INDOL-B-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIA RECEPTOR
ANTAGONISTS
The present invention relates to compounds of the general formula (I)
Figure imgf000002_0001
wherein
Ais selected from the following groups (a), (b), (c), (d), (e), (f), (g) and (h):
Figure imgf000002_0002
GO
wherein in (a) the dotted line is either nil or a double bond; R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl which are optionally substituted by one or more B, or is -(CH2)m-Ra wherein Ra is: CN, OR1, NR1R11, C3_6-cycloalkyl, 3 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2)n- (CO) -Rb or -(CH2)n- (SO2) -Rb, wherein Rb is: Ci_6-alkyl, Ci-6- alkoxy, C3-6-cycloalkyl,
-(CH2)m-NRmRlv, NR1R11, C3_6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or R1 and R3 together with the indole ring to which they are attached form a 5 or
6 membered heterocycloalkyl which can be substituted by =0, C(O)O-C1-O- alkyl or C1-6- alkyl; R2 is one or more of H, OH, halo, CN, nitro, C1-6- alkyl optionally substituted by -
NRmRlv, Ci_6-alkoxy, -O-CH2-C2_6-alkenyl, benzyloxy, or two R2 may form an oxo or dioxo bridge together with the indole ring to which they are attached; R3 is H, or is halo, or is -(CO)-RC, wherein Rc is: C1^- alkyl,
-(CH2VNR1R11, -(CH2)n-NRmRlv,
5 or 6 membered heterocycloalkyl optionally substituted by C1-6- alkyl, or is Ci-ό-alkyl or aryl, which are optionally substituted by halo,
-O(CO)-Ci_6-alkyl, or by-NH(CO)Rd, wherein Rd is C^-alky! optionally substituted by halo or nitro, or Rd is aryl or a 5 or 6 membered heteroaryl, which are optionally substituted by halo, nitro, C^-alky! or Q-ό-haloalkyl;
R is one or more of H, halo, Q-o-alkyl or Q-ό-alkoxy optionally substituted by OH, or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached; R5 is H, Ci_6- alkyl or aryl;
R6 is H or Q-β-alkyl;
R7 is H or -SO2-R6 wherein Re is Ci_6-alkyl or aryl; R8 is H or C1-6- alkyl;
X is CH2 or C=O;
B is halo, CN, NR1R11, Ci_6-alkyl optionally substituted by CN, halo or Ci_6-alkoxy,
Ci_6-alkoxy, Ci-e-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1_6-alkyl, -C(O) NR1R11, - C(O)-Ci_6-alkyl, -S(O)2-Ci_6-alkyl, -S(O)2- NR1R11, (CRmRlv)n-phenyl, or (CRmRlv)n-5 or 6 membered heteroaryl wherein the phenyl or 5 or 6 membered heteroaryl moiety is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, CN, NR1R11, Ci_6-alkyl optionally substituted by CN, halo or C1-6- alkoxy, Q-ό-alkoxy, Ci-ό-haloalkoxy, C3_6-cycloalkyl, -C(O)O-C1_6-alkyl, - C(O)-NR1R11, -C(O)-Ci_6-alkyl, -S(O)2-Ci_6-alkyl, -S(O)2- NR1R11;
R1 and R11 are H, C1-6-alkyl, Ci_6-alkyl-NRmRlv, -(CO)O-C1-6-alkyl, -C(O)-NRmRlv, -C(O)-
Ci_6-alkyl, -S(O)2-Ci_6-alkyl, -S(O)2- NRmRlv or OH; R111 and R1V are H or C1-6-alkyl; m is 1 to 6; n is O to 4; as well as pharmaceutically acceptable salts thereof.
The compounds of formula (I) may contain some asymmetric carbon atoms. Accordingly, the present invention includes all stereioisomeric forms of the compounds of formula (I), including each of the individual enantiomers and mixtures thereof.
It has been found that the compounds of formula (I) have a good activity on the
Via receptor. Therefore, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of medicaments for the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders. Vasopressin is a 9 amino acid peptide mainly produced by the paraventricular nucleus of the hypothalamus. Three vasopressin receptors, all belonging to the class I G- protein coupled receptors, are known. The Via receptor is expressed in the brain, liver, vascular smooth muscle, lung, uterus and testis, the VIb or V3 receptor is expressed in the brain and pituitary gland, the V2 receptor is expressed in the kidney where it regulates water excretion and mediates the antidiuretic effects of vasopressin.
In the periphery vasopressin acts as a neurohormone and stimulates vasoconstriction, glycogenolysis and antidiuresis. In the brain vasopressin acts as a neuromodulator and is elevated in the amygdala during stress ( Ebner, K, C. T. Wotjak, et al. (2002). "Forced swimming triggers vasopressin release within the amygdala to modulate stress-coping strategies in rats." Eur J Neurosci 15(2): 384-8). The Via receptor is extensively expressed in the brain and particularly in limbic areas like the amygdala, lateral septum and hippocampus which are playing an important role in the regulation of anxiety. Indeed Via knock-out mouse show a reduction in anxious behavior in the plus- maze, open field and light-dark box ( Bielsky, I. R, S. B. Hu, et al. (2003). "Profound Impairment in Social Recognition and Reduction in Anxiety-like Behavior in Vasopressin Via Receptor Knockout Mice." Neuropsvchopharmacologv) . The downregulation of the Via receptor using antisense oligonucleotide injection in the septum also causes a reduction in anxious behavior ( Landgraf, R., R. Gerstberger, et al. (1995). "Vl vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety- related behavior in rats." Regul Pept 59(2): 229-39).
The Via receptor is also mediating the cardiovascular effects of vasopressin in the brain by centrally regulating blood pressure and heart rate in the solitary tract nucleus (Michelini, L. C. and M. Morris (1999). "Endogenous vasopressin modulates the cardiovascular responses to exercise." Ann N Y Acad Sci 897: 198-211). In the periphery it induces the contraction of vascular smooth muscles and chronic inhibition of the Via receptor improves hemodynamic parameters in myocardial infarcted rats ( Van Kerckhoven, R., I. Lankhuizen, et al. (2002). "Chronic vasopressin V(IA) but not V(2) receptor antagonism prevents heart failure in chronically infarcted rats." Eur J Pharmacol 449(1-2): 135-41).
Thus vasopressin receptor antagonists are useful as therapeutics in the conditions of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.
The preferred indications with regard to the present invention are the treatment of anxious and depressive disorders. As used herein, the term "aryl" means a monovalent cyclic aromatic hydrocarbon moiety consisting of a mono-, bi- or tricyclic aromatic ring. Examples of aryl moieties include, but are not limited to, optionally substituted phenyl, naphthyl, phenanthryl, fluorenyl, indenyl, pentalenyl, azulenyl, oxydiphenyl, biphenyl, methylenediphenyl, aminodiphenyl, diphenylsulfidyl, diphenylsulfonyl, diphenylisopropylidenyl, benzodioxanyl, benzofuranyl, benzodioxylyl, benzopyranyl, benzoxazinyl, benzoxazinonyl, benzopiperadinyl, benzopiperazinyl, benzopyrrolidinyl, benzomorpholinyl, methylenedioxyphenyl, ethylenedioxyphenyl, as well as those specifically illustrated by the examples herein below. Substituents for aryl include but are not limited to halogen, C1-6- alkyl, Q-ό-alkoxy as well as those specifically listed and illustrated by the description and examples herein below. Preferred aryl are phenyl and naphthyl and still preferably phenyl.
The term "C1-6- alkyl" denotes a saturated straight- or branched-chain group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n- butyl, i-butyl, 2-butyl, t-butyl and the like. Preferred C1-6- alkyl groups are Ci-4-groups, i.e. with 1 - 4 carbon atoms.
The term "Ci-ό-alkoxy" denotes a group wherein the alkyl residues are as defined above, and which is attached via an oxygen atom. Preferred Q-ό-alkoxy groups are methoxy and ethoxy as well as those specifically illustrated by the examples herein below.
The term "C2_6-alkenyl" denotes a carbon chain of 2 to 6 carbon atoms comprising a double bond in its chain. C2_6-alkenyl groups include ethenyl, propen- 1-yl, propen-2-yl, buten-1-yl, buten-3-yl, penten-1-yl, penten-2-yl, penten-3-yl, penten-4-yl, hexen-1-yl, hexen-2-yl, hexen-3-yl, hexen-4-yl and hexen-5-yl, as well as those specifically illustrated by the examples herein below.
The term "benzyloxy" denotes a benzyl group attached via an oxygen atom.
The term "halogen" or "halo" denotes chlorine (Cl), iodine (I), fluorine (F) and bromine (Br). - D -
The term "Ci-ό-haloalkyl" denotes a Ci-ό-alkyl group as defined above which is substituted by one or more halogen. Examples of Ci-ό-haloalkyl include but are not limited to methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n- hexyl substituted by one or more Cl, F, Br or I atom(s) as well as those groups specifically illustrated by the examples herein below. Preferred Ci-ό-haloalkyl are difluoro- or trifluoro- methyl or ethyl.
"Ci-ό-haloalkoxy" denotes a Q-ό-alkoxy group as defined above which is substituted by one or more halogen. Examples of Q-ό-haloalkoxy include but are not limited to methoxy or ethoxy, substituted by one or more Cl, F, Br or I atom(s) as well as those groups specifically illustrated by the examples herein below. Preferred Q-ό-haloalkoxy are difluoro- or trifluoro-methoxy or ethoxy.
The term "C3-6-cycloalkyl" denotes a monovalent or divalent saturated carbocyclic moiety consisting of a monocyclic ring. Cycloalkyl can optionally be substituted with one, two, three or four substituents, wherein each substituent is independently hydroxy, Ci_6- alkyl, Q-ό-alkoxy, halogen, amino, unless otherwise specifically indicated. Examples of cycloalkyl moieties include optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl and optionally substituted cyclohexyl as well as those specifically illustrated by the examples herein below.
The term "3 to 7 membered heterocycloalkyl" means a monovalent saturated moiety, consisting of one ring of 3 to 7 atoms as ring members, including one, two, or three heteroatoms chosen from nitrogen, oxygen or sulfur, the rest being carbon atoms. 3 to 7 membered heterocycloalkyl can optionally be substituted with one, two, three or four substituents, wherein each substituent is independently hydroxy, C1-6- alkyl, Q-ό-alkoxy, Ci-ό-thioalkyl, halo, Q-ό-haloalkyl, Ci-ό-hydroxyalkyl, alkoxycarbonyl, amino, C1-6- alkylamino, di(C1_6)alkylamino, aminocarbonyl, or carbonylamino, unless otherwise specifically indicated. Examples of heterocyclic moieties include, but are not limited to, oxirane, optionally substituted oxetane, optionally substituted tetrahydro-furanyl, optionally substituted piperidinyl, optionally substituted pyrrolidinyl, optionally substituted morpholinyl, optionally substituted piperazinyl, optionally substituted azepane or homopiperazine, and the like or those which are specifically exemplified herein. Substituents can be selected from Ci-6-alkyl, Ci-6-alkoxy, Ci-6-haloalkyl, halo, CN, OH, NH2, as well as those substituents which are are specifically illustrated in the examples hereinafter. The term "5 or 6 membered heteroaryl" means an aromatic ring of 5 or 6 ring atoms as ring members containing one, two, or three ring heteroatoms selected from N, O, or S, the rest being carbon atoms. 5 or 6 heteroaryl can optionally be substituted with one, two, three or four substituents, wherein each substituent is independently hydroxy, C1-6- alkyl, Q-ό-alkoxy, Ci-ό-thioalkyl, halo, Ci-ό-haloalkyl, Ci-ό-hydroxyalkyl, alkoxycarbonyl, amino, Ci-ό-alkylamino, di(C1_6)alkylamino, aminocarbonyl, or carbonylamino, unless otherwise specifically indicated. Examples of heteroaryl moieties include, but are not limited to, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted thiazolyl, optionally substituted pyrazinyl, optionally substituted pyrrolyl, optionally substituted pyrazinyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted furanyl, and those which are specifically exemplified herein.
The term "sulfonylaryl" denotes an aryl group as defined hereinabove which is attached via a sulfonyl group.
The expression "two R2 may form an oxo or dioxo bridge together with the indole ring to which they are attached notes an oxo or dioxo bridge of the following formulae:
Figure imgf000008_0001
which bind two adjacent carbon atoms of the phenyl or indole ring of the compound of formula (I) to which either R2 is binding.
Examples of group illustrating the expression "R1 and R3 together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which can be substituted by =0. C(O)O-C1-6-alkyl or Q-e-alkyl" are:
Figure imgf000008_0002
or as well as those specifically illustrated by the examples.
The term "pharmaceutically acceptable acid addition salts" embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic - o - acid, tartaric acid, methane- sulfonic acid, p-toluenesulfonic acid, as well as those specifically illustrated by the examples herein below.
In a certain embodiment, the compounds of formula (I) are those compounds wherein: A is selected from (a), (b), (c), (d), (e), (f), (g) or (h) and wherein
R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl which are optionally substituted by one or more B, or is -(CH2)m-Ra wherein Ra is:
OR1, CN, NR1R11,
C3_6-cycloalkyl, 3 to 7 membered-heterocycloalkyl, aryl or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2)n- (CO) -Rb or -(CH2)n- (SO2) -Rb, wherein Rb is: Ci-6- alkoxy, NR1R11,
4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroarylwhich are optionally substituted by one or more B, or R1 and R3 together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which can be substituted by =0, C(O)O-C1-O- alkyl or C1-6- alkyl;
R2 is one or more of H, OH, halo, C1-6- alkyl optionally substituted by -NRmRlv, C1-6- alkoxy;
R3 is H, or is halo or is -(CO)-RC, wherein Rc is:
Ci_6-alkyl - (CH2VNR1R11,
-(CH2)n-NRmRlv,
5 or 6 membered heterocycloalkyl optionally substituted by Ci-ό-alkyl, or is Ci-ό-alkyl or aryl, which are optionally substituted by halo, R4 is is one or more of H, halo, or Ci_6- alkoxy optionally substituted by OH, or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
R5 is H or aryl; R6 is H;
R7 is H or -SO2-R6 wherein Re is Ci_6-alkyl or aryl;
R8 is H or Q-β-alkyl;
X is CH2 or C=O;
B is halo, CN, NH2, Ci-ό-alkyl optionally substituted by CN or Q-ό-alkoxy, C1-6- alkoxy, Ci-e-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1_6-alkyl, -(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci-ό-alkyl optionally substituted by CN or halo, Q-ό-alkoxy; R1 and R11 are H, C1-6-alkyl, Ci_6-alkyl-NRmRlv, -(CO)O-C1-6-alkyl, -C(O)-NRmRlv, -C(O)- Q-β-alkyl, -S(O)2-Ci_6-alkyl or -S(O)2- NR1UR1V or OH;
R111 and R1V are H or C1-6-alkyl; m is 1 to 6; n is O to 4; as well as pharmaceutically acceptable salts thereof.
In another embodiment, the compounds of formula (I) are those compounds wherein: A is selected from (a), (b), (c), (d) or (e), and wherein R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl which are optionally substituted by one or more B, or is -(CH2)m-Ra wherein Ra is: CN, OR1, NR1R11,
C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb or -(CH2),,- (SO2) -Rb, wherein Rb is:
Ci-β-alkyl, Ci-6- alkoxy, C3-6-cycloalkyl, -(CH2)m-NRmRlv, NR1R11,
C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or R1 and R3 together with the indole ring to which they are attached form a 5 or
6 membered heterocycloalkyl which can be substituted by (CO); R2 is one or more of H, OH, halo, CN, nitro, C1-6- alkyl optionally substituted by -
NRmRlv, Ci_6-alkoxy, -O-CH2-C2_6-alkenyl, benzyloxy, or two R2 may form an oxo or dioxo bridge together with the indole ring to which they are attached; R3 is H, or is halo, or is -(CO)-RC, wherein Rc is: C1-6- alkyl,
-(CHz)n-NR1R11, -(CH2)n-NRmRlv,
5 or 6 membered heterocycloalkyl optionally substituted by Ci-ό-alkyl, or is Ci-ό-alkyl or aryl, which are optionally substituted by halo,
-O(CO)-C1_6-alkyl, or by-NH(CO)Rd, wherein Rd is Ci-ό-alkyl optionally substituted by halo or nitro, or Rd is aryl or a 5 or 6 membered heteroaryl, which are optionally substituted by halo, nitro, Ci-ό-alkyl or Q-ό-haloalkyl; R4 is one or more of H, halo, C1-6- alkyl or Q-ό-alkoxy or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached; R5 is H, Ci_6- alkyl or aryl;
R6 is H or Ci_6-alkyl;
R7 is H or -SO2-R6 wherein Re is Ci_6-alkyl or aryl; B is halo, CN, NR1R11, Ci_6-alkyl optionally substituted by CN, halo or Ci_6-alkoxy,
Ci_6-alkoxy, Ci-e-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1_6-alkyl, -C(O) NR1R11, - C(O)-Ci_6-alkyl, -S(O)2-Ci_6-alkyl, -S(O)2- NR1R11, (CRmRlv)n-phenyl, or (CRmRlv)n-5 or 6 membered heteroaryl wherein the phenyl or 5 or 6 membered heteroaryl moiety is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, CN, NR1R11, Ci_6-alkyl optionally substituted by CN or Ci_6-alkoxy, Ci_6-alkoxy, Q-e-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, -C(O)- NR1R11, -C(O)-Ci_6-alkyl, -S(O)2-Ci_6-alkyl, -S(O)2- NR1R11;
R1 and R11 are H, C1-6-alkyl, Ci_6-alkyl-NRmRlv, -(CO)O-C1-6-alkyl, -C(O)-NRmRlv, -C(O)- Ci_6-alkyl, -S(O)2-Ci_6-alkyl or -S(O)2- NR1UR1V;
R111 and R1V are H or C1-6-alkyl; m is 1 to 6; n is O to 4; as well as pharmaceutically acceptable salts thereof.
In another embodiment, the compounds of formula (I) are those compounds wherein:
A is selected from (a), (b), (c), (d) or (e), and wherein R1 is H, or is Ci-6- alkyl, or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl which are optionally substituted by one or more B, or is -(CH2)m-Ra wherein Ra is: CN, NR1R11, C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb or -(CH2),,- (SO2) -Rb, wherein Rb is: C1-O- alkoxy, NR1R11, 4 to 7 membered-heterocycloalkyl, aryl, which are optionally substituted by one or more B, or R1 and R3 together with the indole ring to which they are attached form a 5 or
6 membered heterocycloalkyl which can be substituted by (CO);
R2 is one or more of H, OH, halo, C1-6- alkyl optionally substituted by -NRmRlv, C1-6- alkoxy;
R3 is H, or is -(CO)-RC, wherein Rc is: -(CH2VNR1R11, -(CH2)n-NRmRlv, 5 or 6 membered heterocycloalkyl optionally substituted by C1-6- alkyl, or is Ci-ό-alkyl or aryl, which are optionally substituted by halo, R4, R5 and R6 are H;
R7 is H or -SO2-R6 wherein Re is Ci-ό-alkyl or aryl;
B is halo, NH2, Q-o-alkyl optionally substituted by CN or Q-ό-alkoxy, Q-ό-alkoxy, Ci-e-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1_6-alkyl, -(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci-ό-alkyl optionally substituted by CN or halo, Q-ό-alkoxy;
R1 and R11 are H, Ci_6-alkyl, Ci_6-alkyl-NRmRlv, -(CO)O-Ci_6-alkyl, -C(O)-NRmRlv, -C(O)- Ci_6-alkyl, -S(O)2-Ci_6-alkyl or -S(O)2- NR1UR1V;
R111 and R1V are H or Ci_6-alkyl; m is 1 to 6; n is O to 4; as well as pharmaceutically acceptable salts thereof.
In another embodiment, the compound of formula (I) are those compounds wherein:
A is selected from (a), (b), (c), (d) or (e), and wherein R1 is H or,
Ci-ό-alkyl optionally substituted by CN or, Ci-6- alkoxy or, aryl or,
5 or 6 membered heteroaryl or, sulfonylaryl or,
-(CH2)m-Ra wherein Ra is C3_6-cycloalkyl, 5 or 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more substituents selected from the group consisting of: halo, CN, Ci_6-alkyl, Q-ό-alkoxy, Q-ό-haloalkoxy, -C(O)O-C1_6-alkyl and phenyl optionally substituted by halo, Q-o-alkyl, Ci-ό-haloalkyl or C1-O- alkoxy, -(CH2)I11-NR1R11 or,
-(CH2)n-(CO)-Rb, wherein Rb is aryl or 5 or 6 membered-heterocycloalkyl; R2 is one or more of H, halo, CN, nitro, C^-allcyl, C1-6- alkoxy, -O-CH2-C2_6-alkenyl, benzyloxy, or two R2 may form an oxo or dioxo bridge together with the indole ring to which they are attached; R3 is H or, - - halo or,
-(CO)-RC, wherein Rc is C1-6- alkyl, 5 or 6 membered heterocycloalkyl optionally substituted by C1-6-alkyl, or Rc is -(CH2VNR1R11 or, Ci-ό-alkyl or aryl, which are optionally substituted by: -O(CO)-C1_6-alkyl, or by-NH(CO)Rd, wherein Rd is C^-alky! optionally substituted by halo or nitro, or Rd is aryl or a 5 or 6 membered heteroaryl, which are optionally substituted by halo, nitro, C^-allcyl or Q-ό-haloalkyl; R4 is one or more of H, halo, Ci_6- alkyl or Q-ό-alkoxy or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
R5 is H, Ci_6- alkyl or aryl;
R6 is H or Q-β-alkyl;
R7 is H or -SO2-R6 wherein Re is Ci_6-alkyl or aryl;
R1 and R11 are independently selected from H, C^-alky! or -(CO)O-C1_6-alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
As it can be seen from the definition of A in the compounds of formula (I), said compounds of formula (I) encompass the compounds of formulae (I- a), (I-b), (I-c), (I- d) , (I-e) , (I-f) , (I-g) and (I-h) as follows:
Figure imgf000014_0001
- -
Figure imgf000015_0001
- -
Figure imgf000016_0001
- -
Figure imgf000017_0001
wherein R1 to R8 and X are as defined hereinabove in connection with formula (I).
In a certain embodiment the compounds of the invention are those compounds of formula (I- a):
Figure imgf000017_0002
wherein the dotted line is either nil or a double bond; R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is sulfonylaryl, or is -(CH2)m-Ra wherein Ra is:
OR1, CN, NR1R11,
C3-6-cycloalkyl, 3 to 6 membered-heterocycloalkyl, aryl or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb, wherein Rb is: Ci-6- alkoxy, NR1R11,
6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B; R2 is one or more of H, halo, C1-6- alkyl; R3 is H, or is Ci-6- alkyl, or is -(CO)-RC, wherein Rc is: Ci_6-alkyl -(CHz)n-NR1R11, R4 is is one or more of H, halo, or Q-ό-alkoxy optionally substituted by OH, or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached; R5 is H; R6 is H; B is halo, CN, Q-o-alkyl optionally substituted by CN or Q-ό-alkoxy, Q-ό-alkoxy, C1- 6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, -(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, C1-6- alkyl optionally substituted by CN or halo, C1-6- alkoxy; R1 and R11 are H, C1-6-alkyl, Ci_6-alkyl-NRmRlv, -C(O)-C1-6-alkyl, -S(O)2-Ci_6-alkyl or OH; R111 and R1V are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
Further, in a certain embodiment the compounds of the invention are those compounds of formula (I- a) as described above, wherein R1 is H or,
-(CH2)m-Ra wherein Ra is aryl which is optionally substituted by one or more substituents selected from the group consisting of: halo, CN, C1-6-a]kyl, Ci_6-alkoxy, Ci-e-haloalkoxy, -C(O)O-C1_6-alkyl and phenyl optionally substituted by halo, C1-6- alkyl, Ci-ό-haloalkyl or C1-O- alkoxy; R2 is H or halo; R3 is H or Q-6-alkyl; and R4, R5 and R6 are H; - - m is 1 to 6; as well as pharmaceutically acceptable salts thereof.
The following compounds are examples according to the invention: l'-[( 1-benzyl- 2-methyl-lH-indol-3-yl)carbonyl]spiro[indene-l,4'-piperidine] ;
1'- [(1-benzyl- 2-methyl-lH-indol-3-yl)carbonyl]-2,3-dihydrospiro[in dene- 1,4'- piperidine] ; l'-[( 1-benzyl- lH-indol-3-yl)carbonyl]spiro[indene-l,4'-piperidine] ; r-[(2-methyl-lH-indol-3-yl)carbonyl]spiro[indene-l,4'-piperidine] ; r-[(6-chloro-lH-indol-3-yl)carbonyl]spiro[indene-l,4'-piperidine] ; and r-[(6-chloro-lH-indol-3-yl)carbonyl]-2,3-dihydrospiro[indene-l,4'-piperidine].
In a certain embodiment the compounds of the invention are those compounds of formula (I-b):
Figure imgf000019_0001
R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is sulfonylaryl, or is -(CH2)m-Ra wherein Ra is:
OR1,
CN,
NR1R11,
C3-6-cycloalkyl, 3 to 6 membered-heterocycloalkyl, aryl or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb, wherein Rb is:
Ci-6- alkoxy,
NR1R11, 5 or 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B; R2 is one or more of H, halo, C1-6- alkyl; R3 is H, or is Ci-6- alkyl, or is -(CO)-RC, wherein Rc is: Ci_6-alkyl -(CHz)n-NR1R11,
R4 is is one or more of H, halo, or Q-ό-alkoxy optionally substituted by OH, or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached; R6 is H;
R7 is H or -SO2-R6 wherein Re is Ci_6-alkyl or aryl;
B is halo, CN, Ci-ό-alkyl optionally substituted by CN or Q-ό-alkoxy, Q-ό-alkoxy, C1- 6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1_6-alkyl, -(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, C1-6- alkyl optionally substituted by CN or halo, C1-6- alkoxy;
R1 and R11 are H, C1-6-alkyl, Ci_6-alkyl-NRmRlv, -C(O)-C1-6-alkyl, -S(O)2-Ci_6-alkyl or OH; R111 and R1V are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
Further, in a certain embodiment the compounds of the invention are those compounds of formula (I-b) as described above, wherein R1 is H, or is -(CH2)m-Ra wherein Ra is aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more subsituents selected from the group consisting of: halo, CN, C1-6- alkyl, C1-6- alkoxy, C1-6-haloalkoxy, -C(O)O-C1-6-alkyl and phenyl optionally substituted by halo, Ci-ό-haloalkyl or C1-6- alkoxy, or is -(CH2)I11-NR1R11, or is -(CH2)n-(CO)-Rb, wherein Rb is aryl or 5 or 6 membered-heterocycloalkyl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb wherein Rb is NR1R11, R2 is H or halo;
R3 is H or C1-6- alkyl; R4 is H or halo; R6 is H;
R7 is H or -SO2-R6 wherein Re is Ci_6-alkyl or aryl;
B is halo, NH2, Q-o-alkyl optionally substituted by CN or Q-ό-alkoxy, Q-ό-alkoxy, Ci-e-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1_6-alkyl, -(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci-ό-alkyl optionally substituted by CN or halo, Q-ό-alkoxy; R1, R11 are independently selected from H or C1-6- alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
In another embodiment thereof,
R1 is H or,
-(CH2)m-Ra wherein Ra is aryl which is optionally substituted by one or more sub situ ents selected from the group consisting of: halo, CN, Q-6-alkyl, Ci_6-alkoxy, Ci-e-haloalkoxy, -C(O)O-C1_6-alkyl and phenyl optionally substituted by halo, Ci-ό-haloalkyl or Q-ό-alkoxy;
R2 is H or halo;
R3 is H or C1-6- alkyl;
R4 is H or halo; R6 is H;
R7 is H or -SO2-R6 wherein Re is C1-6-alkyl; m is 1 to 6; as well as pharmaceutically acceptable salts thereof.
The following compounds are examples according to the invention:
l'-[( l-benzyl-2-methyl- lH-indol-3-yl)carbonyl] - l-(methylsulfonyl)- 1,2- dihydrospiro[indole-3,4'-piperidine] ; r-{[6-chloro-l-(3-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-l,2-dihydrospiro[indole-
3,4'-piperidine] ; l'-{[6-chloro-l-(2-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-l,2-dihydrospiro[indole-
3,4'-piperidine] ; r-lfo-chloro-l-CS^-difluorobenzoyO-lH-indol-S-yljcarbonylJ-l^-dihydrospirofindole-
3,4'-piperidine] ; l'-{[6-chloro-l-(2,3-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-l,2-dihydrospiro[indole-
3,4'-piperidine] ; l'-({6-chloro-l-[(3,5-difluorophenyl)sulfonyl]-lH-indol-3-yl}carbonyl)-l,2- dihydrospiro[indole-3,4'-piperidine] ;
2-[6-chloro-3-(l,2-dihydro-lΗ-spiro[indole-3,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl]-l-(3,5-difluorophenyl)ethanone;
2-[6-chloro-3-(l,2-dihydro-lΗ-spiro[indole-3,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] - l-(3,4-difluorophenyl)ethanone;
2-[6-chloro-3-(l,2-dihydro-lΗ-spiro[indole-3,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] - l-(2-fluorophenyl)ethanone; 2-[6-chloro-3-(l,2-dihydro-lΗ-spiro[indole-3,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl]-N,N-diethylethanamine; and r-{[6-chloro-l-(pyridin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-l,2-dihydrospiro[indole-
3,4'-piperidine].
Preferred are the following compounds: l'-[(6-chloro-lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'-piperidine] ; l'-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'- piperidine] ; r-lfo-chloro-l-CS^-difluorobenzy^-lH-indol-S-yljcarbonylJ-l^-dihydrospirofindole- 3,4'-piperidine] ; l'-{[6-chloro-l-(3-fluorobenzyl)-lH-indol-3-yl]carbonyl}-l,2-dihydrospiro[indole-3,4'- piperidine] ;
2-[6-chloro-3-(l,2-dihydro-lΗ-spiro[indole-3,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] -N,N-diethylacetamide; 2-[6-chloro-3-(l,2-dihydro-lΗ-spiro[indole-3,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] -N,N-dimethylacetamide;
2-[6-chloro-3-(l,2-dihydro-lΗ-spiro[indole-3,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] - l-pyridin-2-ylethanone; r-{[6-chloro-l-(pyridin-3-ylmethyl)-lH-indol-3-yl]carbonyl}-l,2-dihydrospiro[indole- 3,4'-piperidine] ; - -
In a certain embodiment the compounds of the invention are those compounds of formula (I-c):
Figure imgf000023_0001
R1 is H, or is C1-6- alkyl optionally substituted by CN, or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl which are optionally substituted by one or more B, or is -(CH2)m-Ra wherein Ra is: OR1, CN, NR1R11, C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb wherein Rb is: Ci-6- alkoxy, NR1R11, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or R1 and R3 together with the indole ring to which they are attached form a 5 or
6 membered heterocycloalkyl which can be substituted by =0;
R2 is one or more of H, halo, C^-alky! optionally substituted by-NRmRlv, C1-6- alkoxy;
R3 is H, or is Ci-6- alkyl, or is halo, or is -(CO)-RC, wherein Rc is: C1-6- alkyl, -(CHz)n-NR1R11, -(CH2)n-NRmRlv,
5 or 6 membered heterocycloalkyl optionally substituted by Ci-ό-alkyl; R4 is one or more of H, halo, or Q-ό-alkoxy optionally substituted by OH, or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
B is halo, NH2, Q-o-alkyl optionally substituted by CN or Q-ό-alkoxy, Q-ό-alkoxy, Ci-e-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1_6-alkyl, -(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci-ό-alkyl optionally substituted by CN or halo, Q-ό-alkoxy; R1 and R11 are H, C1-6-alkyl, Ci_6-alkyl-NRmRlv, -(CO)O-C1-6-alkyl, -C(O)-NRmRlv, -C(O)-
Ci_6-alkyl, -S(O)2-Ci_6-alkyl, -S(O)2- NRmRlv; R111 and R1V are H or C1-6-alkyl; m is 1 to 6; n is O to 4; as well as pharmaceutically acceptable salts thereof.
In a further embodiment thereof, R1 is H or,
C1-6-alkyl optionally substituted by CN or,
-(CH2)m-Ra wherein Ra is aryl which is optionally substituted by one or more sub situ ents selected from the group consisting of: halo, CN, C1-6- alkyl, C1-6- alkoxy, C1-6-haloalkoxy, -C(O)O-C1-6-alkyl and phenyl optionally substituted by halo, Ci-ό-haloalkyl or Q-ό-alkoxy;
R2 is H or halo; R3 is H, C1-6- alkyl or,
-(CO)-RC, wherein Rc is 5 or 6 membered heterocycloalkyl optionally substituted by Q-6-alkyl, or Rc is - (CH2VNR1R11; R4 is H, halo, Ci_6- alkoxy or two R4 may form a dioxo bridge together with the phenyl ring to which they are attached;
R1 and R11 are independently selected from H, Ci-ό-alkyl and -(CO)O-C1_6-alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
The following compounds are examples according to the invention: r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-
3-one;
4- {6-chloro-3- [(3-OXO- l'H,3H-spiro[2-benzofuran- l,4'-piperidin] - l'-yl)carbonyl] - IH- indol- l-yl}butanenitrile; 2- {6-chloro-3- [(3-oxo- l'H,3H-spiro[2-benzofuran- l,4'-piperidin] - l'-yl)carbonyl] - IH- indol- l-yl}propanenitrile; r-({l-[2-(3,4-dimethoxyphenyl)ethyl]-5-methoxy-2-methyl-lH-indol-3-yl}carbonyl)-
3H-spiro[2-benzofuran-l,4'-piperidin] -3-one; l'-{[l-(4-ethoxyphenyl)-5-methoxy- 2- methyl- lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one;
5-bromo-r-{[6-chloro-l-(2-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one;
5-bromo-l'-{[6-chloro-l-(2,3-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one; S-bromo-l'-do-chloro-l-fCS^-difluoropheny^sulfonyy-lH-indol-S-ylJcarbony^-SH- spiro[2-benzofuran-l,4'-piperidin] -3-one; and l'-[(l-biphenyl-3-yl-6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidin] -3-one.
Preferred are the following compounds: l'-[(6-chloro-lH-indol-3-yl)carbonyl]-6-methoxy-3H-spiro[2-benzofuran-l,4'- piperidin] -3-one;
6-chloro-r-[(6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-
3-one; r-({6-chloro-2-[(4-methylpiperidin-l-yl)carbonyl]-lH-indol-3-yl}carbonyl)-5-fluoro-
3H-spiro[2-benzofuran-l,4'-piperidin] -3-one;
6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indole-2-carboxamide;
6-chloro-N-[2-(dimethylamino)ethyl]-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran- l,4'-piperidin] - l'-yl)carbonyl] - lH-indole-2-carboxamide; l'-{[6-chloro-2-(piperazin-l-ylcarbonyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one; r-{[6-chloro-2-(morpholin-4-ylcarbonyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin] -3-one; r-({6-chloro-2-[(4-methylpiperazin-l-yl)carbonyl]-lH-indol-3-yl}carbonyl)-5-fluoro-
3H-spiro[2-benzofuran-l,4'-piperidin] -3-one; l'-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-5-bromo-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one;
S-bromo-r-fCθ-chloro-lH-indol-S-y^carbonyy-SH-spirofl-benzofuran-l^'-piperidin]-
3-one; l'-{[6-chloro-l-(3-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'- piperidin] -3-one; l'-{[6-chloro-l-(2-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'- piperidin] -3-one; l'-{[6-chloro-l-(2,3-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- 1,4' -piperidin] -3-one; r-({6-chloro-l-[(3,5-difluorophenyl)sulfonyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one; r-{[6-chloro-l-(3-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one; r-{[6-chloro-l-(2-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one; r-{[6-chloro-l-(3,5-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one; l'-{[6-chloro-l-(2,3-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one; r-({6-chloro-l-[(3,5-difluorophenyl)sulfonyl]-lH-indol-3-yl}carbonyl)-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin] -3-one;
5-bromo-r-{[6-chloro-l-(3-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one; 5-bromo-r-{[6-chloro-l-(3,5-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one; l'-[(l-biphenyl-2-yl-6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidin] -3-one; l'-{[l-(biphenyl-3-ylcarbonyl)-6-chloro-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one; l'-[(l- {[4- amino-2-(methoxymethyl)pyrimidin-5-yl] methyl }-6-chloro-lH-indol-3- yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin] -3-one; r-({l-[(4-amino-2-methylpyrimidin-5-yl)methyl]-6-chloro-lH-indol-3-yl}carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin] -3-one; r-tCT-chloro-l-oxo-l^^^-tetrahydropyrazinof l^-aJindol-lO-y^carbonyy-S-fluoro-
3H-spiro[2-benzofuran-l,4'-piperidin] -3-one; - D - l'-( {6-chloro- 1-[( l,4-dibenzylpiperazin-2-yl)methyl] - lH-indol-3-yl}carbonyl)-5-fluoro- 3H-spiro[2-benzofuran-l,4'-piperidin]-3-one;
6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-l'- yl)carbonyl] -N-methyl- lH-indole-2-carboxamide; 6-chloro-3-[(5-fluoro-3-oxo-rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'- yl)carbonyl] -N- [2-(methylamino)ethyl]-lH-indole-2-carboxamide hydrochloride; 2-{6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- l-yl}-N-[2-(dimethylamino)ethyl] acetamide; and 2- {6-chloro-3- [(3-oxo- l'H,3H-spiro[2-benzofuran- l,4'-piperidin] - l'-yl)carbonyl] - IH- indol-l-yl}-N-[2-(dimethylamino)ethyl] acetamide.
Particularly preferred are the following compounds: r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-6-chloro-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one; r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-4-fluoro-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one; l'-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-6-methoxy-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one; l'-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-5-methoxy-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one; r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-7-chloro-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one; r-[(6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; r-[(6-chloro-lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]- 3-one; r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'- piperidin] -3-one;
6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] -N,N- dimethyl- lH-indole-2-carboxamide; tert-butyl {2-[({6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'- piperidin] - l'-yl)carbonyl] - lH-indol-2-yl}carbonyl) amino] ethyl Jmethylcarbamate;
6-chloro-N,N-diethyl-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indole-2-carboxamide; r-{[6-chloro-2-(piperidin-l-ylcarbonyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one; r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-7H-spiro[furo[3,4-f] [l,3]benzodioxole-
5,4'-piperidin] -7-one;
3- {6-chloro-3- [(3-OXO- l'H,3H-spiro[2-benzofuran- l,4'-piperidin] - l'-yl)carbonyl] - IH- indol- l-yl}propanenitrile; {6-chloro-3-[(3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-yl)carbonyl]-lH- indol- l-yl}acetonitrile; l'-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-6-(2-hydroxyethoxy)-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]- 3-one; l'-{[6-chloro-l-(3,5-difluorophenyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one; l'-{[6-chloro-l-(3,5-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one; l'-{[6-chloro-l-(3,5-difluorobenzyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one; l'-{[6-chloro-l-(3-fluorobenzyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'- piperidin] -3-one; l'-({6-chloro-l-[2-(3-fluorophenyl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one; l'-({6-chloro-l-[2-(2,5-difluorophenyl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidin] -3-one; l'-{[6-chloro-l-(3,5-difluorobenzyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one; l'-{[6-chloro-l-(3-fluorobenzyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one; l'-({6-chloro-l-[2-(3-fluorophenyl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin] -3-one;
5-bromo-l'-{[6-chloro-l-(3,5-difluorobenzyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one;
5-bromo-r-{[6-chloro-l-(3-fluorobenzyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one;
5-bromo-l'-({6-chloro-l-[2-(3-fluorophenyl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidin] -3-one; l'-({6-chloro-l-[2-(2-fluorophenyl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran-l,4'-piperidin] -3-one; - o - l'-({6-chloro-l-[2-(3,4-difluorophenyl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; r-lfό-chloro-l-CS-fluoropheny^-lH-indol-S-yllcarbonylJ-SH-spirofl-benzofuran-l,^- piperidin]-3-one; r-{[6-chloro-l-(2-oxo-2-piperidin-l-ylethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; r-{[6-chloro-l-(2-morpholin-4-yl-2-oxoethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one;
2- {6-chloro-3- [(3-OXO- l'H,3H-spiro[2-benzofuran- l,4'-piperidin] - l'-yl)carbonyl] - IH- indol- l-yl}-N,N-dimethylacetamide;
2- {6-chloro-3- [(3-oxo- l'H,3H-spiro[2-benzofuran- l,4'-piperidin] - l'-yl)carbonyl] - IH- indol-l-yl}-N,N-diethylacetamide; r-{[6-chloro-l-(piperidin-l-ylcarbonyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; tert-butyl {6-chloro-3-[(3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- l-yl}acetate; r-[(6-chloro-l-pyridin-2-yl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one; l'-[(6-chloro-l-pyridin-2-yl-lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one; r-({6-chloro-l-[(2-methylpyridin-4-yl)methyl]-lH-indol-3-yl}carbonyl)-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; r-({6-chloro-l-[(6-chloropyridin-3-yl)methyl]-lH-indol-3-yl}carbonyl)-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; r-({6-chloro-l-[(3-chloro-6-methylpyridazin-4-yl)methyl]-lH-indol-3-yl}carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; r-{[6-chloro-l-(pyridin-4-ylmethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; l'-{[6-chloro-l-(2-pyridin-4-ylethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; r-{[6-chloro-l-(pyridin-4-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one; l'-{[6-chloro-l-(2-oxo-2-pyridin-2-ylethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-({6-chloro-l-[2-(5-methyl-2-phenyl-l,3-oxazol-4-yl)-2-oxoethyl]-lH-indol-3- yl}carbonyl)-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; r-{[6-chloro-l-(pyridin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; l-lό-chloro-S-fCS-fluoro-S-oxo-lΗ^H-spirofl-benzofuran-l^'-piperidin]-!'- yl)carbonyl] - lH-indol- l-yl}-N,N-dimethylacetamide; r-({6-chloro-l-[2-(dimethylamino)ethyl]-lH-indol-3-yl}carbonyl)-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; r-{[6-chloro-l-(pyridin-3-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one; r-{[6-chloro-l-(pyrazin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; r-{[6-chloro-l-(pyrimidin-5-ylmethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one;
3-{6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-l'- yl)carbonyl] - lH-indol- l-yl}propanenitrile; tert-butyl {6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- l-yl}acetate; l'-{[6-chloro-l-(2-morpholin-4-yl-2-oxoethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; r-({l-[(4-benzylmorpholin-2-yl)methyl]-6-chloro-lH-indol-3-yl}carbonyl)-5-fluoro- 3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; r-({6-chloro-l-[(5-methylisoxazol-3-yl)methyl]-lH-indol-3-yl}carbonyl)-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-({6-chloro-l-[2-(4-methylpiperazin-l-yl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; r-{[6-chloro-l-(pyridin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one; l'-( {6-chloro- l-[(5-cyclopropyl-2-methyl- l,3-oxazol-4-yl)methyl] - lH-indol-3- yl}carbonyl)-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-( {6-chloro- 1-[( 1 -methyl- lH-imidazol-5-yl)methyl] - lH-indol-3-yl}carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-( {6-chloro- l-[(3-methylisoxazol-5-yl)methyl] -lH-indol-3-yl }carbonyl)-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-({6-chloro-l-[(l,5-dimethyl-lH-pyrazol-3-yl)methyl]-lH-indol-3-yl}carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-( {6-chloro- l-[(3,5-dimethylisoxazol-4-yl)methyl] -lH-indol-3-yl }carbonyl)-5-fluoro-
3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; r-({6-chloro-l-[(2,5-dimethyl-l,3-oxazol-4-yl)methyl]-lH-indol-3-yl}carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-({6-chloro-l-[(3-fluorooxetan-3-yl)methyl]-lH-indol-3-yl}carbonyl)-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; r-({6-chloro-l-[(3-fluorooxetan-3-yl)methyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; l'-[(6-chloro- 1- {[ l-(methoxymethyl)-cyclopropyl]methyl}- lH-indol-3-yl)carbonyl] -5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one;
[l-({6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-l'- yl)carbonyl] - lH-indol- l-yljmethy^cyclopropyl] acetonitrile; l'-[(6-chloro- 1- {[ l-(methoxymethyl)-cyclopropyl]methyl}- lH-indol-3-yl)carbonyl] -3H- spiro[2-benzofuran-l,4'-piperidin]-3-one;
[l-({6-chloro-3- [(3-OXO- lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-yl)carbonyl]- IH- indol- l-yl}methyl)cyclopropyl] acetonitrile; r-({6-chloro-l-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-lH-indol-3-yl}carbonyl)-5-fluoro-
3H-spiro[2-benzofuran- l,4'-piperidin] -3-one hydrochloride; l'-({6-chloro-l-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidin] -3-one; tert-butyl 2-({6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]- l'-yl)carbonyl] - lH-indol- l-yl}methyl)morpholine-4-carboxylate; tert-butyl 2-({6-chloro-3-[(3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-l'- yl)carbonyl] - lH-indol- l-yl}methyl)morpholine-4-carboxylate; r-{[6-chloro-l-(morpholin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran- l,4'-piperidin] -3-one dihydrochloride; r-{[6-chloro-l-(morpholin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidin] -3-one hydrochloride;
2-{6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- l-yl}acetamide;
2-{6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- l-yl}-N-methylacetamide; l'-{[6-chloro-l-(2-oxo-2-piperazin-l-ylethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin] -3-one; r-{[l-(3,5-difluorobenzyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one; r-{[l-(3,5-difluorobenzyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'- piperidin] -3-one; - -
N,N-diethyl-2-{3-[(3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-yl)carbonyl]- lH-indol-l-yl}acetamide; and
2-{6-chloro-5-methyl-3-[(3-oxo-lΗ,3H-spiro[2-benzomran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- l-yl}-N,N-dimethylacetamide.
In a certain embodiment the compounds of the invention are those compounds of formula (I- d):
Figure imgf000032_0001
wherein R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl which are optionally substituted by one or more B, or is -(CH2)m-Ra wherein Ra is: OR1,
CN, NR1R11, C3_6-cycloalkyl, 3 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2)n- (CO) -Rb wherein Rb is:
Ci-6- alkoxy, NR1R11, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or R1 and R3 together with the indole ring to which they are attached form a 5 or
6 membered heterocycloalkyl which can be substituted by C(O)O-C1_6-alkyl or Ci-6- alkyl; R2 is one or more of H, halo, Ci_6- alkyl, Q-ό-alkoxy; R3 is H, or is Ci-6- alkyl, or is -(CO)-RC, wherein Rc is C1-6-alkyl, or -(CH2)D-NR1R11; R4 is one or more of H, halo, or Q-ό-alkoxy optionally substituted by OH, or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
R5 is H or aryl;
B is halo, NH2, Ci-ό-alkyl optionally substituted by CN or Q-ό-alkoxy, Q-ό-alkoxy, Ci-e-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, -(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, C1-6- alkyl optionally substituted by CN or halo, Q-ό-alkoxy; R1 and R11 are H, C1-6-alkyl, Ci_6-alkyl-NRmRlv, -(CO)O-C1-6-alkyl, -C(O)-NRmRlv, -C(O)- Ci_6-alkyl, -S(O)2-Ci_6-alkyl, -S(O)2- NRmRlv or OH;
R111 and R1V are H or C1-6-alkyl; m is 1 to 6; n is O to 4; as well as pharmaceutically acceptable salts thereof.
In a further embodiment thereof, R1 is H or,
Ci-ό-alkyl optionally substituted by CN or,
-(CH2)m-Ra wherein Ra is C3_6-cycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more substituents selected from the group consisting of: halo, CN, C1-6- alkyl, C1-6- alkoxy, -C(O)O-C1-6-alkyl and phenyl optionally substituted by halo, C1-6- alkyl Ci-ό-haloalkyl or C1-6- alkoxy, -(CH2)I11-NR1R11 or, -(CH2V (CO) -Rb, wherein Rb is aryl;
R2 is H, halo or C1-6- alkoxy;
R3 is H or,
-(CO)-RC, wherein Rc is Ci_6-alkyl or,
Ci_6-alkyl;
R4 is H or halo;
R5 is H or aryl; R1 and R11 are C1-6-alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
The following compounds are examples according to the invention: r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-3-phenyl-3H-spiro[2-benzofuran-l,4'- piperidine] ; l'-[(l-benzyl-5-methoxy- 2-methyl- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran- l,4'-piperidine] ; r-[(l-{[2-(4-chlorophenyl)-l,3-thiazol-4-yl]methyl}-2-methyl-lH-indol-3-yl)carbonyl]-
3H-spiro[2-benzofuran-l,4'-piperidine] ; r-[(l-{[2-(4-chlorophenyl)-l,3-thiazol-4-yl]methyl}-2-methyl-lH-indol-3-yl)carbonyl]-
3H-spiro[2-benzofuran-l,4'-piperidine] ; 1'- {[2-methyl- 1-( {5-methyl-2-[3-(trifluoromethyl)phenyl] - l,3-oxazol-4-yl}methyl)- IH- indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'-piperidine] ; r-[(l-{[2-(2-fluorophenyl)-5-methyl-l,3-oxazol-4-yl]methyl}-2-methyl-lH-indol-3- yl)carbonyl] -3H-spiro[2-benzofuran- l,4'-piperidine] ; l'-[(l-{[2-(4-isopropylphenyl)-5-methyl-l,3-oxazol-4-yl]methyl}-2-methyl-lH-indol-3- yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] ; l'-[(l-{[2-(4-ethylphenyl)-5-methyl-l,3-oxazol-4-yl]methyl}-2-methyl-lH-indol-3- yl)carbonyl] -3H-spiro[2-benzofuran- l,4'-piperidine] ; r-[(2-methyl-l-{[5-methyl-2-(2-methylphenyl)-l,3-oxazol-4-yl]methyl}-lH-indol-3- yl)carbonyl] -3H-spiro[2-benzofuran- l,4'-piperidine] ; 1'- {[2-methyl- 1-( {5-methyl-2-[4-(trifluoromethyl)phenyl] - l,3-oxazol-4-yl}methyl)- IH- indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'-piperidine] ;
1'- {[2-methyl- 1-( {5-methyl-2-[2-(trifluoromethyl)phenyl] - l,3-oxazol-4-yl}methyl)- IH- indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'-piperidine] ; r-[(5-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] ; r-[(l-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] ; r-(lH-indol-3-ylcarbonyl)-3H-spiro[2-benzofuran-l,4'-piperidine] ;
2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] propanenitrile;
3-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] propanenitrile; 4-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl]butanenitrile; r-dό-chloro-l-fCB^-difluoropheny^sulfonyy-lH-indol-S-ylJcarbony^-SH-spirofl- benzofuran- l,4'-piperidine] ; l'-lf l-φiphenyl-S-ylcarbony^-ό-chloro-lH-indol-S-yycarbonylJ-SH-spirofl- benzofuran- l,4'-piperidine] ; l'-[(l-biphenyl-2-yl-6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidine] ; l'-[(l-biphenyl-2-yl-6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidine] ; r-dό-chloro-l-fCl^-dibenzylpiperazin^-y^methyy-lH-indol-S-ylJcarbony^-SH- spiro[2-benzofuran- 1,4' -piperidine] ; tert-butyl 10-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyi)-3,4- dihydropyrazino[l,2-a]indole-2(lH)-carboxylate; and r-dl-CS^-bisCtrifluoromethy^benzyy-ό-chloro-l-methyl-lH-indol-S-ylJcarbony^-SH- spiro[2-benzofuran- 1,4' -piperidine] .
The following compounds are preferred examples according to the invention:
1'- [(1-benzyl- 2- methyl- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran- 1,4'- piperidine] ; l'-[( 1-benzyl- 2-methyl-lH-indol-3-yl)carbonyl]-6-chloro-3H-spiro[2-benzofuran- 1,4'- piperidine] ; l'-[(2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] ;
1'- [(1-benzoyl- 2- methyl- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran- 1,4'- piperidine] ;
1'- {[2- methyl- l-(phenylsuhconyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- 1,4'- piperidine] ; l'-{[l-(cyclohexylmethyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-
1,4' -piperidine] ; r-{[l-(3-fluorobenzyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'- piperidine] ; r-({2-methyl-l-[2-(trifluoromethoxy)benzyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran- 1,4' -piperidine] ; l'-{[l-(3,5-dimethylbenzyl)-2- methyl- lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- 1,4' -piperidine] ; methyl 4- {[2-methyl-3-( l'H,3H-spiro[2-benzofuran- l,4'-piperidin] - l'-ylcarbonyl)- IH- indol-1-yl] methyl Jbenzoate;
4- {[2-methyl-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]- l'-ylcarbonyl)- lH-indol-1- yl] methyl Jbenzonitrile; l'-{[l-(3,5-difluorobenzyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine] ; l'-{[l-(2-chlorobenzyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'- piperidine] ; l'-{[l-(2-methoxybenzyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine] ; l'-{[l-(4-methoxybenzyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine] ; r-[(l-{[2-(2-methoxyphenyl)-5-methyl-l,3-oxazol-4-yl]methyl}-2-methyl-lH-indol-3- yl)carbonyl] -3H-spiro[2-benzofuran- l,4'-piperidine] ; r-[(l-benzyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] ; r-[(6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] ;
N,N-dimethyl-2-[3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH- indol-l-yl]ethan amine;
2-methyl-l-[3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-2- yl]butan-l-one;
[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin] -l'-ylcarbonyl)- lH-indol-1- yl] acetonitrile; l'-{[6-chloro-l-(3-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'- piperidine] ; l'-{[6-chloro-l-(2-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'- piperidine] ; l'-{[6-chloro-l-(3,5-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine] ; l'-{[6-chloro-l-(2,3-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine] ; l'-{[6-chloro-l-(3,5-difluorobenzyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine] ; l'-{[6-chloro-l-(3-fluorobenzyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'- piperidine] ; l'-{[6-chloro-l-(2-oxo-2-piperidin-l-ylethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; - JO - l'-{[6-chloro-l-(2-morpholin-4-yl-2-oxoethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ;
2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] -N,N-dimethylacetamide; 2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] -N,N-diethylacetamide; r-{[6-chloro-l-(piperidin-l-ylcarbonyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; tert-butyl [6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH- indol-1-yl] acetate; l'-{[6-chloro-l-(3,5-difluorophenyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine] ; l'-{[6-chloro-l-(3-fluorophenyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'- piperidine] ; 2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] - l-(2-fluorophenyl)ethanone; r-[(6-chloro-l-pyridin-2-yl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidine] ; r-{[6-chloro-l-(pyridin-4-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- 1,4' -piperidine] ;
2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] - l-pyridin-2-ylethanone; r-{[6-chloro-l-(pyridin-3-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-
1,4' -piperidine] ; r-{[6-chloro-l-(pyridin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-
1,4' -piperidine] ; r-{[6-chloro-l-(pyrazin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-
1,4' -piperidine] ; r-{[6-chloro-l-(pyrimidin-5-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- 1,4' -piperidine] ;
2-[6-chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)-lH-indol-l- yl] -N,N-dimethylethan amine; l'-{[6-chloro-l-(2-oxo-2-piperazin-l-ylethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- 1,4' -piperidine] ; r-({l-[(4-benzylmorpholin-2-yl)methyl]-6-chloro-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran- 1,4' -piperidine] ; r-({6-chloro-l-[(5-methylisoxazol-3-yl)methyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran- l,4'-piperidine] ; l'-({6-chloro-l-[2-(4-methylpiperazin-l-yl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran- l,4'-piperidine] ; 4-( 1- {l-[(2-cyclopropyl-4-methylcyclopenta- 1,4-dien- l-yl)methyl] -6-methyl- lH-inden-
3-yl}vinyl)-2',3'-dihydrospiro[cyclohexane-l,r-indene] ; r-dό-chloro-l-CCl-methyl-lH-imidazol-S-y^methyy-lH-indol-S-ylJcarbony^-SH- spiro[2-benzofuran- l,4'-piperidine] ; r-({6-chloro-l-[(3-methylisoxazol-5-yl)methyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran- l,4'-piperidine] ; l'-( {6-chloro- 1-[( 1,5- dimethyl- lH-pyrazol-3-yl)methyl] - lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran- l,4'-piperidine] ; l'-( {6-chloro- l-[(3,5-dimethylisoxazol-4-yl)methyl] - lH-indol-3-yl }carbonyl)-3H- spiro[2-benzofuran- l,4'-piperidine] ; r-({6-chloro-l-[(2,5-dimethyl-l,3-oxazol-4-yl)methyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran- l,4'-piperidine] ; l'-( {6-chloro- l-[(3-fluorooxetan-3-yl)methyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran- l,4'-piperidine] ; r-[(6-chloro-l-{[l-(methoxymethyl)-cyclopropyl]methyl}-lH-indol-3-yl)carbonyl]-3H- spiro[2-benzofuran- l,4'-piperidine] ;
(l-{[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] methyl Jcyclopropyl) acetonitrile; l'-({6-chloro-l-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran- l,4'-piperidine] ; tert-butyl 2-{[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)- lH-indol-1-yl] methyl }morpholine-4-carboxylate;
1'- {[6-chloro- l-(morpholin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] hydrochloride;
2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl]-N-[2-(dimethylamino)ethyl]acetamide;
2-[6-chloro-5-methyl-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH- indol- 1-yl] -N,N-dimethylacetamide;
2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] acetamide; 2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl]-N-[2-(methylamino)ethyl] acetamide; - o -
N-(2-aminoethyl)-2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- ylcarbonyl)- lH-indol- 1-yl] acetamide;
2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yljethan amine; 2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] -N-methylethan amine;
2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] -N-methylacetamide; l'-{[6-chloro-l-(2-morpholin-4-ylethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; l'-{[6-chloro-l-(3-morpholin-4-ylpropyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; r-{[6-chloro-l-(oxiran-2-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine] ; 2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yljethanol; r-({6-chloro-l-[(2-methylpyridin-4-yl)methyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran- l,4'-piperidine] ; r-({6-chloro-l-[(3S)-piperidin-3-ylmethyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran- l,4'-piperidine] ;
2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] -N-hydroxyethan amine; r-{[6-chloro-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; r-({6-chloro-l-[(l-methylpyrrolidin-3-yl)methyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran- l,4'-piperidine] ; r-[(6-chloro-l-{[(3S)-l-methylpiperidin-3-yl]methyl}-lH-indol-3-yl)carbonyl]-3H- spiro[2-benzofuran- l,4'-piperidine] ; r-{[6-chloro-l-(pyrrolidin-3-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; r-({6-chloro-l-[(2S)-pyrrolidin-2-ylmethyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran- l,4'-piperidine] ; r-[(6-chloro-2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidine] ; r-(l,2,3,4-tetrahydropyrazino[l,2-a]indol-10-ylcarbonyl)-3H-spiro[2-benzofuran-l,4'- piperidine] hydrochloride; - -
1'- [(2-methyl- 1,2,3,4- tetrahydropyrazino[ 1,2- a] indol- 10- yl)carbonyl] -3H-spiro[2- benzofuran- l,4'-piperidine] ; r-[(6-chloro-2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidine] ; N-{2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-
1-yl] ethyl Jacetamide;
N-{2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol- l-yl]ethyl}methanesulfonamide;
N-{2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol- 1-yl] ethyl }-N-methylacetamide;
N-{2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-
1-yl] ethyl }-N-methylmethanesulfonamide; r-[(6-chloro-l-{[(2S)-l-methylpyrrolidin-2-yl]methyl}-lH-indol-3-yl)carbonyl]-3H- spiro[2-benzofuran-l,4'-piperidine] ; and r-[(6-chloro-l-{[(2R)-l-methylpyrrolidin-2-yl]methyl}-lH-indol-3-yl)carbonyl]-3H- spiro[2-benzofuran- l,4'-piperidine] .
In a certain embodiment the compounds of the invention are those compounds of formula (I-e):
Figure imgf000040_0001
wherein R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is sulfonylaryl, or is -(CH2)m-Ra wherein Ra is:
OR1, CN, NR1R11,
C3_6-cycloalkyl, 3 to 6 membered-heterocycloalkyl, aryl or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb, wherein Rb is: Ci-6- alkoxy,
NR1R11, 5 or 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B; R2 is one or more of H, halo, C1-6- alkyl;
R3 is H, or is Ci-6- alkyl, or is -(CO)-RC, wherein R' ; is:
Ci-6-alkyl
-(CHz)n-NR1R11,
R4 is is one or more of H. halo. or may form an oxo or dioxo bridge together with the phenyl ring to which they are attached; R6 is H;
B is halo, CN, Q-o-alkyl optionally substituted by CN or Q-ό-alkoxy, Q-ό-alkoxy, C1- 6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, -(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci-ό-alkyl optionally substituted by CN or halo, Q-ό-alkoxy;
R1 and R11 are H, C1-6-alkyl, Ci-6-alkyl-NRmRlv, -C(O)-C1-6-alkyl, -S(O)2-Ci-6-alkyl or OH; R111 and R1V are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
Further, in a certain embodiment the compounds of the invention are those compounds of formula (I-e), wherein R1 is H or,
-(CH2)m-Ra wherein Ra is 5 or 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl or, -(CH2)I11-NR1R11 or, -(CH2)n-(CO)-Rb, wherein Rb is 5 or 6 membered-heterocycloalkyl; R2 is one or more of H or halo;
R3 is H, or is Ci-6- alkyl;
R4 is one or more of H or halo ; R6 is H;
R1 and R11 are C1-6-alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof. The following compounds are examples according to the invention: r-fCθ-chloro-lH-indol-S-y^carbonyy spirof l-benzofuran-S^'-piperidine] ; r-fCl-benzyl-l-methyl-lH-indol-S-y^carbonyy spirof l-benzofuran-S^'-piperidine] ; r-(lH-indol-3-ylcarbonyl)spiro[l-benzofuran-3,4'-piperidine] ; r-[(6-chloro-5-fluoro-lH-indol-3-yl)carbonyl] spiro[l-benzofuran-3,4'-piperidine] ; 2- [6-chloro-3-( l'H-spiro[ l-benzofuran-3,4'-piperidin] - l'-ylcarbonyl)- lH-indol- 1-yl] -
N,N-dimethylethan amine; r-{[6-chloro-l-(2-pyrrolidin-l-ylethyl)-lH-indol-3-yl]carbonyl}spiro[l-benzofuran-
3,4'-piperidine] ;
3- [6-chloro-3-( l'H-spiro[ l-benzofuran-3,4'-piperidin] - l'-ylcarbonyl)- lH-indol- 1-yl] - N,N-dimethylpropan-l-amine; r-{[6-chloro-l-(2-morpholin-4-ylethyl)-lH-indol-3-yl]carbonyl}spiro[l-benzofuran-
3,4'-piperidine] ;
2- [6-chloro-3-( l'H-spiro[ l-benzofuran-3,4'-piperidin] - l'-ylcarbonyl)- lH-indol- 1-yl] -
N,N-diethylethan amine; l'-({6-chloro-l-[2-(lH-pyrrol-l-yl)ethyl]-lH-indol-3-yl}carbonyl)spiro[l-benzofuran-
3,4'-piperidine] ; and l'-{[6-chloro-l-(2-oxo-2-piperidin-l-ylethyl)-lH-indol-3-yl]carbonyl}spiro[l- benzofuran-3,4'-piperidine] .
In a certain embodiment the compounds of the invention are those compounds of formula (I-f): - -
Figure imgf000043_0001
wherein R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is sulfonylaryl, or is -(CH2)m-Ra wherein Ra is: OR1, CN, NR1R11, C3_6-cycloalkyl, 3 to 6 membered-heterocycloalkyl, aryl or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb, wherein Rb is: Ci-6- alkoxy, NR1R11, 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B; R2 is one or more of H, halo, C1-6- alkyl; R3 is H, or is C1-O- alkyl, or is - (CO) -Rc, wherein Rc is:
Ci-6-alkyl -(CH2VNR1R11,
R4 is is one or more of H, halo, or Q-ό-alkoxy optionally substituted by OH, or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
B is halo, CN, Ci-ό-alkyl optionally substituted by CN or Q-ό-alkoxy, Q-ό-alkoxy, C1- 6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, -(CRmRlv)n-phenyl, wherein the - - phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci-ό-alkyl optionally substituted by CN or halo, Q-ό-alkoxy;
R1 and R11 are H, C1-6-alkyl, Ci_6-alkyl-NRmRlv, -C(O)-C1-6-alkyl, -S(O)2-Ci_6-alkyl or OH; R111 and R1V are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
Further, in a certain embodiment the compounds of the invention are those compounds of formula (I-f) , wherein
R1 is H;
R2 is one or more of H or halo;
R3 is H;
R4 is one or more of H or halo ; as well as pharmaceutically acceptable salts thereof.
The following compounds are examples according to the invention: 5-bromo-r-(lH-indol-3-ylcarbonyl)spiro[indole-3,4'-piperidin]-2(lH)-one; and 5-bromo-r-[(6-chloro-lH-indol-3-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(lH)-one.
In a certain embodiment the compounds of the invention are those compounds of formula (I-g):
Figure imgf000044_0001
wherein R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is sulfonylaryl, or is -(CH2)m-Ra wherein Ra is: OR1, CN, 5 NR1R11,
C3_6-cycloalkyl, 3 to 6 membered-heterocycloalkyl, aryl or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb, wherein Rb is:
Ci-6- alkoxy, 0 NR1R11,
6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B; R2 is one or more of H, halo, C1-6- alkyl; R3 is H, 5 or is Ci-6- alkyl, or is -(CO)-RC, wherein Rc is: Ci-6-alkyl -(CHz)n-NR1R11,
R4 is is one or more of H, halo, or Q-ό-alkoxy optionally substituted by OH, or two R4 0 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
B is halo, CN, Ci-ό-alkyl optionally substituted by CN or Q-ό-alkoxy, Q-ό-alkoxy, C1- 6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, -(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the 5 group consisting of: halo, Ci-ό-alkyl optionally substituted by CN or halo, Q-ό-alkoxy;
R1 and R11 are H, C1-6-alkyl, Ci-6-alkyl-NRmRlv, -C(O)-C1-6-alkyl, -S(O)2-Ci-6-alkyl or OH; R111 and R1V are H or C1-6-alkyl; m is 1 to 6; O n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
Further, in a certain embodiment the compounds of the invention are those compounds of formula (I-g), wherein 5 R1 is H or, - -
-(CH2)m-Ra wherein Ra is aryl;
R2 is one or more of H or halo;
R3 is H, or is Ci-6- alkyl;
R4 is H;
R6 is H; as well as pharmaceutically acceptable salts thereof.
The following compounds are examples according to the invention:
(SS5RR)- r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-3',5'-dimethyl-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one;
(RS5SR)- l'-[(6-chloro- lH-indol-3-yl)carbonyl] -3', 5' -dimethyl- 3H-spiro[2-benzofuran- l,4'-piperidin]-3-one;
(RS5SR)- r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-3',5'-dimethyl-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; and (lr,3'R,5'S)-r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-3',5'-dimethyl-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one.
In a certain embodiment the compounds of the invention are those compounds of formula (I-h) :
Figure imgf000046_0001
wherein R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is sulfonylaryl, or is -(CH2)m-Ra wherein Ra is:
OR1, - -
CN,
NR1R11,
C3-6-cycloalkyl, 3 to 6 membered-heterocycloalkyl, aryl or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2)n- (CO) -Rb, wherein Rb is:
Ci-6- alkoxy, NR1R11, 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B; R2 is one or more of H, halo, C1-O- alkyl; R3 is H, or is Ci-6- alkyl, or is -(CO)-RC, wherein Rc is:
Ci-6-alkyl -(CH2VNR1R11,
R4 is is one or more of H, halo, or Q-ό-alkoxy optionally substituted by OH, or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
R8 is H or Ci-e-alkyl; X is CH2 or C=O;
B is halo, CN, C^-alky! optionally substituted by CN or Q-ό-alkoxy, Q-ό-alkoxy, C1. 6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, -(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci-ό-alkyl optionally substituted by CN or halo, Q-ό-alkoxy;
R1 and R11 are H, Q-e-alkyl, Q-e-alkyl-NR111^, -C(O)-C1-6-alkyl, -S(O)2-C1-6-alkyl or OH; R111 and R1V are H or Ci-6-alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
Further, in a certain embodiment the compounds of the invention are those compounds of formula (I-h), wherein R1 is H, or is -(CH2V (CO) -Rb, wherein Rb is NR1R11; - -
R2 is one or more of H or halo;
R3 is H;
R4 is H;
R8 is H or C1-6- alkyl;
X is CH2 or C=O;
R1 and R11 are H or Ci-6- alkyl; as well as pharmaceutically acceptable salts thereof.
The following compounds are examples according to the invention: l'-[(6-chloro-lH-indol-3-yl)carbonyl]spiro[iso indole- l,4'-piperidin]-3(2H)-one; 1'- [(6-chloro- lH-indol-3-yl)carbonyl] -2-methyl-2,3-dihydrospiro[isoin dole- 1,4'- piperidine] ; r-fCό-chloro-lH-indol-S-y^carbonyy-l^-dihydrospirofisoindole-l^'-piperidinel i and 2- {6-chloro-3-[(3-oxo-2,3-dihydro-l'H-spiro[iso indole- l,4'-piperidin]- l'-yl)carbonyl] - lH-indol-l-yl}-N-methylacetamide.
The invention also encompasses the compounds of formula (I), (I- a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h) for a use in the prevention or treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.
The invention also encompasses a pharmaceutical composition comprising a compound of formula (I), (I- a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h), which pharmaceutical composition is useful against dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.
The invention further encompasses the use of a compound of formula (I), (I- a), (I- b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h) for the preparation of a medicament which is useful against dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.
In a certain embodiment, the compounds of the invention can be manufactured according to a process comprising the step of reacting a compound of formula (II):
Figure imgf000049_0001
with a compound of formula A-H in order to obtain the compound of formula (I), wherein A, R1, R2 and R3 are as defined hereinabove.
In another embodiment, the compounds of the invention can be manufactured according to a process comprising the step of reacting a compound of formula (III) :
Figure imgf000049_0002
with an electrophile compound of formula R1- Y in order to obtain the compound of formula (I), wherein R1, R2 and R3 are as defined hereinabove and Y is halo, preferably Br or Cl.
In still another embodiment, the compounds of the invention can be manufactured according to a process comprising the step of reacting a compound of formula (IV):
Figure imgf000049_0003
with an amine of formula HNR1R11 in order to obtain the compound of formula (I), wherein R1, R2, R3, Ri and R11 are as defined hereinabove.
The preparation of the compounds of the invention of formulae (I), (I- a), (I-b), (I- c), (I-d), (I-e), (I-f), (I-g) or (I-h) is described more in details with the following general schemes A, B and C, wherein R1, R2, R3 and A are as defined hereinabove: - -
General scheme A
Figure imgf000050_0001
General scheme A
Compounds of formula (I) can be prepared via an amide coupling between an indole 3-carboxylic acid (II) and a spiropiperidine (A-H). Indole 3-carboxylic acids (II) are either commercially available or readily prepared using a procedure described in J.Med.Chem. 1991, 34, 140. Alternatively, they can be prepared following the general scheme D as described hereinafter. The spiropiperidine derivatives A-H are either commercially available or can be prepared using commercially available starting materials and conventional methods. Spiropiperidines A-H of group (h) can be prepared as described in general scheme E. General scheme A is hereinafter further illustrated with general scheme and procedure I to which, e.g., examples 1 to 24, 34, 39-43, 66-70, 77-80 and 123-126 refer.
General scheme B
Figure imgf000050_0002
R1 — B(OH),
General scheme B
Compounds of formula (I) with R1 different from H can be prepared by N- deprotonation of an indole derivative (III) (a compound of formula (I) wherein R1 is H) followed by treatment with an electrophilic reactant R1- Y (wherein Y is a leaving group) which is either commercially available or easily prepared according to methods well known in the art and commercially available starting materials. Alternatively, compounds (I) can be prepared by coupling of an indole derivative (III) with a boronic acid R1- - -
B(OH)2 using a transition metal catalyst such as Cu(OAc)2 in the presence of pyridine, molecular sieves and air in dichloromethane. Derivatives (III) are prepared using the method described in the general scheme A General scheme B is hereinafter further illustrated with general schemes and procedures II and III to which, e.g., examples 46 to 65, 81 to 87, 93-103, 133-136, 142-144, 150-154, 161-168, 170, 172-175, 180, 182, 183, 188-193, 195-197, 201-203, 220, 224, 228-247, 253-260, 263, 266, and 267 refer, as well as general schemes and procedures V (e.g. examples 104-115, 117, 204-212), VI (e.g. examples 155-157, 222, 223, 225, 226), VII (e.g. examples 88-92, 128-132, 137-141, 145- 149, 158, 214-218, 221) and VIII.
General scheme C
Figure imgf000051_0001
General scheme C
Compounds of formula (I) wherein R3 is an amide (-CONR1R11) can be prepared via an amide coupling between an indole 2-carboxylic acid (IV) and an amine NHR1R11. The indole 2-carboxylic acid derivatives (IV) are readily prepared using commercially available starting products and conventional methods. General scheme C is hereinafter further illustrated with general scheme and procedure IV to which, e.g., examples 24 to 33 refer.
- -
General scheme D
Figure imgf000052_0001
NaH / Ri-Y
Figure imgf000052_0002
General scheme D
The treatment of an indole derivative (Va) with triflu or o acetic anhydride in DMF affords intermediate (VI) which can be hydrolysed with an aqueous sodium hydroxide solution to give the 3-carboxylic acid indole derivative (Ha). Alternatively, (VI) can react with an electrophilic reactant R1- Y to give (VII), which is then converted to the corresponding carboxylic acid derivative (lib) with NaH/H2O in DMF (see J. Org Chem., 1993, 10, 2862). Intermediate (VII) can alternatively be obtained by treatment of an indole derivative (Vb) with triflu or o acetic anhydride in DMF, dichloromethane or 1,2- dichloroethane. Addition of a suitable base may be advantageous.
- -
General scheme E
Figure imgf000053_0001
General scheme E
Cyclization of a bromophenylacetonitrile derivative (VIII) affords a 4-bromoaryl-2- cyanopiperidine derivative (IX). The cyano group is transformed to an azidocarbonyl group using standard functional group transformations to give a compound of formula (X). Upon heating in toluene an azide (X) undergoes a Curtius rearrangement. The crude intermediate isocyanate is trapped to form a lactam of formula (XI) after bromine- lithium exchange using tert-butyllithium at -100 0C. N-Deprotection affords spiropiperidine (XII). Alternatively, lactam (XI) can be N- alkylated to give lactam (XV). Both, lactam (XI) and (XV), are reduced using standard conditions to afford spiropiperidines (XIV) and (XVI) after N-deprotection, respectively. - -
The following general procedures I to VIII are meant to give examples of the preparation of the compounds of the invention according to general schemes A to C.
The following general procedure I is an example of the preparation of the compounds of the invention according to general scheme A General procedure I
Figure imgf000054_0001
General procedure I - amide coupling:
To a stirred solution of an indole-3-carboxylic acid derivative (1 mmol) in 10 ml CH2Cl2 was added (1.3 mmol) EDC, (1.3 mmol) HOBt, (1.3 mmol) Et3N and (1 mmol) of the amine derivative. The mixture was stirred overnight at RT and then poured onto water and extracted with CH2Cl2. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Flash chromatography or preparative HPLC afforded the title compound.
The following general procedures II and III are examples of the preparation of the compounds of the invention according to general scheme B:
General procedure II
Figure imgf000054_0002
General procedure II:
To a stirred solution of 30 mg (0.09 mmol) of l'-[(2-methyl-lH-indol-3- yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (the preparation of which have - - been described in example 43) in 3 ml DMF was added 4 mg (0.10 mmol) NaH (60% in oil). The mixture was stirred at RT for 30 min. and then the electrophilic reactant R1- Y (0.15 mmol) was added. The mixture was stirred an additional 18 hours and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Purification by preparative HPLC afforded the corresponding derivatives.
General procedure III
Figure imgf000055_0001
General procedure III:
To a stirred solution of 20 mg (0.054 mmol) of l'-[(6-chloro-lH-indol-3- yl)carbonyl]spiro[l-benzofuran-3,4'-piperidine] (the preparation of which have been described in example 77) in 3 ml DMF was added 8.8 mg (0.11 mmol) NaH (60% in oil). The mixture was stirred at RT for 30 min. and then the electrophilic reactant R^Y(O-OS mmol) was added. The mixture was stirred an additional 18 hours at 6O0C and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Purification by preparative HPLC afforded the corresponding derivatives.
The following general procedure IV is an example of preparation of the compounds of the invention according to general scheme C:
- -
General procedure IV
Figure imgf000056_0001
General procedure IV:
To a stirred solution of 6-chloro-3-[(5-fluoro-3-oxo-l'H,3H-spiro[2-benzofuran- l,4'-piperidin]-l'-yl)carbonyl]-lH-indole-2-carboxylic acid (1 mmol) (the preparation of which have been described in example 24d) in 10 ml CH2Cl2 was added (1.3 mmol) EDC, (1.3 mmol) HOBt, (1.3 mmol) Et3N and (1 mmol) of the amine derivative (wherein R1 and R11 are as defined hereinabove). The mixture was stirred overnight at RT and then poured onto water and extracted with CH2Cl2. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Flash chromatography or preparative HPLC afforded the title compound.
The following general procedures V to VIII are examples of the preparation of the compounds of the invention according to general scheme B:
General procedure V
Figure imgf000056_0002
- -
General procedure V:
To a stirred solution of an indole derivative (III) (0.079 mmol) in 2 ml DMF was added NaH (0.10 mmol, 60% in oil). The mixture was stirred at room temperature for 30 min. and then the electrophile R1- Y (0.15 mmol) was added. The mixture was stirred for an additional 18 hours and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Purification by preparative HPLC afforded the corresponding derivatives.
General procedure VI
Figure imgf000057_0001
General procedure VI - aryl coupling:
To a solution of the indole in dichloromethane was added anhydrous Cu(OAc)2 (2 eq), the boronic acid (3 eq) and pyridine (4 eq), and the reaction mixture stirred 16h at room temperature in the presence of 0.4 nm molecular sieve under an open to air atmosphere. Filtration through decalite, washing with dichloromethane and concentration gave the crude product which was purified by silica gel chromatography (hexane/ethyl acetate) to give the desired product.
General procedures VII and VIII
Figure imgf000057_0002
General procedure VII - acylation: A solution of the indole in dry DMF was treated with sodium hydride (1.05 eq) and stirred for 15 min at room temperature, then treated with an acid chloride (1.1 eq) and stirred at room temperature for 2h. Purification by preparative HPLC yielded the desired product.
General Procedure VIII - sulphonylation :
A solution of the indole in dry DMF was treated with sodium hydride (1.05 eq) and stirred for 15 minat room temperature, then treated with a sulphonyl chloride (1.1 eq) and stirred at room temperature for 2h. Purification by preparative HPLC yielded the desired product.
Results - Via activity
Material & Method:
The human Via receptor was cloned by RT-PCR from total human liver RNA The coding sequence was subcloned in an expression vector after sequencing to confirm the identity of the amplified sequence. To demonstrate the affinity of the compounds from the present invention to the human Via receptor binding studies were performed. Cell membranes were prepared from HEK293 cells transiently transfected with the expression vector and grown in 20 liter fermenters with the following protocol.
5Og of cells are resuspended in 30ml freshly prepared ice cold Lysis buffer (5OmM HEPES, ImM EDTA, 1OmM MgC12 adjusted to pH= 7.4 + complete cocktail of protease inhibitor (Roche Diagnostics)). Homogenized with Polytron for lmin and sonicated on ice for 2x 2 minutes at 80% intensity (Vibracell sonicator). The preparation is centrifuged 20 min at 500 g at 40C, the pellet is discarded and the supernatant centrifuged lhour at 43'00Og at 40C (19'000rpm). The pellet is resuspended in 12.5 ml Lysis buffer+ 12.5ml Sucrose 20% and homogenized using a Polytron for 1-2 min. The protein concentration is determined by the Bradford method and aliquots are stored at -8O0C until use. For binding studies 60mg Yttrium silicate SPA beads (Amersham) are mixed with an aliquot of membrane in binding buffer (50 mM Tris, 12OmM NaCl, 5 mM KCl, 2 mM CaC12, 10 mM MgC12) for 15 minutes with mixing. 50ul of bead/membrane mixture is then added to each well of a 96 well plate, followed by 50ul of 4 nM 3H- Vasopressin (American Radiolabeled Chemicals). For total binding measurement lOOul of binding buffer are added to the respective wells, for non-specific binding lOOul of 8.4mM cold vasopressin and for compound testing lOOul of a serial dilution of each compound in 2% DMSO. The plate is incubated Ih at room temperature, centrifuged 1 min at lOOOg and counted on a Packard - -
Top-Count. Non-specific binding counts are subtracted from each well and data is normalized to the maximum specific binding set at 100%. To calculate an IC 50 the curve is fitted using a non-linear regression model (XLfit) and the Ki is calculated using the Cheng- Pru sso ff equation.
Figure imgf000059_0001
- -
Figure imgf000060_0001
- -
Figure imgf000061_0001
- -
Figure imgf000062_0001
The compounds of formula (I) as well as their pharmaceutically usable acid addition salts can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
The compounds of formula (I) and their pharmaceutically usable acid addition salts can be processed with pharmaceutically inert, inorganic or organic excipients for the production of tablets, coated tablets, dragees and hard gelatine capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc can be used as such excipients e.g. for tablets, dragees and hard gelatine capsules.
Suitable excipients for soft gelatine capsules are e.g. vegetable oils, waxes, fats, semisolid and liquid polyols etc.
Suitable excipients for the manufacture of solutions and syrups are e.g. water, polyols, saccharose, invert sugar, glucose etc. - D -
Suitable excipients for injection solutions are e.g. water, alcohols, polyols, glycerol, vegetable oils etc.
Suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats, semi- liquid or liquid polyols etc.
Moreover, the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 10 to 1000 mg per person of a compound of general formula (I) should be appropriate, although the above upper limit can also be exceeded when necessary.
The following Examples illustrate the present invention without limiting it. All temperatures are given in degrees Celsius.
Example A
Tablets of the following composition are manufactured in the usual manner:
mg/tablet
Active substance 5
Lactose 45
Corn starch 15
Microcrystalline cellulose 34
Magnesium stearate 1
Tablet weight 100
Example B
Capsules of the following composition are manufactured:
mg/capsule - -
Active substance 10 Lactose 155 Corn starch 30 Talc 5
Capsule fill weight 200
The active substance, lactose and corn starch are firstly mixed in a mixer and then in a comminuting machine. The mixture is returned to the mixer, the talc is added thereto and mixed thoroughly. The mixture is filled by machine into hard gelatine capsules.
Example C
Suppositories of the following composition are manufactured:
mg/supp.
Active substance 15
Suppository mass 1285 Total 1300
The suppository mass is melted in a glass or steel vessel, mixed thoroughly and cooled to 450C. Thereupon, the finely powdered active substance is added thereto and stirred until it has dispersed completely. The mixture is poured into suppository moulds of suitable size, left to cool; the suppositories are then removed from the moulds and packed individually in wax paper or metal foil.
EXAMPLES
Examples of compounds of formula (I-a)
Example 1 l'-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]spiro[in dene- 1,4' -piperidine] - -
Figure imgf000065_0001
Amide coupling according to general procedure I described hereinabove: - Amine: spiro[indene-l,4'-piperidine] prepared as described in J. Med. Chem. 1992, 35, 2033, - Acid: l-Benzyl-2-methyl-lH-indole-3-carboxylic acid (the preparation of which is described hereinafter), ES-MS m/e (%): 433.5 (M+H+). l-Benzyl-2-methyl- lH-indole-3-carboxylic acid To a stirred solution of 0.50 g (3.10 mmol) 2-methyl-lH-indole-3-carboxylic acid (described in J.Heterocyclic Chem. 1977, 14, 1123) in 5 ml DMF was added 0.27 g (6.75 mmol) of NaH (60% in oil). The mixture was stirred at RT for 30 min. and then 0.39 ml (3.28 mmol) of benzyl bromid was added. The mixture was stirred an additional hour and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Crystallization in Et2O afforded l-Benzyl-2-methyl-lH-indole-3-carboxylic acid.
Example 2 l'-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-2,3-dihydrospiro[in dene- 1,4'- piperidine]
Figure imgf000065_0002
Amide coupling according to general procedure I described hereinabove: - DJ -
- Amine: 2,3-dihydrospiro[indene-l,4'-piperidine] prepared as described in J. Med. Chem. 1992, 35, 2033,
- Acid: l-Benzyl-2-methyl-lH-indole-3-carboxylic acid (described in example 1), ES-MS m/e (%): 435.5 (M+H+).
Example 3 r-[(l-benzyl-lH-indol-3-yl)carbonyl]spiro[indene-l,4'-piperidine]
Figure imgf000066_0001
Amide coupling according to general procedure I described hereinabove:
- Amine: spiro[indene-l,4'-piperidine] prepared as described in J. Med. Chem. 1992, 35, 2033,
- Acid: 1-benzyl- lH-indole-3-carboxyric acid (the preparation of which is described hereinafter),
ES-MS m/e (%): 419.4 (M+H+).
1-benzyl- lH-indole-3-carboxylic acid To a stirred solution of 0.50 g (3.10 mmol) lH-indole-3-carboxylic acid in 5 ml DMF was added 0.27 g (6.75 mmol) of NaH (60% in oil). The mixture was stirred at RT for 30 min. and then 0.39 ml (3.28 mmol) of benzyl bromid was added. The mixture was stirred an additional hour and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Crystallization in Et2O afforded 0.61 g (78%) of 1-benzyl- lH-indole-3-carboxylic acid as a white solid. ES-MS m/e (%): 250 (M-H+).
Example 4 r-[(2-methyl-lH-indol-3-yl)carbonyl]spiro[indene-l,4'-piperidine] - -
Figure imgf000067_0001
Amide coupling according to general procedure I described hereinabove: - Amine: spiro[indene-l,4'-piperidine] prepared as described in J.Med.Chem. 1992, 35, 2033, - Acid: 2-Methyl-lH-indole-3-carboxylic acid prepared as described in J.Heterocydic Chem. 1977, 14, 1123, ES-MS m/e (%): 343.2. (M+H+).
Example 5 l'-[(6-chloro-lH-indol-3-yl)carbonyl]spiro[in dene- 1,4' -piperidine]
Figure imgf000067_0002
Amide coupling according to general procedure I described hereinabove:
- Amine: spiro[indene-l,4'-piperidine] prepared as described in J.Med.Chem. 1992, 35, 2033,
- Acid: ό-chloro-lH-indole-S-carboxylic acid (the preparation of which is described hereinafter),
ES-MS m/e (%): 363.4 (M+H+). 6-chloro- lH-indole-3-carboxylic acid - -
Using a procedure described in J. Med. Chem. 1991, 34, 140, from 7.0 g (0.046 mmol) of 6-chloro-lH-indole was prepared 5.80 g (64%) of ό-chloro-lH-indole-S-carboxylic acid as a light brown solid. ES-MS m/e (%): 194 (M-H+).
Example 6 r-[(6-chloro-lH-indol-3-yl)carbonyl]-2,3-dihydrospiro[indene-l,4'-piperidine]
Figure imgf000068_0001
Amide coupling according to general procedure I described hereinabove: - Amine: 2,3-dihydrospiro[indene-l,4'-piperidine] prepared as described in J.Med.Chem. 1992, 35, 2033, - Acid: ό-chloro-lH-indole-S-carboxylic acid (described in example 5), ES-MS m/e (%): 365.4 (M+H+).
Examples of compounds of formula (I-b)
Example 7 r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-l-(methylsulfonyl)-l,2- dihydrospiro[indole-3,4'-piperidine]
Figure imgf000068_0002
- o -
Amide coupling according to general procedure I described hereinabove:
- Amine: l-(methylsulfonyl)-l,2-dihydrospiro[indole-3,4'-piperidine] prepared as described in Tetrahedron, 1997, 53, 10983,
- Acid: l-Benzyl-2-methyl-lH-indole-3-carboxyric acid (described in example 1), ES-MS m/e (%): 514.6 (M+H+).
Example 8 r-[(6-chloro-lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'-piperidine]
Figure imgf000069_0001
Amide coupling according to general procedure I described hereinabove:
- Amine: l,2-dihydrospiro[indole-3,4'-piperidine] prepared as described in Tetrahedron, 2004, 60, 4875-4878,
- Acid: ό-chloro-lH-indole-S-carboxylic acid (described in example 5), ES-MS m/e (%): 366.4 (M+H+).
Example 9 l'-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'- piperidine]
- -
Figure imgf000070_0001
Amide coupling according to general procedure I described hereinabove: - Amine: l,2-dihydrospiro[indole-3,4'-piperidine] prepared as described in Tetrahedron, 2004, 60, 4875-4878, - Acid: l-Benzyl-l-methyl-lH-indole-S-carboxylic acid (described in example 1), ES-MS m/e (%): 436.6 (M+H+).
Examples of compounds of formula (I-c)
Example 10 r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-6-chloro-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one
Figure imgf000070_0002
Amide coupling according to general procedure I described hereinabove:
- Amine: 6-chloro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one prepared as described in European patent application EP722941,
- Acid: l-Benzyl-2-methyl-lH-indole-3-carboxylic acid (described in example 1), ES-MS m/e (%): 485.5 (M+H+). - -
Example 11 l'-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-4-fluoro-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one
Figure imgf000071_0001
Amide coupling according to general procedure I described hereinabove:
- Amine: 4-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one prepared as described in EP722941,
- Acid: l-Benzyl-2-methyl-lH-indole-3-carboxylic acid (described in example 1), ES-MS m/e (%): 469.5 (M+H+).
Example 12 r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-6-methoxy-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one
Figure imgf000071_0002
Amide coupling according to general procedure I described hereinabove: - Amine: 6-methoxy-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one prepared as described in EP722941, - Acid: l-Benzyl-2-methyl-lH-indole-3-carboxylic acid (described in example 1), - -
ES-MS m/e (%): 481.4 (M+H+).
Example 13 l'-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-5-methoxy-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one
Figure imgf000072_0001
Amide coupling according to general procedure I described hereinabove:
- Amine: 5-methoxy-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one prepared as described in EP722941,
- Acid: l-Benzyl-2-methyl-lH-indole-3-carboxylic acid (described in example 1), ES-MS m/e (%): 481.6 (M+H+).
Example 14 r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-7-chloro-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one
Figure imgf000072_0002
Amide coupling according to general procedure I described hereinabove:
- Amine: 7-chloro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (the preparation of which is described hereinafter),
- Acid: l-Benzyl-2-methyl-lH-indole-3-carboxylic acid (described in example 1), ES-MS m/e (%): 485.5 (M+H+). - -
7-chloro-3H-spiror2-benzofuran-l,4'-piperidinl-3-one
Following the general procedure described in J.Org.Chem. 1976,41, 2628, from 2-bromo- 3-chloro-benzoic acid (the preparation of which is described in J.Org.Chem. 203, 68, 2030) and l-benzyl-piperidin-4-one was prepared 7-chloro-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one, after debenzylation (Pd/C, H2, MeOH/HCl), as a white solid. ES-MS m/e (%): 238.7 (M+H+).
Example of compounds of formula (I-g)
Example 15
(^,i?i?)-r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-3',5'-dimethyl-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000073_0001
Amide coupling according to general procedure I described hereinabove: - Amine: (SS,RR)-3',5'-dimethyl-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one prepared as described in WO9929696, - Acid: l-Benzyl-2-methyl-lH-indole-3-carboxylic acid (described in example 1), ES-MS m/e (%): 479.6 (M+H+).
Examples of compounds of formula (I-c)
Example 16 r-[(6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one - -
Figure imgf000074_0001
Amide coupling according to general procedure I described hereinabove: - Amine: 3H-spiro[2-benzofuran-l,4'-piperidin]-3-one prepared as described in J. Org. Chem, 1976, 41, 2628, - Acid: ό-chloro-lH-indole-S-carboxylic acid (described in example 5), ES-MS m/e (%): 381.4 (M+H+).
Example 17 l'-[(6-chloro-lH-indol-3-yl)carbonyl]-6-methoxy-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one
Figure imgf000074_0002
Amide coupling according to general procedure I described hereinabove:
- Amine: 6-methoxy-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one prepared as described in EP722941,
- Acid: ό-chloro-lH-indole-S-carboxylic acid (described in example 5), ES-MS m/e (%): 411.4 (M+H+).
Example of compounds of formula (I-g) Example 18 - -
(i?5l,5<i?)-r-[(6-chloro-lH-indol-3-yl)carbonyl]-3',5'-dimethyl-3H-spiro[2-benzoflιran- l,4'-piperidin]-3-one
Figure imgf000075_0001
Amide coupling according to general procedure I described hereinabove: - Amine: (lr,3'R,5'S)-3',5'-dimethyl-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one prepared as described in WO9929696;
- Acid: ό-chloro-lH-indole-S-carboxylic acid (described in example 5), ES-MS m/e (%): 409.4 (M+H+).
Examples of compounds of formula (I-c)
Example 19 r-[(6-chloro-lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-
3-one
Figure imgf000075_0002
Amide coupling according to general procedure I described hereinabove: - -
- Amine: 5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one prepared as described in WO2001014376,
- Acid: ό-chloro-lH-indole-S-carboxylic acid (described in example 5), ES-MS m/e (%): 399.4 (M+H+).
Example 20
6-chloro-r-[(6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-
3-one
Figure imgf000076_0001
Amide coupling according to general procedure I described hereinabove: - Amine: 6-chloro-3H-spiro[2-benzofuran-l,4'-piperidin] -3-one prepared as described in EP722941,
- Acid: ό-chloro-lH-indole-S-carboxylic acid (described in example 88), ES-MS m/e (%): 415.3 (M+).
Example of compounds of formula (I-g) Example 21
(R5,5R)-lI-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-3I,5I-dimethyl-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000076_0002
- D -
Amide coupling according to general procedure I described hereinabove: - Amine: (lr,3'R,5'S)-3',5'-dimethyl-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one prepared as described in WO9929696,
- Acid: l-Benzyl^-methyl-lH-indole-S-carboxylic acid (described in example 1), ES-MS m/e (%): 479.6 (M+H+).
Examples of compounds of formula (I-c)
Example 22 r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one
Figure imgf000077_0001
Amide coupling according to general procedure I described hereinabove:
- Amine: 3H-spiro[2-benzofuran-l,4'-piperidin]-3-one prepared as described in J. Org. Chem. 1976, 41, 2628,
- Acid: l-Benzyl-2-methyl-lH-indole-3-carboxylic acid (described in example 1), ES-MS m/e (%): 451.6 (M+H+).
Example 23 r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one
- -
Figure imgf000078_0001
Amide coupling according to general procedure I described hereinabove: - Amine: 5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one prepared as described in WO2001014376, - Acid: l-Benzyl-l-methyl-lH-indole-S-carboxylic acid (described in example 1), ES-MS m/e (%): 469.6 (M+H+).
Example 24 r-({6-chloro-2-[(4-methylpiperidin-l-yl)carbonyl]-lH-indol-3-yl}carbonyl)-5-fluoro- 3H-spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000078_0002
a) 6-Chloro-3-formyl-lH-indole-2-carboxylic acid ethyl ester
To a stirred solution of 2.36 g (0.011 mol) of 6-chloro-lH-indole-2-carboxylic acid ethyl ester in DMF (20 ml) was added phosphorus oxychloride (1.08 ml, 0.012 mol) at RT. The solution was heated at 60 C for 2 hours, then cooled to RT, and poured into water. The ph was adjusted to 7 by careful addition of aq. NaOH 2N. The resulting brown precipitate was collected by filtration and dried over night in a vacuum oven (500C). The title compound was obtained as light brown solid, 2.05 g (77%). - o - b) ό-Chloro-lH-indole^^-dicarboxylic acid 2-ethyl ester
To a solution of 0.104 g (0.413 mmol) of ό-Chloro-S-formyl-lH-indole-l-carboxylic acid ethyl ester in a mixture of tert-butanol (10 ml) and H2O (5 ml), was added 2-methyl-2- butene (2 ml) followed by a solution OfNaClO2 (0.344 g, 3.80 mmol) and NaH2PO4 (0.399 g, 2.90 mmol) in water (2 ml). The mixture was stirred overnight at RT. The organic solvents were removed, and then the aqueous solution diluted with water, and washed twice with hexane. The ph of the aqueous phase was adjusted to 3 by addition of aq. HCl IN, and the product extracted with EtOAc. The combined organic phases were dried over Na2SO4 and concentrated in vacuo to afford 15 mg (14%) of 6-chloro-lH- indole-2,3-dicarboxylic acid 2-ethyl ester as a light yellow solid.
c) lH-indole-2-carboxylic acid, 6-chloro-3-r(5-fluoro-3-oxospirorisobenzofuran- 1(3H) ,4'-piperidinl - l'-vDcarbonyll -ethyl ester
Amide coupling according to general procedure I described hereinabove: - Amine: 5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one prepared as described in WO2001014376,
- Acid: 6-chloro-lH-indole-2,3-dicarboxylic acid 2-ethyl Ester (the preparation of which is described hereinafter),
d) 6-chloro-3-r(5-fluoro-3-oxo-lΗ,3H-spiror2-benzofuran-l,4'-piperidinl-r- vDcarbonyll - lH-indole-2-carboxylic acid
To a solution of 1.89 g (4.02 mmol) of lH-indole-2-carboxylic acid, 6-chloro-3-[(5- fluoro-3-oxospiro[isobenzofuran-l(3H),4'-piperidin]-r-yl)carbonyl]-, ethyl ester in EtOH (150 ml), was added an aqueous solution of IiOH (7.8 ml, IM). The resulting white suspension was stirred at 800C overnight, cooled to RT, and then poured in 500 ml aq. HCl (IN). The product was extracted with 3 times 500 ml OfCH2Cl2, and the combined organic phases were dried over Na2SO4 and concentrated in vacuo to afford 1.42 g (72%) of 6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'- piperidin]-l'-yl)carbonyl]-lH-indole-2-carboxylic acid as a white solid.
e) r-({6-chloro-2-r(4-methylpiperidin-l-yl)carbonyll-lH-indol-3-yl]carbonyl)-5- fluoro-3H-spiror2-benzofuran-l,4'-piperidinl-3-one
Amide coupling according to general procedure IV described hereinabove:
- Amine: commercially available 4-methyl-piperidine, - Acid: 6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl]-lH-indole-2-carboxylic acid (described in step d hereinabove), ES-MS m/e (%): 525 (M+H+)
Example 25
6-chloro-3-[(5-fluoro-3-oxo-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indole-2-carboxamide
Figure imgf000080_0001
Amide coupling according to general procedure IV described hereinabove:
- Amine: commercial available ammonium hydroxide,
- Acid: 6-chloro-3-[(5-fluoro-3-oxo-rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'- yl)carbonyl]-lH-indole-2-carboxylic acid (described in example 24), ES-MS m/e (%): 442 (M+H+).
Example 26
6-chloro-N-[2-(dimethylamino)ethyl]-3-[(5-fluoro-3-oxo-rH,3H-spiro[2-benzofuran- l,4'-piperidin]-l'-yl)carbonyl]-lH-indole-2-carboxamide
Figure imgf000080_0002
Amide coupling according to general procedure IV described hereinabove:
- Amine: commercially available Nl, Nl-dimethyl-ethane-l,2-diamine,
- Acid: 6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl]-lH-indole-2-carboxylic acid (described in example 24), - -
ES-MS m/e (%):513 (M+H+).
Example 27 l'-{[6-chloro-2-(piperazin-l-ylcarbonyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000081_0001
Amide coupling according to general procedure IV described hereinabove:
- Amine: commercially available piperazine,
- Acid: 6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl]-lH-indole-2-carboxylic acid (described in example 24), ES-MS m/e (%):511 (M+H+).
Example 28 r-{[6-chloro-2-(morpholin-4-ylcarbonyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000081_0002
Amide coupling according to general procedure IV described hereinabove:
- Amine: commercially available morpholine,
- Acid: 6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl]-lH-indole-2-carboxylic acid (described in example 24), - o -
ES-MS m/e (%):512 (M+H+).
Example 29
6-chloro-3-[(5-fluoro-3-oxo-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] -N,N-dimethyl- lH-indole-2-carboxamide
Figure imgf000082_0001
Amide coupling according to general procedure IV described hereinabove:
- Amine: commercially available dimethylamine,
- Acid: 6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl]-lH-indole-2-carboxylic acid (described in example 24), ES-MS m/e (%): 471 (M+H+).
Example 30 tert-butyl {2-[({6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'- piperidin]-r-yl)carbonyl]-lH-indol-2-yl}carbonyl)amino]ethyl}methylcarbamate
Figure imgf000082_0002
Amide coupling according to general procedure IV described hereinabove:
- Amine: commercially available (2-Amino-ethyl)-methyl-carbamic acid tert-butyl ester,
- Acid: 6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl]-lH-indole-2-carboxylic acid (described in example 24), - -
ES-MS m/e (%): 599 (M+H+).
Example 31
6-chloro-N,N-diethyl-3-[(5-fluoro-3-oxo-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indole-2-carboxamide
Figure imgf000083_0001
Amide coupling according to general procedure IV described hereinabove:
- Amine: commercially available diethyl- amine,
- Acid: 6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl]-lH-indole-2-carboxylic acid (described in example 24), ES-MS m/e (%): 498 (M+H+).
Example 32 r-({6-chloro-2-[(4-methylpiperazin-l-yl)carbonyl]-lH-indol-3-yl}carbonyl)-5-fluoro- 3H-spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000083_0002
Amide coupling according to general procedure IV described hereinabove:
- Amine: commercially available 1-methyl-piperazine,
- Acid: 6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl]-lH-indole-2-carboxylic acid (described in example 24), - -
ES-MS m/e (%):524 (M+H+).
Example 33 l'-{[6-chloro-2-(piperidin-l-ylcarbonyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000084_0001
Amide coupling according to general procedure IV described hereinabove:
- Amine: commercially available piperidine,
- Acid: 6-chloro-3-[(5-fluoro-3-oxo-rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'- yl)carbonyl]-lH-indole-2-carboxylic acid (described in example 24), ES-MS m/e (%): 510 (M+H+).
Example 34 r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-7H-spiro[furo[3,4- f][l,3]benzodioxole-5,4'-piperidin]-7-one
Figure imgf000084_0002
Amide coupling according to general procedure I described hereinabove:
- Amine: 7H-spiro[furo[3,4-f][l,3]benzodioxole-5,4'-piperidin]-7-one prepared as described in DE2458176A1,
- Acid: l-Benzyl-2-methyl-lH-indole-3-carboxylic acid (described in example 1), - o -
ES-MS m/e (%): 495 (M+H+).
Example 35
3-{6-chloro-3-[(3-oxo-rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)carbonyl]-lH- indol-l-yl}propanenitrile
Figure imgf000085_0001
To a stirred solution of 100 mg (0.26 mmol) of l'-[(6-chloro-lH-indol-3-yl)carbonyl]- 3H-spiro[2-benzofuran-l,4'-piperidine]-3-one (the preparation of which has been described in example 16) in 5 ml DMF was added 11.5 mg (0.28 mmol) NaH (60% in oil). The mixture was stirred at RT for 30 min. and then 35 mg (0.26 mmol) of 3-bromo- propionitrile was added. The mixture was stirred an additional hour and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Flash chromatography (CH2Cl2/Me0H, 99:1; SiO2) afforded 48 mg (29%) of 3-{6-chloro-3-[(3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'- piperidin]-l'-yl)carbonyl]-lH-indol-l-yl}propanenitrile as a light yellow solid. ES-MS m/e (%): 434(M+H+).
Example 36
4-{6-chloro-3-[(3-oxo-rH,3H-spiro[2-benzofuran-l,4'-piperidin]-r-yl)carbonyl]-lH- indol-l-yl}butanenitrile
- -
Figure imgf000086_0001
To a stirred solution of 100 mg (0.26 mmol) of l'-[(6-chloro-lH-indol-3-yl)carbonyl]- 3H-spiro[2-benzofuran-l,4'-piperidine]-3-one (the preparation of which has been described in example 16) in 5 ml DMF was added 11.5 mg (0.28 mmol) NaH (60% in oil). The mixture was stirred at RT for 30 min. and then 37 mg (0.26 mmol) of 4-bromo- butyronitrile was added. The mixture was stirred overnight and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Flash chromatography (CH2Cl2/Me0H, 99:1; SiO2) afforded 69 mg (59%) of 4-{6-chloro-3-[(3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-yl) carbonyl] - lH-indol- l-yl}butanenitrile as a light yellow solid. ES-MS m/e (%): 448(M+H+).
Example 37
{6-chloro-3-[(3-oxo-rH,3H-spiro[2-benzofuran-l,4'-piperidin]-r-yl)carbonyl]-lH- indol-l-yl}acetonitrile
Figure imgf000086_0002
To a stirred solution of 100 mg (0.26 mmol) of l'-[(6-chloro-lH-indol-3-yl)carbonyl]-
3H-spiro[2-benzofuran-l,4'-piperidine]-3-one (the preparation of which has been described in example 16) in 5 ml DMF was added 11.5 mg (0.28 mmol) NaH (60% in oil). The mixture was stirred at RT for 30 min. and then 31 mg (0.26 mmol) of bromo- - 0 - acetonitrile was added. The mixture was stirred overnight and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Flash chromatography (EtOAc/Hx, 1:6; SiO2) afforded 58 mg (34%) of {6-chloro-3-[(3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- l-yl}acetonitrile as a light yellow solid. ES-MS m/e (%): 420(M+H+).
Example 38
2-{6-chloro-3-[(3-oxo-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-r-yl)carbonyl]-lH- indol-l-yl}propanenitrile
Figure imgf000087_0001
To a stirred solution of 100 mg (0.26 mmol) of l'-[(6-chloro-lH-indol-3-yl)carbonyl]- 3H-spiro[2-benzofuran-l,4'-piperidine]-3-one (the preparation of which has been described in example 16) in 5 ml DMF was added 11.5 mg (0.28 mmol) NaH (60% in oil). The mixture was stirred at RT for 30 min. and then 35 mg (0.26 mmol) of 2-bromo- propionitrile was added. The mixture was stirred overnight and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Flash chromatography (EtOAc/Hx, 2:1; SiO2) afforded 54 mg (34%) of 2- {6-chloro-3- [(3-oxo- l'H,3H-spiro[2-benzofuran- l,4'-piperidin] - l'-yl) carbonyl]-lH-indol-l-yl}propanenitrile as a light yellow solid. ES-MS m/e (%): 434(M+H+).
Examples of compounds of formula (I-d)
Example 39 r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidine] - -
Figure imgf000088_0001
Amide coupling according to general procedure I described hereinabove: - Amine: spiro[isobenzofuran-l(3H),4'-piperidine] pepared as described in J. Org. Chem. 1976, 41, 2628, - Acid: l-Benzyl-2-methyl-lH-indole-3-carboxylic acid (described in example 1). ES-MS m/e (%): 437.5 (M+H+).
Example 40 r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-6-chloro-3H-spiro[2-benzofuran-l,4'- piperidine]
Figure imgf000088_0002
Amide coupling according to general procedure I described hereinabove: - Amine: 6-chloro-3H-spiro[2-benzofuran-l,4'-piperidine] prepared as described in WO2004004714, - Acid: l-Benzyl-2-methyl-lH-indole-3-carboxylic acid (described in example 1) ES-MS m/e (%): 471.3 (M+H+). - -
Example 41 l'-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-3-phenyl-3H-spiro[2-benzofuran-l,4'- piperidine]
Figure imgf000089_0001
Amide coupling according to general procedure I described hereinabove:
- Amine: 3-phenyl-3H-spiro[2-benzofuran-l,4'-piperidine] prepared as described in J. Med. Chem. 1976, 19, 1315,
- Acid: l-Benzyl^-methyl-lH-indole-S-carboxylic acid (described in example 1) ES-MS m/e (%): 513.6 (M+H+).
Example 42 r-[(l-benzyl-5-methoxy-2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran- l,4'-piperidine]
Figure imgf000089_0002
Amide coupling according to general procedure I described hereinabove:
- Amine: spiro[isobenzofuran-l(3H),4'-piperidine] prepared as described in J. Org. Chem. 1976, 41, 2628, - -
- Acid: l-benzyl-S-methoxy-l-methyl-lH-indole-S-carboxylic acid (commercially available),
ES-MS m/e (%): 467.4 (M+H+).
Example 43 r-[(2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine]
Figure imgf000090_0001
Amide coupling according to general procedure I described hereinabove: - Amine: spiro[isobenzofuran-l(3H),4'-piperidine] pepared as described in J. Org. Chem. 1976, 41, 2628, - Acid: 2-Methyl-lH-indole-3-carboxylic acid (described in J.Heterocydic Chem. 1977, 14, 1123), ES-MS m/e (%): 347.3 (M+H+).
Example 44 l'-[(l-benzoyl-2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidine]
Figure imgf000090_0002
To a stirred solution of 40 mg (0.11 mmol) of l'-[(2-methyl-lH-indol-3-yl)carbonyl]- 3H-spiro[2-benzofuran-l,4'-piperidine] (the preparation of which has been described in example 43) in 3 ml DMF was added 5 mg (0.11 mmol) NaH (60% in oil). The mixture was stirred at RT for 30 min. and then 19 mg (0.13 mmol) of benzoyl chloride was added. - -
The mixture was stirred an additional hour and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Re-crystallization in Et2O afforded 51 mg (98%) of l'-[(l- benzoyl-2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] as white crystals. ES-MS m/e (%): 451.3 (M+H+).
Example 45 r-{[2-methyl-l-(phenylsulfonyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'- piperidine]
Figure imgf000091_0001
To a stirred solution of 40 mg (0.11 mmol) of l'-[(2-methyl-lH-indol-3-yl)carbonyl]-
3H-spiro[2-benzofuran-l,4'-piperidine] (the preparation of which has been described in example 43) in 3 ml DMF was added 5 mg (0.11 mmol) NaH (60% in oil). The mixture was stirred at RT for 30 min. and then 24 mg (0.14 mmol) of benzenesulfonyl chloride was added. The mixture was stirred an additional hour and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Re-crystallization in Et2O afforded 45 mg (80%) of l'-{[2-methyl- l-(phenylsulfonyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'-piperidine] as white crystals. ES-MS m/e (%): 487.4 (M+H+).
Example 46 r-{[l-(cyclohexylmethyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine] - -
Figure imgf000092_0001
Following the general procedure II described hereinabove above with bromomethyl- cyclohexane as electrophile; the title compound was obtained as white solid. ES-MS m/e (%): 443.5 (M+H+).
Example 47 l'-{[l-(3-fluorobenzyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'- piperidine]
Figure imgf000092_0002
Following the general procedure II described hereinabove with l-bromomethyl-3-fluoro- benzene as electrophile; the title compound was obtained as white solid. ES-MS m/e (%): 455.4 (M+H+).
Example 48 r-({2-methyl-l-[2-(trifluoromethoxy)benzyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran-l,4'-piperidine] - -
Figure imgf000093_0001
Following the general procedure II described hereinabove with l-bromomethyl-2- trifluoromethoxy-benzene as electrophile; the title compound was obtained as white solid. ES-MS m/e (%): 521.4 (M+H+).
Example 49 l'-{[l-(3,5-dimethylbenzyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine]
Figure imgf000093_0002
Following the general procedure II described hereinabove with l-bromomethyl-3,5- dimethyl-benzene as electrophile, the title compound was obtained as white solid. ES-MS m/e (%): 465.4 (M+H+).
Example 50 methyl 4- {[2-methyl-3-(l'H,3H-spiro[2-benzofuran- 1,4' -piperidin]-l'-ylcarbonyl)- IH- indol-l-yl]methyl}benzoate - -
Figure imgf000094_0001
Following the general procedure II described hereinabove with 4-bromomethyl-benzoic acid methyl ester as electrophile; the title compound was obtained as white solid. ES-MS m/e (%): 495.5 (M+H+).
Example 51
4-{[2-methyl-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)-lH-indol-l- yl] methyl Jbenzonitrile
Figure imgf000094_0002
Following the general procedure II described hereinabove with 4-bromomethyl- benzonitrile as electrophile; the title compound was obtained as white solid. ES-MS m/e (%): 462.4 (M+H+).
Example 52 l'-{[l-(3,5-difluorobenzyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine] - -
Figure imgf000095_0001
Following the general procedure II described hereinabove with l-bromomethyl-3,5- difluoro-benzene as electrophile; the title compound was obtained as white solid. ES-MS m/e (%): 473.4 (M+H+).
Example 53 l'-{[l-(2-chlorobenzyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'- piperidine]
Figure imgf000095_0002
Following the general procedure II described hereinabove with l-bromomethyl-2-chloro- benzene as electrophile; the title compound was obtained as white solid. ES-MS m/e (%): 471.3 (M+H+).
Example 54 l'-{[l-(2-methoxybenzyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine] - -
Figure imgf000096_0001
Following the general procedure II described hereinabove with l-chloromethyl-2- methoxy-benzene as electrophile; the title compound was obtained as white solid. ES-MS m/e (%): 467.4 (M+H+).
Example 55 l'-{[l-(4-methoxybenzyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine]
Figure imgf000096_0002
Following the general procedure II described hereinabove with l-chloromethyl-4- methoxy-benzene as electrophile; the title compound was obtained as white solid. ES-MS m/e (%): 467.4 (M+H+).
Example 56 l'-[(l-{[2-(4-chlorophenyl)-l,3-thiazol-4-yl]methyl}-2-methyl-lH-indol-3-yl)carbonyl]-
3H-spiro[2-benzofuran-l,4'-piperidine] - -
Figure imgf000097_0001
Following the general procedure II described hereinabove with 4-chloromethyl-2-(4- chloro-phenyl)-thiazole (commercially available) as electrophile, the title compound was obtained as a white solid. ES-MS m/e (%): 554.3.(M+H+).
Example 57 l'-[(l-{[2-(4-chlorophenyl)-l,3-thiazol-4-yl]methyl}-2-methyl-lH-indol-3-yl)carbonyl]-
3H-spiro[2-benzofuran-l,4'-piperidine]
Figure imgf000097_0002
Following the general procedure II described hereinabove with 4-bromomethyl-2-(4- chloro-phenyl)-5-methyl-thiazole (the preparation of which has been described in WO2004020420) as electrophile, the title compound was obtained as a white solid. ES-MS m/e (%):.568.3 (M+H+).
Example 58 l'-[(l-{[2-(2-methoxyphenyl)-5-methyl-l,3-oxazol-4-yl]methyl}-2-methyl-lH-indol-3- yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] - -
Figure imgf000098_0001
Following the general procedure II described hereinabove with 4-chloromethyl-2-(2- methoxy-phenyl)-5-methyl-oxazole (the preparation of which has been described in WO2002092084 & WO2004031162) as electrophile, the title compound was obtained as a white solid.
ES-MS m/e (%): 548.5 (M+H+).
Example 59 r-{[2-methyl-l-({5-methyl-2-[3-(trifluoromethyl)phenyl]-l,3-oxazol-4-yl}methyl)-lH- indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'-piperidine]
Figure imgf000098_0002
Following the general procedure II described hereinabove with 4-chloromethyl-5-methyl- 2-(3-trifluoromethyl-phenyl)-oxazole (the preparation of which has been described in WO2004031162) as electrophile, the title compound was obtained as a white solid. ES-MS m/e (%):.586.3 (M+H+).
Example 60 r-[(l-{[2-(2-fluorophenyl)-5-methyl-l,3-oxazol-4-yl]methyl}-2-methyl-lH-indol-3- yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] - -
Figure imgf000099_0001
Following the general procedure II described hereinabove with 4-chloromethyl-2-(2- fluoro-phenyl)-5-methyl-oxazole (commercially available) as electrophile, the title compound was obtained as a white solid. ES-MS m/e (%):.536.4 (M+H+).
Example 61 l'-[(l-{[2-(4-isopropylphenyl)-5-methyl-l,3-oxazol-4-yl]methyl}-2-methyl-lH-indol-3- yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine]
Figure imgf000099_0002
Following the general procedure II described hereinabove with 4-chloromethyl-2-(4- isopropyl-phenyl)-5-methyl-oxazole (the preparation of which has been described in WO2002092084 & WO2004031162) as electrophile, the title compound was obtained as a white solid. ES-MS m/e (%):.560.4 (M+H+).
Example 62 r-[(l-{[2-(4-ethylphenyl)-5-methyl-l,3-oxazol-4-yl]methyl}-2-methyl-lH-indol-3- yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] - -
Figure imgf000100_0001
Following the general procedure II described hereinabove with 4-chloromethyl-2-(4- ethyl-phenyl)-5-methyl-oxazole (the preparation of which has been described in WO2002092084) as electrophile, the title compound was obtained as a white solid. ES-MS m/e (%):.546.4 (M+H+).
Example 63 r-[(2-methyl-l-{[5-methyl-2-(2-methylphenyl)-l,3-oxazol-4-yl]methyl}-lH-indol-3- yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine]
Figure imgf000100_0002
Following the general procedure II described hereinabove with 4-chloromethyl-5-methyl- 2-o-tolyl-oxazole (the preparation of which has been described in WO2004031162) as electrophile, the title compound was obtained as a white solid. ES-MS m/e (%):532.3 (M+H+).
Example 64 r-{[2-methyl-l-({5-methyl-2-[4-(trifluoromethyl)phenyl]-l,3-oxazol-4-yl}methyl)-lH- indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'-piperidine] - -
Figure imgf000101_0001
Following the general procedure II described hereinabove with 4-chloromethyl-5-methyl- 2-(4-trifluoromethyl-phenyl)-oxazole (the preparation of which has been described in J. Med. Chem. 2000, 43, 995-1010) as electrophile, the title compound was obtained as a white solid. ES-MS m/e (%):.586.3 (M+H+).
Example 65 r-ICl-methyl-l-dS-methyl-l-tl-Ctrifluoromethy^phenyll-l^-oxazoM-ylJmethyl)-!!!- indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'-piperidine]
Figure imgf000101_0002
Following the general procedure II described hereinabove with 4-chloromethyl-5-methyl- 2-(2-trifluoromethyl-phenyl)-oxazole (the preparation of which has been described in WO2004031162) as electrophile, the title compound was obtained as a white solid. ES-MS m/e (%):.586.5 (M+H+).
Example 66 r-[(5-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] - -
Figure imgf000102_0001
Amide coupling according to general procedure I described hereinabove: - Amine: spiro[isobenzofuran-l(3H),4'-piperidine] prepared as described in J.Org.Chem. 1976, 41, 2628, - Acid: S-Chloro-lH-indole-S-carboxylic acid (commercially available), ES-MS m/e (%):.367.1 (M+H+).
Example 67 r-[(l-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine]
Figure imgf000102_0002
Amide coupling according to general procedure I described hereinabove:
- Amine: spiro[isobenzofuran-l(3H),4'-piperidine] prepared as described in J.Org.Chem. 1976, 41, 2628,
- Acid: l-Methyl-lH-indole-S-carboxylic acid (commercially available), ES-MS m/e (%): 347.5 (M+H+).
Example 68 r-[(l-benzyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine]
Figure imgf000103_0001
Amide coupling according to general procedure I described hereinabove: - Amine: spiro[isobenzofuran-l(3H),4'-piperidine] prepared as described in J.Org.Chem. 1976, 41, 2628, - Acid: l-benzyl-lH-indole-3-carboxylic acid (described in example 3), ES-MS m/e (%): 423.6 (M+H+).
Example 69 r-[(6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine]
Figure imgf000103_0002
Amide coupling according to general procedure I described hereinabove:
- Amine: spiro[isobenzofuran-l(3H),4'-piperidine] prepared as described in J.Org.Chem. 1976, 41, 2628,
- Acid: 6-chloro- lH-indole-3-carboxyric acid (the preparation of which is described hereinafter), ES-MS m/e (%):.367.2 (M+H+).
6-chloro- lH-indole-3-carboxylic acid
Using a procedure described in J. Med. Chem. 1991, 34, 140, from 7.0 g (0.046 mmol) of
6-chloro- lH-indole was prepared 5.80 g (64%) of 6-chloro- lH-indole-3-carboxylic acid as a light brown solid. ES-MS m/e (%): 194 (M-H+). - -
Example 70 l'-(lH-indol-3-ylcarbonyl)-3H-spiro[2-benzofuran-l,4'-piperidine]
Figure imgf000104_0001
Amide coupling according to general procedure I described hereinabove:
- Amine: spiro[isobenzofuran-l(3H),4'-piperidine] prepared as described in J. Org. Chem. 1976, 41, 2628,
- Acid: lH-Indole-3-carboxylic acid (commercially available), ES-MS m/e (%):.333.3 (M+H+).
Example 71
N,N-dimethyl-2-[3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH- indol-l-yl]ethan amine
Figure imgf000104_0002
To a stirred solution of 20 mg (0.060 mmol) of l'-(lH-indol-3-ylcarbonyl)-3H-spiro[2- benzofuran-l,4'-piperidine] ( the preparation of which has been described in example 70) in DMF (3 ml) at RT, was added 2.9 mg (0.072 mmol) of NaH (60% in oil). The mixture was stirred 20 min. and then 13 mg (0.072 mmol) of (2-chloro-ethyl)-dimethyl-amine in 1 ml of DMF was added. The mixture was stirred an additional 5 hours at 5O0C and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Flash chromatography (CH2Cl2/ MeOH 8/2) afforded 11 mg (48%) of N,N-dimethyl-2-[3-(lΗ,3H-spiro[2-benzofuran-l,4'- - - piperidin]-r-ylcarbonyl)-lH-indol-l-yl]ethanamine as a viscous oil. ES-MS m/e (%): 404.3 (M+H+).
Example 72 l-methyl-l-tS-CrH^H-spiroCl-benzofuran-l^'-piperidinj-r-ylcarbony^-lH-indol-l- yl]butan-l-one
Figure imgf000105_0001
Amide coupling according to general procedure I described hereinabove: - Amine: spiro[isobenzofuran-l(3H),4'-piperidine] prepared as described in J. Org. Chem. 1976, 41, 2628, - Acid: 2-(2-Methyl-butyryl)-lH-indole-3-carboxylic acid (commercially available), ES-MS m/e (%):.417 (M+H+).
Example 73
2-[6-chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)-lH-indol-l- yl]propanenitrile
Figure imgf000105_0002
To a stirred solution of 100 mg (0.26 mmol) of l'-[(6-chloro-lH-indol-3-yl)carbonyl]- 3H-spiro[2-benzofuran-l,4'-piperidine] (the preparation of which has been described in example 69) in 5 ml DMF was added 11.5 mg (0.28 mmol) NaH (60% in oil). The mixture was stirred at RT for 30 min. and then 35 mg (0.26 mmol) of 2-bromo- propionitrile was added. The mixture was stirred overnight and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Flash chromatography (EtOAc/Hx, 1:1; SiO2) afforded 93 mg (91%) of 2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH- indol-1-yl] propanenitrile as a light yellow solid. ES-MS m/e (%): 420(M+H+).
Example 74
3-[6-chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)-lH-indol-l- yljpropanenitrile
Figure imgf000106_0001
To a stirred solution of 100 mg (0.26 mmol) of l'-[(6-chloro-lH-indol-3-yl)carbonyl]- 3H-spiro[2-benzofuran-l,4'-piperidine] (the preparation of which has been described in example 69) in 5 ml DMF was added 11.5 mg (0.28 mmol) NaH (60% in oil). The mixture was stirred at RT for 30 min. and then 35 mg (0.26 mmol) of 3-bromo- propionitrile was added. The mixture was stirred for two days at RT and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Flash chromatography (EtOAc/Hx, 2:1; SiO2) afforded 105 mg (96%) of 3-[6-chloro-3-(lΗ,3H-spko[2-benzofuran-l,4'-piperidin]-l'- ylcarbonyl)-lH-indol-l-yl] propanenitrile as a white solid. ES-MS m/e (%): 420(M+H+).
Example 75
4-[6-chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl]butanenitrile
Figure imgf000107_0001
To a stirred solution of 100 mg (0.26 mmol) of l'-[(6-chloro-lH-indol-3-yl)carbonyl]- 3H-spiro[2-benzofuran-l,4'-piperidine] (the preparation of which has been described in example 69) in 5 ml DMF was added 11.5 mg (0.28 mmol) NaH (60% in oil). The mixture was stirred at RT for 30 min. and then 35 mg (0.26 mmol) of 4-bromo- butyronitrile was added. The mixture was stirred for two days at RT and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Flash chromatography (EtOAc/Hx, 2:1; SiO2) afforded 99 mg (88%) of 4-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- ylcarbonyl)- lH-indol- l-yl]butanenitrile as a white solid. ES-MS m/e (%): 434(M+H+).
Example 76
[6-chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yljacetonitrile
Figure imgf000107_0002
To a stirred solution of 100 mg (0.26 mmol) of l'-[(6-chloro-lH-indol-3-yl)carbonyl]- 3H-spiro[2-benzofuran-l,4'-piperidine] (the preparation of which has been described in example 69) in 5 ml DMF was added 11.5 mg (0.28 mmol) NaH (60% in oil). The mixture was stirred at RT for 30 min. and then 35 mg (0.26 mmol) of bromo-acetonitrile was added. The mixture was stirred overnight at RT and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. Flash chromatography (EtOAc/Hx, 2:1; SiO2) afforded 43 mg (41%) of [6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH- indol-1-yl] acetonitrile as a white solid. ES-MS m/e (%): 406(M+H+).
Examples of compounds of formula (I-e)
Example 77 r-fCθ-chloro-lH-indol-S-y^carbonyyspirofl-benzofuran-S^'-piperidine]
Figure imgf000108_0001
Amide coupling according to general procedure I described hereinabove:
- Amine: commercially available spiro[l-benzofuran-3,4'-piperidine],
- Acid: ό-chloro-lH-indole-S-carboxylic acid (described in example 5), ES-MS m/e (%): 367.4 (M+H+).
Example 78 r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]spiro[l-benzofuran-3,4'-piperidine]
Figure imgf000108_0002
Amide coupling according to general procedure I described hereinabove:
- Amine: commercially available spiro[l-benzofuran-3,4'-piperidine],
- Acid: l-Benzyl-2-methyl-lH-indole-3-carboxylic acid (described in example 1), ES-MS m/e (%): 437.6 (M+H+). - -
Example 79 l'-(lH-indol-3-ylcarbonyl)spiro[l-benzofuran-3,4'-pipeπdine]
Figure imgf000109_0001
Amide coupling according to general procedure I described hereinabove:
- Amine: commercially available spiro[l-benzofuran-3,4'-piperidine],
- Acid: lH-Indole-3-carboxylic acid (commercially available), ES-MS m/e (%): 333.4 (M+H+).
Example 80 r-fCό-chloro-S-fluoro-lH-indol-S-y^carbonyyspirofl-benzofuran-S^'-piperidine]
Figure imgf000109_0002
Amide coupling according to general procedure I described hereinabove:
- Amine: commercially available spiro[l-benzofuran-3,4'-piperidine],
- Acid: ό-chloro-S-fluoro-lH-indole-S-carboxylic acid (the preparation of which is described hereinafter),
ES-MS m/e (%): 385.1 (M+H+). a) 6-chloro-5-fluoro-lH-indole:
Following the procedure described in WO9747598, from 6-chloro-5-fluoro-lH-indole- 2,3-dione was prepared 6-chloro-5-fluoro-lH-indole. b) 6-chloro-5-fluoro-lH-indole-3-carboxylic acid: - -
Following a procedure described in J. Med. Chem. 1991, 34, 140, from 0.25 g (1.47 mmol) of 6-chloro-5-fluoro-lH-indole was prepared 0.35 g (90%) of 6-chloro-5-fluoro-lH- indole-3-carboxylic acid as a light brown solid. ES-MS m/e (%): 213 (M-H+).
Example 81 2-[6-chloro-3-(rH-spiro[l-benzofuran-3,4'-piperidin]-r-ylcarbonyl)-lH-indol-l-yl]-
N,N-dimethylethan amine
Figure imgf000110_0001
Following the general procedure III as described hereinabove with commercially available (2-chloro-ethyl)-dimethyl-amine as electrophile, the title compound was obtained as colorless viscous oil. ES-MS m/e (%): 438.1 (M+H+).
Example 82 r-{[6-chloro-l-(2-pyrrolidin-l-ylethyl)-lH-indol-3-yl]carbonyl}spiro[l-benzofuran-
3,4'-piperidine]
Figure imgf000110_0002
Following the general procedure III as described hereinabove with commercially available l-(2-chloro-ethyl)-pyrrolidine as electrophile, the title compound was obtained as a colorless viscous oil. ES-MS m/e (%): 464.0 (M+H+). Example 83
3-[6-chloro-3-(rH-spiro[l-benzofuran-3,4'-piperidin]-l'-ylcarbonyl)-lH-indol-l-yl]-
N,N-dimethylpropan-l-amine
Figure imgf000111_0001
Following the general procedure III as described hereinabove with commercially available (3-chloro-propyl)-dimethyl-amine as electrophile, the title compound was obtained as colorless viscous oil. ES-MS m/e (%): 452.0 (M+H+).
Example 84 l'-{[6-chloro-l-(2-morpholin-4-ylethyl)-lH-indol-3-yl]carbonyl}spiro[l-benzofuran-
3,4'-piperidine]
Figure imgf000111_0002
Following the general procedure III as described hereinabove with commercially available 4-(2-chloro-ethyl)-morpholine as electrophile, the title compound was obtained as a colorless viscous oil.
ES-MS m/e (%): 480.1 (M+H+).
Example 85
2-[6-chloro-3-(rH-spiro[l-benzofuran-3,4'-piperidin]-l'-ylcarbonyl)-lH-indol-l-yl]-
N,N-diethylethan amine - -
Following the general procedure III as described hereinabove with commercially available (2-bromo-ethyl)-diethyl-amine as electrophile, the title compound was obtained as colorless viscous oil. ES-MS m/e (%): 466.2 (M+H+).
Example 86 l'-({6-chloro-l-[2-(lH-pyrrol-l-yl)ethyl]-lH-indol-3-yl}carbonyl)spiro[l-benzofuran-
3,4'-piperidine]
Figure imgf000112_0002
Following the general procedure III as described hereinabove with commercially available l-(2-chloro-ethyl)-lH-pyrrole as electrophile, the title compound was obtained as a white solid. ES-MS m/e (%): 460.2 (M+H+).
Example 87 l'-{[6-chloro-l-(2-oxo-2-piperidin-l-ylethyl)-lH-indol-3-yl]carbonyl}spiro[l- benzofuran-3,4'-piperidine] - -
Figure imgf000113_0001
Following the general procedure III as described hereinabove with commercially available 2-chloro-l-piperidin-l-yl-ethanone as electrophile, the title compound was obtained as a white solid. ES-MS m/e (%): 492.2 (M+H+).
Examples of compounds of formula (I-b)
Example 88
r-{[6-Chloro-l-(3-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine
Figure imgf000113_0002
Following the general procedure VII as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'-piperidine] (prepared according to example 8) with commercially available 3-fluorobenzoyl chloride gave the title compound.
ES-MS m/e (%): 488.5(M+H+). - -
Example 89
l'-{[6-Chloro-l-(2-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-l,2-dihydrospiro[indole-
3,4'-piperidine
Figure imgf000114_0001
Following the general procedure VII as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'-piperidine] (prepared according to example 8) with commercially available 2-fluorobenzoyl chloride gave the title compound.
ES-MS m/e (%): 488.4(M+H+).
Example 90
r-{[6-Chloro-l-(3,5-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-l,2- dihydrospiro[indole-3,4'-piperidine
Figure imgf000114_0002
Following the general procedure VII as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'-piperidine] (prepared according to example 8 above) with commercially available 3,5-difluorobenzoyl chloride gave the title compound.
ES-MS m/e (%): 506.4(M+H+).
Example 91
r-{[6-Chloro-l-(2,3-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-l,2- dihydrospiro[indole-3,4'-piperidine
Figure imgf000115_0001
Following the general procedure VII as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'-piperidine] (prepared according to example 8) with commercially available 2,3-difluorobenzoyl chloride gave the title compound.
ES-MS m/e (%): 506.4(M+H+).
Example 92
r-({6-Chloro-l-[(3,5-difluorophenyl)sulfonyl]-lH-indol-3-yl}carbonyl)-l,2- dihydrospiro[indole-3,4'-piperidine
- -
Figure imgf000116_0001
Following the general procedure VII as described above, the sulphonylation of l'-[(6- chloro-lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'-piperidine] (prepared according to example 8) with commercially available 3,5-difluorobenzenesulfonyl chloride gave the title compound.
ES-MS m/e (%): 542.4(M-H+).
Example 93
l'-{[6-Chloro-l-(3,5-difluorobenzyl)-lH-indol-3-yl]carbonyl}-l,2-dihydrospiro[indole-
3,4'-piperidine
Figure imgf000116_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'-piperidine] (prepared according to example 8) with commercially available 3,5-difluorobenzyl chloride gave the title compound.
ES-MS m/e (%): 492.4(M+H+).
Example 94 - - r-lfό-Chloro-l-CS-fluorobenzy^-lH-indol-S-yllcarbonylJ-l^-dihydrospirofindole-S,^- piperidine
Figure imgf000117_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'-piperidine] (prepared according to example 8) with commercially available 3-fluorobenzyl chloride gave the title compound.
ES-MS m/e (%): 474.4(M+H+).
Example 95
2-[6-Chloro-3-(l,2-dihydro-rH-spiro[indole-3,4'-piperidin]-l'-ylcarbonyl)-lH-indol- l-yl]-l-(3,5-difluorophenyl)ethanone
Figure imgf000117_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'-piperidine] (prepared according to example 8) with commercially available 2-chloro-l-(3, 5-difluoro-phenyl)-ethanone gave the title compound. - -
ES-MS m/e (%): 520.4(M+H+).
Example 96
2-[6-Chloro-3-(l,2-dihydro-rH-spiro[indole-3,4'-piperidin]-l'-ylcarbonyl)-lH-indol- l-yl]-l-(3,4-difluorophenyl)ethanone
Figure imgf000118_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'-piperidine] (prepared according to example 8) with commercially available 2-chloro-l-(3, 4-difluoro-phenyl)-ethanone gave the title compound.
ES-MS m/e (%): 520.4(M+H+).
Example 97
2-[6-Chloro-3-(l,2-dihydro-rH-spiro[indole-3,4'-piperidin]-r-ylcarbonyl)-lH-indol- l-yl]-l-(2-fluorophenyl)ethanone
Figure imgf000118_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'-piperidine] (prepared according - o - to example 8) with commercially available 2-chloro-l-(2-fluoro-phenyl)-ethanone gave the title compound.
ES-MS m/e (%): 502.5(M+H+).
Example 98
2-[6-Chloro-3-(l,2-dihydro-rH-spiro[indole-3,4'-piperidin]-r-ylcarbonyl)-lH-indol-
1-yl] -N,N-diethylethan amine
Figure imgf000119_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'-piperidine] (prepared according to example 8) with commercially available diethylaminoethyl bromide gave the title compound.
ES-MS m/e (%): 465.4(M+H+).
Example 99
2-[6-Chloro-3-(l,2-dihydro-rH-spiro[indole-3,4'-piperidin]-l'-ylcarbonyl)-lH-indol-
1-yl] -N,N-diethylacetamide
Figure imgf000120_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'-piperidine] (prepared according to example 8) with commercially available 2- chloro-N,N- diethyl- acetamide gave the title compound.
ES-MS m/e (%): 479.5 (M+H+).
Example 100
2-[6-Chloro-3-(l,2-dihydro-rH-spiro[indole-3,4'-piperidin]-l'-ylcarbonyl)-lH-indol-
1-yl] -N,N-dimethylacetamide
Figure imgf000120_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'-piperidine] (prepared according to example 8) with commercially available 2- chloro-N,N- diethyl- acetamide gave the title compound.
ES-MS m/e (%): 451.5(M+H+).
Example 101 - -
2-[6-Chloro-3-(l,2-dihydro-rH-spiro[indole-3,4'-piperidin]-r-ylcarbonyl)-lH-indol- l-yl]-l-pyridin-2-ylethanone
Figure imgf000121_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'-piperidine] (prepared according to example 8) with commercially available 2-chloro-l-pyridin-2-yl-ethanone gave the title compound.
ES-MS m/e (%): 485.4(M+H+).
Example 102
r-{[6-Chloro-l-(pyridin-3-ylmethyl)-lH-indol-3-yl]carbonyl}-l,2-dihydrospiro[indole-
3,4'-piperidine]
Figure imgf000121_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'-piperidine] (prepared according to example 8) with commercially available 3-bromomethyl-pyridine gave the title compound. ES-MS m/e (%): 457.2(M+H+).
Example 103
r-{[6-Chloro-l-(pyridin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-l,2-dihydrospiro[indole-
3,4'-piperidine]
Figure imgf000122_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-l,2-dihydrospiro[indole-3,4'-piperidine] (prepared according to example 8) with methanesulfonic acid pyridin-2-ylmethyl ester (described in WO 9955318) gave the title compound.
ES-MS m/e (%): 457.2(M+H+).
Examples of compounds of formula (I-c)
Example 104
l'-{[6-Chloro-l-(2-oxo-2-piperidin-l-ylethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000123_0001
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (the preparation of which has been described in example 16) with commercially available 2- chloro-1-piperidin-l-yl-ethanone as electrophile, the title compound was obtained as a white powder.
ES-MS m/e (%): 506.0 (M+H+).
Example 105
l'-{[6-Chloro-l-(2-morpholin-4-yl-2-oxoethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000123_0002
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (the preparation of which has been described in example 16) with commercially available 2- chloro-l-morpholin-4-yl-ethanone as electrophile, the title compound was obtained as a white powder.
ES-MS m/e (%): 508.1 (M+H+).
Example 106
2-{6-Chloro-3-[(3-oxo-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-r-yl)carbonyl]-lH- indol-l-yl}-N,N-dimethylacetamide
Figure imgf000124_0001
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (the preparation of which has been described in example 16) with commercially available 2- chloro-N,N-dimethyl-acetamide as electrophile, the title compound was obtained as a white powder.
ES-MS m/e (%): 466.1 (M+H+).
Example 107
2-{6-Chloro-3-[(3-oxo-rH,3H-spiro[2-benzofuran-l,4'-piperidin]-r-yl)carbonyl]-lH- indol-l-yl}-N,N-diethylacetamide
Figure imgf000125_0001
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (the preparation of which has been described in example 16) with commercially available 2- chloro-N,N-diethyl-acetamide as electrophile, the title compound was obtained as a white powder.
ES-MS m/e (%): 494.1 (M+H+).
Example 108
l'-{[6-Chloro-l-(piperidin-l-ylcarbonyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000125_0002
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (the preparation of which has been described in example 16) with commercially available piperidine-1-carbonyl chloride as electrophile, the title compound was obtained as a white powder.
ES-MS m/e (%): 492.1 (M+H+). Example 109
tert-Butyl {6-chloro-3-[(3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- 1-yl Jacetate
Figure imgf000126_0001
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (the preparation of which has been described in example 16) with commercially available chloro-acetic acid tert-butyl ester as electrophile, the title compound was obtained as a white powder.
ES-MS m/e (%): 495.2 (M+H+).
Example 110
2-{6-Chloro-3-[(5-fluoro-3-oxo-rH,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- 1-yl }-N,N-dimethylacetamide
Figure imgf000126_0002
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro-lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one - O -
(the preparation of which has been described in example 19) with commercially available 2-chloro-N,N-dimethyl-acetamide as electrophile, the title compound was obtained as a white solid.
ES-MS m/e (%): 484.0 (M+H+).
Example 111
r-({6-Chloro-l-[2-(dimethylamino)ethyl]-lH-indol-3-yl}carbonyl)-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000127_0001
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro-lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (the preparation of which have been described in example 19) with commercially available (2-chloro-ethyl)-dimethyl-amine as electrophile, the title compound was obtained as a white solid.
ES-MS m/e (%): 470.1 (M+H+).
Example 112
tert-Butyl {6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- 1-yl Jacetate
Figure imgf000128_0001
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro-lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (the preparation of which have been described in example 19) with commercially available chloro-acetic acid tert-butyl ester as electrophile, the title compound was obtained as a white solid.
ES-MS m/e (%): 513.2 (M+H+).
Example 113
l'-{[6-Chloro-l-(2-morpholin-4-yl-2-oxoethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000128_0002
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro-lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (the preparation of which have been described in example 19) with commercially available 2-chloro-l-morpholin-4-yl-ethanone as electrophile, the title compound was obtained as a white solid. - o -
ES-MS m/e (%): 526.2 (M+H+).
Example 114
l'-({6-Chloro-l-[2-(4-methylpiperazin-l-yl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000129_0001
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro-lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (the preparation of which have been described in example 19) with commercially available 2-chloro-l-(4-methyl-piperazin-l-yl)-ethanone as electrophile, the title compound was obtained as a white solid.
ES-MS m/e (%): 539.4 (M+H+).
Example 115
2-{6-Chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- 1-yl Jacetamide
Figure imgf000129_0002
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro-lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (the preparation of which have been described in example 19) with commercially available chloro-acetic acid methyl ester as electrophile, an ester intermediate methyl {6- chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-yl)carbonyl]- lH-indol-l-yl}acetate was obtained as a white solid.
This intermediate compound, methyl {6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2- benzofuran-l,4'-piperidin]-l'-yl)carbonyl]-lH-indol-l-yl}acetate, was then hydrolysed using standard conditions (aq.NaOH IM, MeOH, room temperature) to give {6-chloro- 3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-yl)carbonyl]-lH- indol-l-yl}acetic acid as a white solid.
An amide coupling between {6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran- l,4'-piperidin]-l'-yl)carbonyl]-lH-indol-l-yl}acetic acid and NH4OH (25% in water) afforded the title coumpound as a white solid.
ES-MS m/e (%): 456.4 (M+H+).
Example 116
2-{6-Chloro-3-[(5-fluoro-3-oxo-rH,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- 1-yl }-N-methylacetamide
Figure imgf000130_0001
An amide coupling between {6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran- l,4'-piperidin]-l'-yl)carbonyl]-lH-indol-l-yl}acetic acid (described herein above) and methyl amine afforded the title coumpound as a white solid.
ES-MS m/e (%): 470.3 (M+H+). Example 117
l'-{[6-Chloro-l-(2-oxo-2-piperazin-l-ylethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000131_0001
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro-lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (the preparation of which have been described in example 19) with commercially available 4-(2-Chloro-acetyl)-piperazine-l-carboxylic acid tert-butyl ester as electrophile, the title compound was obtained as a white solid after removal of the Boc protecting group under standard conditions (TFA/ dichloromethane, room temperature).
ES-MS m/e (%): 525.1 (M+H+).
Example 118
2-{6-Chloro-3-[(5-fluoro-3-oxo-rH,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl]-lH-indol-l-yl}-N-[2-(dimethylamino)ethyl]acetamide
Figure imgf000131_0002
- -
An amide coupling between {6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran- l,4'-piperidin]-l'-yl)carbonyl]-lH-indol-l-yl}acetic acid (described herein above) and N,N-dimethyl-ethane-l,2-diamine afforded the title coumpound as a white solid.
ES-MS m/e (%): 527.2 (M+H+).
Example 119
2-{6-Chloro-3-[(3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-pipeπdin]-r-yl)carbonyl]-lH- indol-l-yl}-N-[2-(dimethylamino)ethyl]acetamide
Figure imgf000132_0001
An amide coupling between {6-chloro-3-[(3-oxo-l'H,3H-spiro[2-benzofuran-l,4'- piperidin]-l'-yl)carbonyl]-lH-indol-l-yl}acetic acid (described herein above) and N ,N- dimethyl-ethane-l,2-diamine afforded the title coumpound as a white solid.
ES-MS m/e (%): 509.2 (M+H+).
Example 120
2-{6-Chloro-5-methyl-3-[(3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- 1-yl }-N,N-dimethylacetamide
a) l-(6-Chloro-5-methyl-lH-indol-3-yl)-2,2,2-trifluoro-ethanone
Figure imgf000132_0002
Using a procedure described in J. Med. Chem. 1991, 34, 140, from 0.250 g (0.002 mol) of 6-chloro-5-methyl-lH-indole were prepared 0.38 g (96%) of l-(6-chloro-5methyl-lH- indol-3-yl)-2,2,2-trifluoro-ethanone as a white solid.
b) 2-r6-Chloro-5-methyl-3-(2,2,2-trifluoro-acetyl)-indol- 1-yll -N,N- dimethyl- acetamide
Figure imgf000133_0001
To a stirred solution of l-(6-chloro-5methyl-lH-indol-3-yl)-2,2,2-trifluoro-ethanone (0.38 g) in 10 ml of DMF at 00C were added 64 mg (1.1 eq.) of NaH (60% in oil). After stirring the mixture for 30 min. were added 0.16 ml (1.1 eq.) of dimethylamino- acetyl chloride. The mixture was stirred for an additional hour and then poured onto water and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4 and concentrated in vacuo to afford 300 mg (60%) of the title compound as a white solid.
c) 6-Chloro- l-dimethylcarbamoylmethyl-5-methyl- lH-indole-3-carboxylic acid
Figure imgf000133_0002
Using a similar procedure as described in J. Med. Chem. 1991, 34, 140, from 0.280 g of 2- [6-chloro-5-methyl-3-(2,2,2-trifluoro-acetyl)-indol- 1-yl] -N,N- dimethyl- acetamide were prepared 0.18 g (76%) of the title compound as a white solid.
d) 2-{6-chloro-5-methyl-3-r(3-oxo-lΗ,3H-spiror2-benzofuran-l,4'-piperidinl-r- vDcarbonyll - lH-indol- l-yl]-N,N-dimethylacetamide
Figure imgf000134_0001
Amide coupling according to general procedure I described hereinabove:
- Amine: 3H-spiro[2-benzofuran-l,4'-piperidin]-3-one prepared as described in J. Org. Chem, 1976, 41, 2628,
- Acid: ό-Chloro-l-dimethylcarbamoylmethyl-S-methyl-lH-indole-S-carboxylic acid,
ES-MS m/e (%): 480.3 (M+H+).
Example 121
l'-[(l-Benzyl-2-methyl-lH-indol-3-yl)carbonyl]-5-bromo-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one
a) 5-Bromo-r-methyl-3H-spiror2-benzofuran-l,4'-piperidinl-3-one
Figure imgf000134_0002
Butyllithium (97.2 ml of 1.47 M solution in hexane, 143 mmol) was added dropwise to a solution of 2,5-Dibromo-benzoic acid (20 g, 72 mmol) in dry THF (300 ml) at -78° C over a period of 3.5 h under a nitrogen atmosphere. The reaction mixture was stirred at - 78 0C for 2 h. A solution of N-methyl piperidone (11.31 g, 99 mmol) in hexane (40 mL) was added dropwise during 30 min to the reaction mixture at -78 0C. The reaction mixture was allowed to come to room temperature and stirring was continued for overnight. The reaction mixture was added to a mixture of water (500 ml) and ether (300 mL). The aqueous layer was extracted with ether (5 X 150 mL) and acidified with concentrated HCI (to pH 2-3) and extracted with ether (2 X 150 ml). The acidic solution was boiled for 1 h and then cooled to 0-5 0C and made alkaline (to pH 9-10) with aqueous NaOH. The cold solution was rapidly extracted with chloroform (5 X 300 mL). The combined chloroform extracts were washed with water (150 ml), dried over sodium sulfate and evaporated under reduced pressure. The residue was purified was purified by silica gel (100-200) column chromatography eluting with methanol in dichloromethane (0.5% to 2.5%) to afford the desired product (4.2 g, 20%).
1H-NMR (400MHz, CDCl3): δ 1.71 (d, J = 14.2 Hz, 2H), 2.15-2.24 (m, 2H), 2.37 (s, 3H), 2.45-2.52 (m, 2H), 2.83-2.87 (m, 2H), 7.26 (d, J = 8.25 Hz, IH), 7.75 (dd, J = 7.8, 1.7 Hz, IH). 13C-NMR (100MHz, CDCl3): δ 35.95, 46.05, 51.42, 84.00, 122.54, 122.97, 127.52, 128.64, 137.06, 152.24, 167.77.
b) 5-Bromo-3-oxo-lΗ,3H-spiror2-benzofuran-l,4'-piperidinel-r-carbonitrile
Figure imgf000135_0001
A solution of the N-methylpiperidine (3.0 g, 10 mmol) in choloroform (50 ml) was added dropwise to a stirred boiling solution of cyanogen bromide (12.16 g, 120 mmol) in chloroform (100 ml) under a nitrogen atmosphere and the resulting solution was refluxed for overnight. The reaction mixture was cooled and washed with 25 mL of 5%
HCl and then with 20 ml of water. The organic layer was dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (100-200) eluting with methanol in dichloromethane (0.5% to 1.0%) to get the pure product (1.6 g, 51%).
1H-NMR (400MHz, CDCl3): δ 1.72 (d, J = 14.2Hz, 2H), 2.24-2.32 (m, 2H), 3.37-3.59 (m, 4H), 7.32 (d, J= 8.2 Hz, IH), 7.83 (dd, J = 8.0, 1.7Hz, IH), 8.03 (d, J= 1.7Hz, IH).
c) 5-Bromo-3H-spiror2-benzofuran-l,4'-piperidinl-3-one
Figure imgf000136_0001
A mixture of cyanoamine (1.0 g, 3.2 mmnol) and 20%HCI (12 ml) was heated under reflux under a nitrogen atmosphere for 6 h. The reaction mixture was cooled to 0-5 0C and pH was adjusted to 9-10 with aqueous NaOH solution and rapidly extracted with chloroform (3 X 50 ml). The combined extracts were washed with water, the organic layer was dried over sodium sulfate and evaporated under reduced pressure. The residue was washed with distilled hexane and dried under high vacuum to get the pure product (0.64 g, 70%).
IR (KBr) 3333.84, 290.53, 283525, 2811.07, 2749.38, 1756.04, 1470.28, 1415.14, 1271.03, 1196.28, 1083.84, 929.07, 831.50, 792.35, 734.78, 691.24, 548.46, 534.50 cm"1. 1H-NMR (400MHz, CDCl3): δ 1.66-1.72 (m, 2H), 2.02-2.09 (m, 2H), 3.07-3.18 (m, 4H), 7.29 (d, J = 7.8 Hz, IH), 7.77 (dd, J = 7.8, 1.7 Hz, IH), 7.99 (d, J = 1.7Hz, IH). 13C-NMR (100MHz, CDCl3): δ 6.33, 42.49, 85.23, 122.61, 122.93, 127.39, 128.64, 137.07, 152.44, 167.91. HA-MS: 282.1 and 284.1; C12Hj2 79BrNO2 [MH+] requires 282.1. mp: 162-163 0C.
d) r-r(l-Benzyl-2-methyl-lH-indol-3-yl)carbonyll-5-bromo-3H-spiror2-benzofuran- l,4'-piperidinl-3-one
Figure imgf000136_0002
Following the general procedure I as described above, the acylation of 5-bromo-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one with l-benzyl-2-methyl-lH-indole-3- carboxylic acid (preparation described in example 1), gave the title compound.
ES-MS m/e (%): 531.5(M+H+). - -
Example 122
l'-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-6-(2-hydroxyethoxy)-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
a) 6-fluoro-r-methyl-3H-spiror2-benzofuran-l,4'-piperidinl-3-one
Figure imgf000137_0001
To a solution of the substituted 2-bromo-4-fluoro-benzoic acid (10.9 g, 50 mmol) in dry THF (200 ml) at -78 0C n-butyllithium (1.6 M in hexanes) (lOOmmol) was added drop wise (3 h) and the resulting solution was stirred for an additional 2 h at the same temperature. Freshly distilled N-methyl 4- piperidone (7.91 g, 70mmol) in dry hexane (25 ml) was added over 30 min at the same temperature. The mixture was then allowed to stir at rt and was finally added to ether (200 ml) and water (300 ml). The basic (aqueous) layer was extracted with ether (5 X 100 ml) and the aqueous layer was acidified with concentrated hydrochloric acid (pH 2-3) and extracted with ether. The aqueous solution was boiled for 1 h and was then cooled to 0-5 0C and made alkaline (pH 9-10) with cold aqueous sodium hydroxide. The cold solution was rapidly extracted with chloroform (5 X 200 ml). The combined chloroform extracts were washed with water, dried, concentrated to give light yellow solid which was purified over neutral alumina eluting with a gradient of 30-50% ethyl acetate-hexane to obtain 1.75 g (15%) of the desired product as a white solid.
1H-NMR (CDCl3, 400 MHz): δ 1.68-1.75 (m, 2H), 2.18-2.19 (m, IH), 2.38 (s, 3H), 2.44- 2.52 (m, 2H), 2.68-2.84 (m, 2H), 2.84-2.85 (m, IH), 7.02-7.05 (m, IH), 7.19-7.22 (m, IH), 7.84-7.87 (m, IH); HA-MS: 236 (M + 1).
b) 6-Fluoro-3-oxo-lΗ,3H-spiror2-benzofuran-l,4'-piperidinel-r-carbonitrile - -
Figure imgf000138_0001
To a solution of the 6-fluoro-r-methyl-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (1.17 g, 5 mmol) in dry chloroform (10 ml) was added cyanogenbromide (60 mnol) and the resulting solution was refluxed for 36 h. The reaction mixture was extracted with 5% HCI (5 ml) and then with water (2.5 ml). The chloroform solution was dried (anhydrous MgSO4) and concentrated to give a pale yellow soild which was chromatographed over SiO2 eluting with 1% MeOH-dichloromethaneto give 858 mg (70%) the desired product as a white solid.
1H-NMR (CDCl3, 400 MHz): δ 1.72-1.76 (m, 2H), 2.22-2.30 (m, IH), 3.48-3.60 (m, 4H), 7.09-7.11 (m, IH), 7.11-7.28 (m, IH), 7.89-7.92 (m, IH); IR (KBr): 3492, 3043, 2216, 1760, 1602, 1478 cm"1.
c) 5-(2-hvdroxyethoxy)-3H-spiror2-benzofuran-l,4'-piperidin1-3-one
Figure imgf000138_0002
6-Fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidine]-r-carbonitrile (1.23 g, 5 mmol) was heated with ethylene glycol (5 ml) and sodium hydroxide (0.82 g, 20.5 mmol) for 15-20 min at 130 0C. Most of the ethylene glycol was removed by distillation under high vaccum. The residual reaction mixture was diluted with water and extracted repeatedly with chloroform. The combined organics was dried and concentrated to give a semi solid material which was purified over Al2O3 column upon elution with 5-7% MeOH/CH2CI2 containing NH3 (aqueous) to yield 789 mg (60%) of the desired product as a pale yellow solid.
1H-NMR (d6-DMSO, 400 MHz): δ 1.47-1.50 (m, 2H), 2.03-2.10 (m, 2H), 2.79-2.85 (m, 2H), 2.95-2.97 (m, 2H), 3.73-3.76 (m, 2H), 4.12-4.14 (m, 2H), 7.09 (d, J = 8.4 Hz, IH), - -
7.20 (s, IH), 7.69 (d, J = 8.4 Hz, IH); 13C-NMR (d6-DMSO, 100 MHz) : δ 35.9, 42.3, 59.3, 70.4, 84.6, 106.4, 116.6, 117.0, 126.8, 156.9, 163.9, 168.5; HA-MS: 264.3 (M + 1).
d) r-rf l-Benzyl-2-methyl-lH-indol-3-yl)carbonyll-6-(2-hvdroxyethoxy)-3H-spiror2- benzofuran- l,4'-piperidinl -3- one
Figure imgf000139_0001
Following the general procedure I as described above, the acylation of 5- (2- hydroxyethoxy)-3H-spiro[2-benzofuran- l,4'-piperidin] -3-one with l-benzyl-2-methyl- lH-indole-3-carboxylic acid (preparation described in example 1), gave the title compound.
ES-MS m/e (%): 511.6(M+H+).
Example 123
l'-({l-[2-(3,4-Dimethoxyphenyl)ethyl]-5-methoxy-2-methyl-lH-indol-3-yl}carbonyl)- 3H-spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000139_0002
Following the general procedure I as described above, the acylation of 3H-spiro[2- benzofuran-l,4'-piperidin] -3-one prepared as described in example 16 above, with commercially available l-[2-(3,4-dimethoxy-phenyl)-ethyl]-5-methoxy-2-methyl-lH- indole-3-carboxylic acid, gave the title compound.
ES-MS m/e (%): 555.3 (M+Η+).
Example 124
r-{[l-(4-Ethoxyphenyl)-5-methoxy-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000140_0001
Following the general procedure I as described above, the acylation of 3H-spiro[2- benzofuran-l,4'-piperidin]-3-one prepared as described in example 16, with commercially available l-(4-ethoxyphenyl)-5-methoxy-2-methyl-lH-indole-3-carboxylic acid, gave the title compound.
ES-MS m/e (%): 511.5 (M+Η+).
Example 125
5-Bromo-l'-[(6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one
- -
Figure imgf000141_0001
Following the general procedure I as described above, the acylation of 5-bromo-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one with lH-indole-3-carboxylic acid (commercially available), gave the title compound.
ES-MS m/e (%): 459.3(M+H+).
Example 126
l'-[(l-Benzyl-2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one
Figure imgf000141_0002
Following the general procedure I as described above, the acylation of 3H-spiro[2- benzofuran-l,4'-piperidin]-3-one prepared as described in example 16 above with 1- benzyl-2-methyl-lH-indole-3-carboxylic acid (preparation described in example 1), gave the title compound.
ES-MS m/e (%): 451.6(M+H+).
Example 127 - - r-lfo-Chloro-l-CS^-difluoropheny^-lH-indol-S-yljcarbonylJ-SH-spirofl-benzofuran- l,4'-piperidin]-3-one
Figure imgf000142_0001
Following the general procedure VI as described above, the arylation of l'-[(6-chloro-lH- indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16) with commercially available 3,5-difluorophenylboronic acid gave the title compound.
ES-MS m/e (%): 493.1(M+H+).
Example 128
r-lfό-chloro-l-CS-fluorobenzoy^-lH-indol-S-yllcarbonylJ-SH-spirofl-benzofuran-l,^- piperidin]-3-one
Figure imgf000142_0002
Following the general procedure VII as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared - - according to example 16 above) with commercially available 3-fluorobenzoyl chloride gave the title compound.
ES-MS m/e (%): 503.4(M+H+).
Example 129
l'-{[6-Chloro-l-(2-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one
Figure imgf000143_0001
Following the general procedure VII as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16) with commercially available 2-fluorobenzoyl chloride gave the title compound.
ES-MS m/e (%): 503.4(M+H+).
Example 130
r-{[6-Chloro-l-(3,5-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one
Figure imgf000143_0002
Following the general procedure VII as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16) with commercially available 3,5-difluorobenzoyl chloride gave the title compound.
ES-MS m/e (%): 521.4(M+H+).
Example 131
r-{[6-Chloro-l-(2,3-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one
Figure imgf000144_0001
Following the general procedure VII as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16) with commercially available 2,3-difluorobenzoyl chloride gave the title compound.
ES-MS m/e (%): 521.4(M+H+).
Example 132
r-({6-Chloro-l-[(3,5-difluorophenyl)sulfonyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one - -
Figure imgf000145_0001
Following the general procedure VII as described above, the sulphonylation of l'-[(6- chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16 above) with commercially available 3,5-difluorobenzenesulfonyl chloride gave the title compound.
ES-MS m/e (%): 557.4(M+H+).
Example 133
r-{[6-Chloro-l-(3,5-difluorobenzyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one
Figure imgf000145_0002
Following the general procedure III as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16 above) with commercially available 3,5-difluorobenzyl chloride gave the title compound.
ES-MS m/e (%): 507.4(M+H+).
Example 134 - - r-lfό-Chloro-l-CS-fluorobenzy^-lH-indol-S-yllcarbonylJ-SH-spirofl-benzofuran-l,^- piperidin]-3-one
Figure imgf000146_0001
Following the general procedure III as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16) with commercially available 3-fluorobenzyl chloride gave the title compound.
ES-MS m/e (%): 489.4(M+H+).
Example 135
l'-({6-Chloro-l-[2-(3-fluorophenyl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000146_0002
Following the general procedure III as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16) with commercially available 2-chloro-l-(3-fluoro-phenyl)- ethanone gave the title compound. - -
ES-MS m/e (%): 517.4(M+H+).
Example 136
r-({6-Chloro-l-[2-(2,5-difluorophenyl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000147_0001
Following the general procedure III as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16) with commercially available 2-chloro-l-(2,5-difluoro-phenyl)- ethanoneethanone gave the title compound.
ES-MS m/e (%): 535.4(M+H+).
Example 137
l'-{[6-Chloro-l-(3-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000147_0002
Following the general procedure VII as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with commercially available 3-fluorobenzoyl chloride gave the title compound.
ES-MS m/e (%): 521.4(M+H+).
Example 138
r-{[6-Chloro-l-(2-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000148_0001
Following the general procedure VII as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with commercially available 2-fluorobenzoyl chloride gave the title compound.
ES-MS m/e (%): 521.4(M+H+).
Example 139
r-{[6-Chloro-l-(2,3-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one - -
Figure imgf000149_0001
Following the general procedure VII as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with commercially available 3,5-difluorobenzoyl chloride gave the title compound.
ES-MS m/e (%): 539.4(M+H+).
Example 140
r-{[6-Chloro-l-(2,3-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000149_0002
Following the general procedure VII as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with commercially available 2,3-difluorobenzoyl chloride gave the title compound.
ES-MS m/e (%): 539.3(M+H+). - -
Example 141
r-({6-Chloro-l-[(3,5-difluorophenyl)sulfonyl]-lH-indol-3-yl}carbonyl)-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000150_0001
Following the general procedure VII as described above, the sulphonylation of l'-[(6- chloro-lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with commercially available 3,5- difluorobenzenesulfonyl chloride gave the title compound.
ES-MS m/e (%): 575.3(M+H+).
Example 142
r-{[6-Chloro-l-(3,5-difluorobenzyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000150_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with commercially available 3,5-difluorobenzyl chloride gave the title compound.
ES-MS m/e (%): 525.4(M+H+).
Example 143
l'-{[6-Chloro-l-(3-fluorobenzyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000151_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with commercially available 3-fluorobenzyl chloride gave the title compound.
ES-MS m/e (%): 507.4(M+H+).
Example 144
l'-({6-Chloro-l-[2-(3-fluorophenyl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one - -
Figure imgf000152_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with commercially available 2-chloro-l-(3-fluoro- phenyl) -ethanone gave the title compound.
ES-MS m/e (%): 535.4 (M+H+).
Example 145
5-Bromo-l'-{[6-chloro-l-(3-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000152_0002
Following the general procedure VII as described above, the acylation of 5-bromo-l'-[(6- chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one with commercially available 3-fluorobenzoyl chloride gave the title compound.
ES-MS m/e (%): 581.2(M+H+). - - Example 146
5-Bromo-l'-{[6-chloro-l-(2-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000153_0001
Following the general procedure VII as describeed above, the acylation of 5-bromo-l'- [(6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-onewith commercially available 3-fluorobenzoyl chloride gave the title compound.
ES-MS m/e (%): 581.2(M+H+).
Example 147
5-Bromo-l'-{[6-chloro-l-(3,5-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000153_0002
Following the general procedure VII as describeed above, the acylation of 5-bromo-l'- [(6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one with commercially available 3,5-difluorobenzoyl chloride gave the title compound. - -
ES-MS m/e (%): 599.2(M+H+).
Example 148
5-Bromo-l'-{[6-chloro-l-(2,3-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000154_0001
Following the general procedure VII as describeed above, the acylation of 5-bromo-l'- [(6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one with commercially available 2,3-difluorobenzoyl chloride gave the title compound.
ES-MS m/e (%): 599.2(M+H+)
Example 149
S-Bromo-l'-do-chloro-l-fCS^-difluoropheny^sulfonyy-lH-indol-S-ylJcarbony^-SH- spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000154_0002
Following the general procedure VII as described above, the sulphonylation of 5-bromo- r-[(6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one with commercially available 3,5-difluorobenzenesulfonyl chloride gave the title compound.
ES-MS m/e (%): 635.2(M+H+).
Example 150
5-Bromo-l'-{[6-chloro-l-(3,5-difluorobenzyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000155_0001
Following the general procedure III as described above, the alkylation of 5-bromo- 1'- [(6- chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one with commercially available 3,5-difluorobenzyl chloride gave the title compound.
ES-MS m/e (%): 585.2(M+H+).
Example 151
5-Bromo-r-{[6-chloro-l-(3-fluorobenzyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one - -
Figure imgf000156_0001
Following the general procedure III as described above, the alkylation of 5-bromo-l'-[(6- chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one with commercially available 3-fluorobenzyl chloride gave the title compound.
ES-MS m/e (%): 567.3(M+H+).
Example 152
5-Bromo-l'-({6-chloro-l-[2-(3-fluorophenyl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000156_0002
Following the general procedure III as described above, the alkylation of 5-bromo-l'-[(6- chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one with commercially available 2-chloro-l-(3-fluoro-phenyl)-ethanone gave the title compound.
ES-MS m/e (%): 595.3(M+H+).
Example 153 - - l'-({6-Chloro-l-[2-(2-fluorophenyl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000157_0001
Following the general procedure III as described above, the alkylation of 3H-spiro[2- benzofuran-l,4'-piperidin]-3-one prepared as described in example 16 with commercially available 2-chloro-l-(3-fluoro-phenyl)-ethanone gave the title compound.
ES-MS m/e (%): 517.4(M+H+).
Example 154
r-({6-Chloro-l-[2-(3,4-difluorophenyl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000157_0002
Following the general procedure III as described above, the alkylation of 3H-spiro[2- benzofuran-l,4'-piperidin]-3-one prepared as described in example 16 above with commercially available 2-chloro-l-(3, 4-difluoro-phenyl)-ethanone gave the title compound. ES-MS m/e (%): 535.4(M+H+).
Example 155
l'-{[6-Chloro-l-(3-fluorophenyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one
Figure imgf000158_0001
Following the general procedure VI as described above, the arylation of l'-[(6-chloro-lH- indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16 above) with commercially available 3-fluorophenylboronic acid gave the title compound.
ES-MS m/e (%): 475.0(M+H+).
Example 156
l'-[(l-Biphenyl-3-yl-6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one
- -
Figure imgf000159_0001
Following the general procedure VI as described above, the arylation of l'-[(6-chloro-lH- indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16) with commercially available 3-biphenylboronic acid gave the title compound.
ES-MS m/e (%): 533.0(M+H+).
Example 157
l'-[(l-Biphenyl-2-yl-6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one
Figure imgf000159_0002
Following the general procedure VI as described above, the arylation of l'-[(6-chloro-lH- indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16) with commercially available 2-biphenylboronic acid gave the title compound.
ES-MS m/e (%): 533.0(M+H+). - - Example 158
l'-{[l-(Biphenyl-3-ylcarbonyl)-6-chloro-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000160_0001
Following the general procedure VII as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16) with commercially available biphenyl-3-carbonyl chloride gave the title compound.
ES-MS m/e (%): 561.4(M+H+).
Example 159
r-[(6-Chloro-l-pyridin-2-yl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one
Figure imgf000160_0002
To a solution of r-[(6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one (prepared according to example 16 above) in dry DMF was added NaH - D -
(1 eq) and the reaction mixture stirred at room temperature for 30 min and then treated with 2-fluoropyridine (1.5 eq) and heated at 140 0C under microwave irradiation for 15 min. Purification by preparative HPLC gave the desired product in 38% yield.
ES-MS m/e (%): 458.1(M+H+).
Example 160
r-[(6-Chloro-l-pyridin-2-yl-lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one
Figure imgf000161_0001
To a solution of l'-[(6-chloro-lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) in dry DMF was added NaH (1 eq) and the reaction mixture stirred at room temperature for 30 min and then treated with 2-fluoropyridine (1.5 eq) and heated at 140 0C under microwave irradiation for 15 min. Purification by preparative HPLC gave the desired product in 36% yield.
ES-MS m/e (%): 476.0(M+H+).
Example 161
r-({6-Chloro-l-[(2-methylpyridin-4-yl)methyl]-lH-indol-3-yl}carbonyl)-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one - -
Figure imgf000162_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with 4-chloromethyl-2-methyl-pyridine (described in WO 2006023707) gave the title compound.
ES-MS m/e (%): 504.2(M+H+).
Example 162
r-[(l-{[4-Amino-2-(methoxymethyl)pyrimidin-5-yl]methyl}-6-chloro-lH-indol-3- yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000162_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with 5-chloromethyl-2-methoxy-pyrimidin-4- ylamine gave the title compound. - -
ES-MS m/e (%): 550.2(M+H+).
Example 163
r-({l-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-6-chloro-lH-indol-3-yl}carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000163_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19 above) with 5-chloromethyl-2-methyl-pyrimidin-4- ylamine (described in Pharmaceutical Chemistry Journal (Translation of Khimiko- Farmatsevticheskii Zhurnal) (1999), 33(2), 101-103) gave the title compound.
ES-MS m/e (%): 520.2(M+H+).
Example 164
l'-({6-Chloro-l-[(6-chloropyridin-3-yl)methyl]-lH-indol-3-yl}carbonyl)-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one
- -
Figure imgf000164_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with commercially available 2-chloro-5- chloromethylpyridine gave the title compound.
ES-MS m/e (%): 524.1(M+H+).
Example 165
r-({6-Chloro-l-[(3-chloro-6-methylpyridazin-4-yl)methyl]-lH-indol-3-yl}carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000164_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19 above) with 3-chloro-4-chloromethyl-6-methyl- pyridazine (prepared by US 3453277) gave the title compound. - -
ES-MS m/e (%): 539.1(M+H+).
Example 166
r-{[6-Chloro-l-(pyridin-4-ylmethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000165_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with commercially available 4-bromomethyl- pyridine gave the title compound.
1H-NMR (300MHz, CDC13): δ 1.75 (m, 2H), 2.26-2.39 (m, 2H), 3.3 (m, 2H), 4.45 (m, 2H), 5.6 (s, 2H), 7.15 (m, 3H), 7.65 (m, 3H), 7.8 (d,lH), 7.92 (m,lH), 8.03 (s,lH), 8.52(d,2H)
Example 167
r-{[6-Chloro-l-(2-pyridin-4-ylethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
- -
Figure imgf000166_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with commercially available 4-(2-bromo-ethyl)- pyridine gave the title compound.
ES-MS m/e (%): 504.2(M+H+).
Example 168
r-{[6-Chloro-l-(pyridin-4-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one
Figure imgf000166_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16) with commercially available 4-bromomethyl-pyridine gave the title compound.
ES-MS m/e (%): 472.3(M+H+). - - Example 169
r-{[6-Chloro-l-(2-oxo-2-pyridin-2-ylethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000167_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19 above) with commercially available 2-bromo-l- pyridin-2-ylethanonegave the title compound.
ES-MS m/e (%): 518.4(M+H+).
Example 170
l'-({6-Chloro-l-[2-(5-methyl-2-phenyl-l,3-oxazol-4-yl)-2-oxoethyl]-lH-indol-3- yl}carbonyl)-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000167_0002
- -
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with 2-bromo-l-(5-methyl-2-phenyl-oxazol-4-yl)- ethanone (described in Journal of Medicinal Chemistry (1992), 35(14), 2617-26) gave the title compound.
ES-MS m/e (%): 598.4(M+H+).
Example 171
r-{[6-Chloro-l-(pyridin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
a) Methanesulfonic acid pyridin-3-ylmethyl ester
To a mixture of 2-(hydroxymethyl)pyridine , DMAP and NEt3 was slowly added MsCl at 0 0C and the reaction mixture was stirred at room temperature for Ih. The reaction mixture was extracted with water and dichloromethane The organic phase was dried on Na2SO4, filtered and the solvent was evaporated. Silica gel column chromatography (dichloromethane / MeOH 99:1) gave the title compound in 52% yield.
ES-MS m/e (%): 188.1 (M+H+).
b) r-{r6-chloro-l-(pyridin-2-ylmethyl)-lH-indol-3-yllcarbonyl]-5-fluoro-3H-spiror2- benzofuran- l,4'-piperidinl -3- one
Figure imgf000168_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one - oo -
(prepared according to example 19) with methanesulfonic acid pyridin-2-ylmethyl ester (described in WO 9955318) gave the desired product in 29% yield;
ES-MS m/e (%): 490.0(M+H+).
Example 172
r-{[6-Chloro-l-(pyridin-3-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one
Figure imgf000169_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16) with commercially available 3-bromomethyl-pyridine gave the title compound.
ES-MS m/e (%): 472.1(M+H+).
Example 173
l'-{[6-Chloro-l-(pyrazin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
- o -
Figure imgf000170_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with methanesulfonic acid pyrazin-2-ylmethyl ester (preparation described in WO 2002064574) gave the title compound.
ES-MS m/e (%): 491.0(M+H+).
Example 174
r-{[6-Chloro-l-(pyrimidin-5-ylmethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
a) Methanesulfonic acid pyrimidin-5-ylmethyl ester
To a mixture of pyrimidin-5-yl-methanol, DMAP and NEt3 was slowly added MsCl at 0 0C and the reaction mixture was stirred at room temperature for 3h. The reaction mixture was extracted with water and dichloromethane. The organic phase was dried on Na2SO4, filtered and the solvent was evaporated. Silica gel column chromatography (Ethyl acetate/hexane 1:1) gave the title compound in 40% yield.
b) l'-ire-Chloro-l^pyrimidin-S-ylmethvD-lH-indol^-yllcarbonyll-S-fluoro^H- spiror2-benzofuran-l,4'-piperidinl-3-one - -
Figure imgf000171_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with methanesulfonic acid pyrimidin-5-ylmethyl ester gave the title compound.
ES-MS m/e (%): 491.0(M+H+).
Example 175
3-{6-Chloro-3-[(5-fluoro-3-oxo-rH,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl]-lH-indol-l-yl}propanenitrile
Figure imgf000171_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with commercially available 3-bromo-propionitrile gave the title compound. - -
ES-MS m/e (%): 452.0(M+H+).
Example 176
l'-[(7-Chloro- 1-oxo- l,2,3,4-tetrahydropyrazino[l,2-a]indol- 10- yl)carbonyl] -5-fluoro- 3H-spiro[2-benzofuran-l,4'-piperidin]-3-one
a) 6-Chloro-lH-indole-2,3-dicarboxylic acid 2-ethyl ester
Figure imgf000172_0001
To a solution of commercially available 6-chloro-3-formyl- IH- indole- 2-carboxylic acid ethyl ester in t-BuOΗ and 2-methyl-2-butene (50 eq) was added 9.2 eq NaClO2 (9 eq) and aq. NaH2PO4 (7 eq) and stirred 12h at room temperature. After concentration the mixture was dissolved in H2O and adjusted to pH7 and then extracted with EtOAc; partial concentration of the organic phase precipitated the product in 52% yield.
b) Ethyl 6-chloro-3-r(5-fluoro-3-oxo-lΗ,3H-spiror2-benzofuran-l,4'-piperidinl-r- vDcarbonyll - lH-indole-2-carboxvlate
Figure imgf000172_0002
Following the general procedure I as described above, the acylation ofl'-[(6-chloro-lH- indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with 6-chloro-lH-indole-2,3-dicarboxylic acid 2-ethyl ester gave the title compound..
ES-MS m/e (%): 471.0 (M+Η+). - - c) 6-Chloro-34(5-fluoro-3-oxo-lΗ3H-spiror2-benzofuran-l,4'-piperidin1-r- vDcarbonyll - lH-indole-2-carboxylic acid
Figure imgf000173_0001
A solution of the ethyl 6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'- piperidin] - l'-yl)carbonyl] - lH-indole-2-carboxylate in EtOH was treated with 2 eq. of aq. IN IiOH at 80 0C for 12h, then concentrated and dissolved in IN HCl and extracted with dichloromethane. Evaporation of the solvent gave the title compound in 72% yield.
d) 6-Chloro-N-f2-chloroethyl)-3-rf5-fluoro-3-oxo-lΗ,3H-spiror2-benzofuran-l,4'- piperidinl - l'-vDcarbonyll - lH-indole-2-carboxamide
Figure imgf000173_0002
To a stirred solution of 6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'- piperidin]-l'-yl)carbonyl]-lH-indole-2-carboxylic acid in dichloromethane were added EDC, HOBt, NEt3 and 2-chloroethylamine hydrochloride. The reaction mixture was stirred at room temperature for 2 days. The reaction mixture was poured onto water and extracted with dichloromethane. The combined organic phases were dried over Na2SO4 and the solvent was evaporated. Column chromatography (ethyl acetate/hexane 1:1) gave the desired compound in 59% yield.
MS m/e (%) : 504.0 (M+H+). - - e) 1'-[(7-ChIoTO- 1-oxo- 1,2,3,4- tetrahydropyrazino [1,2- alindol- 10- vDcarbonyll -5-fluoro- 3H-spiro[2-benzofuran-l,4'-piperidin1-3-one
Figure imgf000174_0001
A solution of the 6-chloro-N-(2-chloroethyl)-3-[(5-fluoro-3-oxo-l'H,3H-spiro[2- benzofuran-l,4'-piperidin]-l'-yl)carbonyl]-lH-indole-2-carboxamide in dry DMF was treated with NaH (1 eq) and stirred for Ih at room temperature, then treated with a further portion of NaH (1 eq) and stitted for 2h at room temperature. Dilution with water and extraction with EtOAc followed by washing with aq. NH4Cl gave the crude product which was purified by silica gel chromatography (dichloromethane/MeOH 98:2) to give 42% yield of the desired product.
ES-MS m/e (%): 468.3 (M+H+).
Example 177
l'-({l-[(4-Benzylmorpholin-2-yl)methyl]-6-chloro-lH-indol-3-yl}carbonyl)-5-fluoro- 3H-spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000174_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19 above) with commercially available 4-benzyl-2- (chloromethyl)morpholine gave the title compound.
ES-MS m/e (%): 588.2(M+H+).
Example 178
l'-({6-Chloro-l-[(l,4-dibenzylpiperazin-2-yl)methyl]-lH-indol-3-yl}carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000175_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with l,4-dibenzyl-2-chloromethyl-piperazine (described in Journal of Medicinal Chemistry 1999, 42(9), 1587-1603) gave the title compound.
ES-MS m/e (%): 677.3(M+H+).
Example 179
l'-({6-Chloro-l-[(5-methylisoxazol-3-yl)methyl]-lH-indol-3-yl}carbonyl)-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one - -
Figure imgf000176_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with methanesulfonic acid 5-methyl-isoxazol-3- ylmethyl ester (described in WO 2004092172) gave the title compound.
ES-MS m/e (%): 494.1(M+H+).
Example 180
r-{[6-Chloro-l-(pyridin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one
Figure imgf000176_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16 above) with methanesulfonic acid pyridin-2-ylmethyl ester (described in WO 9955318) gave the title compound.
ES-MS m/e (%): 472.1(M+H+). - - Example 181
6-Chloro-3-[(5-fluoro-3-oxo-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] -N-methyl- lH-indole-2-carboxamide
Figure imgf000177_0001
A suspension of the 6-chloro-3-[(5-fluoro-3-oxo-l'H,3H-spiro[2-benzofuran-l,4'- piperidin]-l'-yl)carbonyl]-lH-indole-2-carboxylic acid in dichloromethane was treated with EDC (1.2 eq), HOBt (1.2 eq) and Et3N (1.2 eq) and the solution stirred at room temperature for 15 min. Methylamine (1 eq) was then added and the reaction mixture stirred at room temperature for 16h. Purification by preparative HPLC yielded the desired product.
ES-MS m/e (%): 456.1(M+H+).
Example 182
l'-({6-Chloro-l-[(5-cyclopropyl-2-methyl-l,3-oxazol-4-yl)methyl]-lH-indol-3- yl}carbonyl)-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one
a) 2-Acetylamino-2-cvclopropanecarbonyl-malonic acid diethyl ester
Figure imgf000177_0002
To a solution of 6 eq KOt-Bu in THF at room temperature was added 6 eq 2- acetylamino-malonic acid diethyl ester and after 5 min 1 eq cyclopropane- carbonylchloride. After 15min, the mixture was concentrated and partitioned between EtOAc and H2O. The organic layer was concentrated to give the desired product in 60% yield.
ES-MS m/e (%): 286.2 (M+H+).
b) 5-Cvclopropyl-2-methyl-oxazole-4-carboxyric acid ethyl ester
Figure imgf000178_0001
2-Acetylamino-2-cyclopropanecarbonyl-malonic acid diethyl ester in DMSO was treated with 2 eq H2O and stirred at room temperature for 6h then extracted with Et2O to give after concentration the title compound in 34% yield.
c) (5-Cvclopropyl-2-methyl-oxazol-4-yl)-methanol
Figure imgf000178_0002
A solution of 5-cyclopropyl-2-methyl-oxazole-4-carboxylic acid ethyl ester in Et2O at O 0C was treated sequentially with (2 x 2.3 eq) IiBH4 and stirred for Ih. 10 eq of MeOH were then added and the solution stirred for 4h at room temperature. Sequential addition of aq NH4Cl (H2 evolution) and then Na2CO3/NaCl gave a mixture which was extracted with EtOAc to give after concentration the title compound in 16% yield.
ES-MS m/e (%): 154.1 (M+H+).
d) r-f{6-Chloro-l-rf5-cvclopropyl-2-methyl-l,3-oxazol-4-yl)methyll-lH-indol-3- yl]carbonyl)-5-fluoro-3H-spiror2-benzofuran-l,4'-piperidin1-3-one - -
Figure imgf000179_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with methanesulfonic acid 5-cyclopropyl-2-methyl- oxazol-4-ylmethyl ester (prepared by mesylation of (5-cyclopropyl-2-methyl-oxazol-4- yl) -methanol) gave the title compound.
ES-MS m/e (%): 534.2(M+H+).
Example 183
r-({6-Chloro-l-[(l-methyl-lH-imidazol-5-yl)methyl]-lH-indol-3-yl}carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000179_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with methanesulfonic acid 3-methyl-3H-imidazol-4- ylmethyl ester (prepared by mesylation of the commercially available (3-methyl-3H- imidazo 1-4- yl) -methanol) gave the title compound.
ES-MS m/e (%): 493.1(M+Η+).
Example 184
r-({6-Chloro-l-[(3-methylisoxazol-5-yl)methyl]-lH-indol-3-yl}carbonyl)-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000180_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with methanesulfonic acid 3-methyl-isoxazol-5- ylmethyl ester (described in Heterocycles, 23(3), 571-83; 1985) gave the title compound.
ES-MS m/e (%): 494.1(M+H+).
Example 185
r-({6-Chloro-l-[(l,5-dimethyl-lH-pyrazol-3-yl)methyl]-lH-indol-3-yl}carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one - -
Figure imgf000181_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with methanesulfonic acid 1,5-dimethyl-lH-pyrazol- 3-ylmethyl ester (prepared by mesylation of commercially available methanesulfonic acid 1,5-dimethyl- lH-pyrazol-3-ylmethyl ester) gave the title compound.
ES-MS m/e (%): 507.2(M+Η+).
Example 186
r-({6-Chloro-l-[(3,5-dimethylisoxazol-4-yl)methyl]-lH-indol-3-yl}carbonyl)-5-fluoro- 3H-spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000181_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19 above) with methanesulfonic acid 3,5-dimethyl- - o - isoxazol-4-ylmethyl ester (prepared by mesylation of the commercially available 1,5- dimethyl-lH-pyrazol-3-yl)-methanol) gave the title compound.
ES-MS m/e (%): 508.2(M+Η+).
Example 187
l'-({6-Chloro-l-[(2,5-dimethyl-l,3-oxazol-4-yl)methyl]-lH-indol-3-yl}carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000182_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19 above) with methanesulfonic acid 2,5-dimethyl- oxazol-4-ylmethyl ester (prepared by mesylation of (2,5-dimethyl-oxazol-4-yl)-methanol, described in Organic Letters (1999), 1(1), 87-90) gave the title compound.
ES-MS m/e (%): 508.1(M+H+).
Example 188
l'-({6-Chloro-l-[(3-fluorooxetan-3-yl)methyl]-lH-indol-3-yl}carbonyl)-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one - -
Figure imgf000183_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with 3-bromomethyl-3-fluoro-oxetane (described in US2005215599) gave the title compound.
ES-MS m/e (%): 487.1(M+H+).
Example 189
l'-({6-Chloro-l-[(3-fluorooxetan-3-yl)methyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one
Figure imgf000183_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16 above) with 3-bromomethyl-3-fluoro-oxetane (described in US2005215599) gave the title compound. - -
ES-MS m/e (%): 469.2(M+H+).
Example 190
r-[(6-Chloro-l-{[l-(methoxymethyl)cyclopropyl]methyl}-lH-indol-3-yl)carbonyl]-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000184_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with 1-bromomethyl-l-methoxymethyl- cyclopropane (described in WO 2001032633) gave the title compound.
ES-MS m/e (%): 497.5(M+H+).
Example 191
[l-({6-Chloro-3-[(5-fluoro-3-oxo-rH,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- 1-yl }methyl)cyclopropyl] acetonitrile
Figure imgf000184_0002
- o -
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with 1-bromomethyl-cyclopropanecarbonitrile (described in EP 148004) gave the title compound.
ES-MS m/e (%): 492.5(M+H+).
Example 192
l'-[(6-Chloro-l-{[l-(methoxymethyl)cyclopropyl]methyl}-lH-indol-3-yl)carbonyl]-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000185_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16 above) with 1-bromomethyl-l-methoxymethyl-cyclopropane (prepared as described in WO 2001032633) gave the title compound.
ES-MS m/e (%): 479.5(M+H+).
Example 193
[l-({6-Chloro-3-[(3-oxo-rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)carbonyl]- lH-indol-l-ylJmethy^cyclopropyljacetonitrile - -
Figure imgf000186_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16) with 1-bromomethyl-l-methoxymethyl-cyclopropane
(prepared by WO 2001032633) gave the title compound.
ES-MS m/e (%): 474.5(M+H+).
Example 194
6-Chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] -N-[2-(methylamino)ethyl]-lH-in dole- 2-carboxamide hydrochloride
Figure imgf000186_0002
A solution of tert-butyl {2-[({6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran- l,4'-piperidin] - l'-yl)carbonyl] - lH-indol-2-yl}carbonyl) amino] ethyl Jmethylcarbamate was treated with 4 eq of HCl in dioxane and stirred at room temperature for 3h then - oo - treated with a further portion of 4 eq of HCl in dioxane. The solution was stirred at room temperature for 16h and evaporated to give the product in 58% yield.
ES-MS m/e (%): 511.2(M+H+).
Example 195
r-dό-Chloro-l-Cl-Ctetrahydro-lH-pyran-Φy^ethyy-lH-indol-S-yljcarbony^-S-fluoro- 3H-spiro[2-benzo furan- 1,4' -piperidin]-3-one hydrochloride
Figure imgf000187_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl] -5-fluoro-3H-sp iro[2-benzo furan- l,4'-piperidin]-3-one (prepared according to example 19) with 4-(2-bromo-ethyl)-tetrahydro-pyran (described in US 2004220214) gave the title compound.
ES-MS m/e (%): 511.2 (M+H+).
Example 196
r-({6-Chloro-l-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzo furan- 1,4' -piperidin]-3-one - o -
Figure imgf000188_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16) with 4-(2-bromo-ethyl)-tetrahydro-pyran (described in US 2004220214) gave the title compound.
ES-MS m/e (%): 493.2 (M+H+).
Example 197
tert-Butyl 2-({6-chloro-3-[(3-oxo-rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'- yl)carbonyl] - lH-indol- 1-yl }methyl)morpholine-4-carboxylate
Figure imgf000188_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16) with 2-chloromethyl-morpholine-4-carboxylic acid tert-butyl ester (described in WO 2006020415) gave the title compound. - oo -
ES-MS m/e (%): 580.0(M+H+).
Example 198
l'-{[6-Chloro-l-(morpholin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzo furan- 1,4' -piperidin]-3-one hydrochloride
Figure imgf000189_0001
tert- Butyl 2-({6-chloro-3-[(3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl]-lH-indol-l-yl}methyl)morpholine-4-carboxylate was dissolved in a solution of HCl (5 eq) in dioxane and stirred at room temperature for 5h. A further portion of HCl (5 eq) in dioxane was added and the solution stirred for an additional 5h at room temperature. Evaporation gave the desired product in 96% yield.ES-MS m/e (%): 480.2 (M+H+).
Example 199
tert-Butyl 2-({6-chloro-3-[(5-fluoro-3-oxo-l'H,3H-spiro[2-benzo furan- 1,4' -piperidin]- l'-yl)carbonyl]-lH-indol-l-yl}methyl)morpholine-4-carboxylate
- -
Figure imgf000190_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with 2-chloromethyl-morpholine-4-carboxylic acid tert-butyl ester (described in WO 2006020415) gave the title compound.
ES-MS m/e (%): 598.2(M+H+).
Example 200
l'-{[6-Chloro-l-(morpholin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one dihydrochloride
Figure imgf000190_0002
tert- Butyl 2-({6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]- l'-yl)carbonyl]-lH-indol-l-yl}methyl)morpholine-4-carboxylate was dissolved in a solution of HCl (5 eq) in dioxane and stirred at room temperature for 5h. A further portion of HCl (5 eq) in dioxane was added and the solution stirred for an additional 5h at room temperature. Evaporation gave the desired product in quantitative yield.ES-MS m/e (%): 498.1 (M+H+).
Example 201
l'-{[l-(3,5-Difluorobenzyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one
Figure imgf000191_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 19) with commercially available 3,5-difluorobenzyl chloride gave the title compound.
ES-MS m/e (%): 491.5(M+H+).
Example 202
r-{[l-(3,5-Difluorobenzyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one
- -
Figure imgf000192_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16) with commercially available 3,5-difluorobenzyl chloride gave the title compound.
ES-MS m/e (%): 473.5(M+H+).
Example 203
N,N-Diethyl-2-{3-[(3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-yl)carbonyl]- lH-indol-l-yl}acetamide
Figure imgf000192_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one (prepared according to example 16) with commercially available 2- chloro-N,N- diethyl- acetamide gave the title compound. ES-MS m/e (%): 460.6(M+H+).
Examples of compounds of formula (I-d)
Example 204
r-{[6-Chloro-l-(2-oxo-2-piperidin-l-ylethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidine]
Figure imgf000193_0001
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro- lH-indol-3-yl)carbonyl] -3H-spiro[2-benzofuran- l,4'-piperidine] (the preparation of which have been described in example 69) with commercially available 2-chloro-l- piperidin-1-yl-ethanone as electrophile, the title compound was obtained as a white powder.
ES-MS m/e (%): 492.1 (M+H+).
Example 205
l'-{[6-Chloro-l-(2-morpholin-4-yl-2-oxoethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidine]
Figure imgf000193_0002
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro- lH-indol-3-yl)carbonyl] -3H-spiro[2-benzofuran- l,4'-piperidine] (the preparation of which have been described in example 69) with commercially available 2-Chloro-l- morpholin-4-yl-ethanone as electrophile, the title compound was obtained as a white powder.
ES-MS m/e (%): 494.1 (M+H+).
Example 206
2-[6-Chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] -N,N-dimethylacetamide
Figure imgf000194_0001
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro- lH-indol-3-yl)carbonyl] -3H-spiro[2-benzofuran- l,4'-piperidine] (the preparation of which have been described in example 69) with commercially available 2-chloro-N,N- dimethyl-acetamide as electrophile, the title compound was obtained as a white powder.
ES-MS m/e (%): 452.0 (M+H+).
Example 207
2-[6-Chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] -N,N-diethylacetamide
Figure imgf000195_0001
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro- lH-indol-3-yl)carbonyl] -3H-spiro[2-benzofuran- l,4'-piperidine] (the preparation of which have been described in example 69) with commercially available 2-chloro-N,N- diethyl- acetamide as electrophile, the title compound was obtained as a white powder.
ES-MS m/e (%): 480.1 (M+H+).
Example 208
l'-{[6-Chloro-l-(piperidin-l-ylcarbonyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidine]
Figure imgf000195_0002
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro- lH-indol-3-yl)carbonyl] -3H-spiro[2-benzofuran- l,4'-piperidine] (the preparation of which have been described in example 69) with commercially available piperidine-1- carbonyl chloride as electrophile, the title compound was obtained as a white powder.
ES-MS m/e (%): 478.0 (M+H+).
Example 209 tert-Butyl [6-chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)-lH- indol- 1-yl] acetate
Figure imgf000196_0001
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (the preparation of which have been described in example 69) with commercially available chloro-acetic acid tert-butyl ester as electrophile, the title compound was obtained as a white solid.
ES-MS m/e (%): 481.3 (M+H+).
Example 210
2-[6-Chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] -N,N-dimethylethan amine
Figure imgf000196_0002
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro- lH-indol-3-yl)carbonyl] -3H-spiro[2-benzofuran- l,4'-piperidine] (the preparation of which have been described in example 69) with commercially available (2-chloro- ethyl)- dimethyl- amine as electrophile, the title compound was obtained as a white solid.
ES-MS m/e (%): 438.4 (M+H+). - o - Example 211
l'-{[6-Chloro-l-(2-oxo-2-piperazin-l-ylethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidine]
Figure imgf000197_0001
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro- lH-indol-3-yl)carbonyl] -3H-spiro[2-benzofuran- l,4'-piperidine] (the preparation of which have been described in example 69) with commercially available 4-(2-chloro- acetyl)-piperazine-l-carboxylic acid tert-butyl ester as electrophile, the title compound was obtained as a white solid after removal of the Boc protecting group under standard conditions (TFA/dichloromethane, room temperature).
ES-MS m/e (%): 493.1 (M+H+).
Example 212
l'-({6-Chloro-l-[2-(4-methylpiperazin-l-yl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidine]
Figure imgf000197_0002
Following the general procedure V as described hereinabove, the alkylation of l'-[(6- chloro- lH-indol-3-yl)carbonyl] -3H-spiro[2-benzofuran- l,4'-piperidine] (the preparation of which have been described in example 69) with commercially available 2-chloro-l-(4- methyl-piperazin-l-yl)-ethanone as electrophile, the title compound was obtained as a white solid.
ES-MS m/e (%): 507.4 (M+H+).
Example 213
2-[6-Chloro-5-methyl-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)- lH-indol-l-yl]-N,N-dimethylacetamide
Figure imgf000198_0001
Amide coupling according to general procedure I described hereinabove:
- Amine: Spiro[isobenzofuran-l(3H),4'-piperidine] pepared as described in J. Org. Chem. 1976, 41, 2628,
- Acid: ό-Chloro-l-dimethylcarbamoylmethyl-S-methyl-lH-indole-S-carboxylic acid,
ES-MS m/e (%): 466.3 (M+H+).
Example 214
r-{[6-Chloro-l-(3-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine - -
Figure imgf000199_0001
Following the general procedure VII as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 3-fluorobenzoyl chloride gave the title compound.
ES-MS m/e (%): 489.4(M+H+).
Example 215
r-{[6-Chloro-l-(2-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine
Figure imgf000199_0002
Following the general procedure VII as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 2-fluorobenzoyl chloride gave the title compound.
ES-MS m/e (%): 489.4(M+H+).
Example 216 - - r-lfo-Chloro-l-CS^-difluorobenzoy^-lH-indol-S-yljcarbonylJ-SH-spirofl-benzofuran- l,4'-piperidine
Figure imgf000200_0001
Following the general procedure VII as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 3,5-difluorobenzoyl chloride gave the title compound.
ES-MS m/e (%): 507.4(M+H+).
Example 217
r-{[6-Chloro-l-(2,3-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine
Figure imgf000200_0002
Following the general procedure VII as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 2,3-difluorobenzoyl chloride gave the title compound. - -
ES-MS m/e (%): 507.4(M+H+).
Example 218
r-({6-Chloro-l-[(3,5-difluorophenyl)sulfonyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran-l,4'-piperidine
Figure imgf000201_0001
Following the general procedure VII as described above, the sulphonylation of l'-[(5- chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 3,5-difluorobenzenesulfonyl chloride gave the title compound.
ES-MS m/e (%): 543.3(M+H+).
Example 219
r-{[6-Chloro-l-(3,5-difluorobenzyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine - -
Figure imgf000202_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 3,5-difluorobenzyl chloride gave the title compound.
ES-MS m/e (%): 493.4(M+H+).
Example 220
r-{[6-Chloro-l-(3-fluorobenzyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'- piperidine
Figure imgf000202_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 3-fluorobenzyl chloride gave the title compound.
ES-MS m/e (%): 475.4(M+H+). - - Example 221
l'-{[l-(Biphenyl-3-ylcarbonyl)-6-chloro-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidine
Figure imgf000203_0001
Following the general procedure VII as described above, the acylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available biphenyl-3-carbonyl chloride gave the title compound.
ES-MS m/e (%): 547.4(M+H+).
Example 222
r-{[6-Chloro-l-(3,5-difluorophenyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine
Figure imgf000203_0002
Following the general procedure VI as described above, the arylation of l'-[(6-chloro-lH- indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 3,5-difluorophenylboronic acid gave the title compound.
ES-MS m/e (%): 478.9(M+H+).
r-lfό-Chloro-l-CS-fluoropheny^-lH-indol-S-yljcarbonylJ-SH-spirofl-benzoluran-l,^- piperidine
Figure imgf000204_0001
Following the general procedure VI as described above, the arylation of l'-[(6-chloro-lH- indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 3-fluorophenylboronic acid gave the title compound.
ES-MS m/e (%): 461.1(M+H+).
Example 224
2-[6-Chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)-lH-indol-l- yl]-l-(2-fluorophenyl)ethanone
- -
Figure imgf000205_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 2-bromo-l-(2-fluoro-phenyl)-ethanonegave the title compound.
ES-MS m/e (%): 503.4(M+H+).
Example 225
l'-[(l-Biphenyl-2-yl-6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidine
Figure imgf000205_0002
Following the general procedure VI as described above, the arylation of l'-[(6-chloro-lH- indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 2-biphenylboronic acid gave the title compound.
ES-MS m/e (%): 519.3(M+H+). - - Example 226
l'-[(l-Biphenyl-2-yl-6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidine
Figure imgf000206_0001
Following the general procedure VI as described above, the arylation of l'-[(6-chloro- IH- indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 3-biphenylboronic acid gave the title compound.
ES-MS m/e (%): 519.3(M+H+).
Example 227
r-[(6-Chloro-l-pyridin-2-yl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidine
Figure imgf000206_0002
To a solution of r-[(6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidine] (prepared according to example 69) in dry DMF was added NaH (1 eq) and ~ O - the reaction mixture stirred at room temperature for 30 minand then treated with 2- fluoropyridine (1.5 eq) and heated at 140 0C under microwave irradiation for 15 min. Purification by preparative HPLC gave the desired product in 24% yield.
ES-MS m/e (%): 444.1(M+H+).
Example 228
r-{[6-Chloro-l-(pyridin-4-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine
Figure imgf000207_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 4-bromomethyl-pyridine gave the title compound.
ES-MS m/e (%): 458.4(M+H+).
Example 229
2-[6-Chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl]-l-pyridin-2-ylethanone - -
Figure imgf000208_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69 above) with commercially available 2-bromo-l-pyridin-2-ylethanone gave the title compound.
ES-MS m/e (%): 486.4(M+H+).
Example 230
r-{[6-Chloro-l-(pyridin-3-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine]
Figure imgf000208_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 3-bromomethyl-pyridine gave the title compound. - o -
ES-MS m/e (%): 458.4(M+H+).
Example 231
r-{[6-Chloro-l-(pyridin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine]
Figure imgf000209_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with methanesulfonic acid pyridin-2-ylmethyl ester (described in WO 9955318) gave the title compound.
ES-MS m/e (%): 458.3(M+H+).
Example 232
r-({l-[(4-Benzylmorpholin-2-yl)methyl]-6-chloro-lH-indol-3-yl)carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidine]
- -
Figure imgf000210_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 4-benzyl-2-(chloromethyl)morpholine gave the title compound.
ES-MS m/e (%): 556.3(M+H+).
Example 233
l'-({6-Chloro-l-[(l,4-dibenzylpiperazin-2-yl)methyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidine]
Figure imgf000210_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69 above) with l,4-dibenzyl-2-chloromethyl-piperazine (described in Journal of Medicinal Chemistry (1999), 42(9), 1587-1603) gave the title compound.
ES-MS m/e (%): 645.3(M+H+).
Example 234
l'-{[6-Chloro-l-(pyrazin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine]
Figure imgf000211_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69 above) with methanesulfonic acid pyrazin-2-ylmethyl ester (preparation described in WO 2002064574) gave the title compound.
ES-MS m/e (%): 459.3(M+H+).
Example 235
r-{[6-Chloro-l-(pyrimidin-5-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidine - -
Figure imgf000212_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with methanesulfonic acid pyrimidin-5-ylmethyl ester (preparation described herein) gave the title compound.
ES-MS m/e (%): 459.3(M+H+).
Example 236
l'-({6-Chloro-l-[(5-methylisoxazol-3-yl)methyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran-l,4'-piperidine]
Figure imgf000212_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with methanesulfonic acid 5-methyl-isoxazol-3-ylmethyl ester (described in WO 2004092172) gave the title compound.
ES-MS m/e (%): 462.2(M+H+). - - Example 237
r-({6-Chloro-l-[(5-cyclopropyl-2-methyl-l,3-oxazol-4-yl)methyl]-lH-indol-3- yl}carbonyl)-3H-spiro[2-benzofuran-l,4'-piperidine
Figure imgf000213_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69 above) with methanesulfonic acid 5-cyclopropyl-2-methyl-oxazol-4-ylmethyl ester (prepared herein) gave the title compound.
ES-MS m/e (%): 502.2(M+H+).
Example 238
r-({6-Chloro-l-[(l-methyl-lH-imidazol-5-yl)methyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidine
Figure imgf000213_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with methanesulfonic acid 3-methyl-3H-imidazol-4-ylmethyl ester (prepared by mesylation of the commercially available (3-methyl-3H-imidazol-4-yl)- methanol) gave the title compound.
ES-MS m/e (%): 461.2(M+Η+).
Example 239
l'-({6-Chloro-l-[(3-methylisoxazol-5-yl)methyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran-l,4'-piperidine]
Figure imgf000214_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with methanesulfonic acid 3-methyl-isoxazol-5-ylmethyl ester (described in Heterocycles, 23(3), 571-83; 1985) gave the title compound.
ES-MS m/e (%): 462.2(M+H+).
Example 240
r-({6-Chloro-l-[(l,5-dimethyl-lH-pyrazol-3-yl)methyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidine - -
Figure imgf000215_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with methanesulfonic acid l,5-dimethyl-lH-pyrazol-3-ylmethyl ester (prepared by mesylation of commercially available methanesulfonic acid 1,5-dimethyl- lH-pyrazol-3-ylmethyl ester) gave the title compound.
ES-MS m/e (%): 475.2(M+Η+).
Example 241
l'-({6-Chloro-l-[(3,5-dimethylisoxazol-4-yl)methyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidine
Figure imgf000215_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with methanesulfonic acid 3,5-dimethyl-isoxazol-4-ylmethyl ester (prepared by mesylation of the commercially available l,5-dimethyl-lH-pyrazol-3-yl)-methanol) gave the title compound. - -
ES-MS m/e (%): 476.2(M+H+).
Example 242
r-({6-Chloro-l-[(2,5-dimethyl-l,3-oxazol-4-yl)methyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidine
Figure imgf000216_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with methanesulfonic acid 2,5-dimethyl-oxazol-4-ylmethyl ester (prepared by mesylation of (2,5-dimethyl-oxazol-4-yl)-methanol, described in Organic Letters 1999, 1(1), 87-90) gave the title compound.
ES-MS m/e (%): 476.2(M+H+).
Example 243
l'-({6-Chloro-l-[(3-fluorooxetan-3-yl)methyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran-l,4'-piperidine]
Figure imgf000216_0002
- -
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with 3-bromomethyl-3-fluoro-oxetane (described in US2005215599) gave the title compound.
ES-MS m/e (%): 455.2(M+H+).
Example 244
l'-[(6-Chloro-l-{[l-(methoxymethyl)cyclopropyl]methyl}-lH-indol-3-yl)carbonyl]-3H- spiro[2-benzofuran-l,4'-piperidine]
Figure imgf000217_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with 1-bromomethyl-l-methoxymethyl-cyclopropane (described in WO 2001032633) gave the title compound.
ES-MS m/e (%): 465.5(M+H+).
Example 245
(l-{[6-Chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol- l-yl]methyl}cyclopropyl)acetonitrile - -
Figure imgf000218_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with l-bromomethyl-cyclopropanecarbonitrile (described in EP 148004) gave the title compound.
ES-MS m/e (%): 460.5(M+H+).
Example 246
r-({6-Chloro-l-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidine]
Figure imgf000218_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with 4-(2-bromo-ethyl)-tetrahydro-pyran (described in US 2004220214) gave the title compound. - o -
ES-MS m/e (%): 479.5(M+H+).
Example 247
tert-Butyl 2-{[6-chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)- lH-indol-l-yl]methyl}morpholine-4-carboxylate
Figure imgf000219_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with 2-chloromethyl-morpholine-4-carboxylic acid tert-butyl ester (described in WO 2006020415) gave the title compound.
ES-MS m/e (%): 566.3(M+H+).
Example 248
l'-{[6-Chloro-l-(morpholin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidine] hydrochloride
- -
Figure imgf000220_0001
tert- Butyl 2-{[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)- lH-indol-l-yl]methyl}morpholine-4-carboxylate (prepared in example 247 above) was dissolved in a solution of HCl (5 eq) in dioxane and stirred at room temperature for 5h. A further portion of HCl (5 eq) in dioxane was added and the solution stirred for an additional 5h at room temperature. Evaporation gave the desired product in quantitative yield.ES-MS m/e (%): 466.2 (M+H+).
Example 249
2-[6-Chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)-lH-indol-l- yl]-N-[2-(dimethylamino)ethyl]acetamide
Figure imgf000220_0002
A solution of [6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)- lH-indol-1-yl] acetic acid (prepared by treatment of the sodium salt of l'-[(6-chloro-lH- indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] with bromoacetic acid at room temperature in DMF), EDC (1 eq), HOBt (1 eq) and Et3N (1 eq) were stirred together at room temperature in DMF for 15 min. N,N-Dimethyl-ethane-l,2-diamine (1 eq) was added and the solution stirred at room temperature for 16h. Purification by prep. HPLC gave 37% of product.
ES-MS m/e (%): 495.6(M+H+).
Example 250
2-[6-Chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl]acetamide
Figure imgf000221_0001
A solution of [6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)- lH-indol-1-yl] acetic acid (prepared as for 2-[6-chloro-3-(l'H,3H-spiro[2-benzofuran- l,4'-piperidin] - l'-ylcarbonyl)- lH-indol- 1-yl] -N-[2-(dimethylamino)ethyl] acetamide), O-(7-azabenzotriazol- l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.05 eq) and Et3N (1.05 eq) were stirred together at room temperature in dry DMF for 15 min. A solution of ammonia (5 eq) in dioxane was added and the solution stirred at room temperature for 16 h. Purification by prep. HPLC gave 31% of product.
ES-MS m/e (%): 424.3(M+H+).
Example 251
2-[6-Chloro-3-(l'H,3H-spiro[2-benzofuran- 1,4' -piperidin]- l'-ylcarbonyl)- lH-indol-1- yl]-N-[2-(methylamino)ethyl]acetamide
Figure imgf000222_0001
A solution of [6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)- lH-indol-1-yl] acetic acid (prepared by treatment of the sodium salt of l'-[(6-chloro-lH- indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] with bromoacetic acid at room temperature in DMF), O-(7-azabenzotriazol-l-yl)-N,N,N' ,N' - tetramethyluronium hexafluorophosphate (1.05 eq) and Et3N (1.05 eq) were stirred together at room temperature in dry DMF for 15min. Commercially available N- (2- aminoethyl)-N-methylcarbamic acid tert-butyl ester (1.5 eq) was added and the solution stirred at room temperature for 2h, then a solution of HCl (15 eq) in dioxane was added and the solution stirred for 2h. Evaporation and purification by prep. HPLC gave 37% of product.
ES-MS m/e (%): 481.3(M+H+).
Example 252
N-(2-Aminoethyl)-2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- ylcarbonyl)-lH-indol-l-yl]acetamide
- -
Figure imgf000223_0001
A solution of [6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)- lH-indol-1-yl] acetic acid (prepared by treatment of the sodium salt of l'-[(6-chloro-lH- indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] with bromoacetic acid at room temperature in DMF), O-(7-azabenzotriazol-l-yl)-N,N,N' ,N' - tetramethyluronium hexafluorophosphate (1.05 eq) and Et3N (1.05 eq) were stirred together at room temperature in dry DMF for 15min. Commercially available N-(tert-
Butoxycarbonyl)-l,2-diaminoethane (1.5 eq) was added and the solution stirred at room temperature for 2h, then a solution of HCl (15 eq) in dioxane was added and the solution stirred for 2h. Evaporation and purification by prep. HPLC gave 39% of product.
ES-MS m/e (%): 467.4(M+H+).
Example 253
2-[6-Chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl]ethan amine
Figure imgf000223_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69 above) with commercially available 2-chloro-ethylamine gave the title compound in 11% yield.
ES-MS m/e (%): 410.2(M+H+).
Example 254
2-[6-Chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)-lH-indol-l- yl] -N-methylethan amine
Figure imgf000224_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available (2-chloro-ethyl)-methyl-amine gave the title compound in 42% yield.
ES-MS m/e (%): 424.2(M+H+).
Example 255
2-[6-Chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] -N-methylacetamide - -
Figure imgf000225_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 2-chloro-N-methyl-acetamide gave the title compound in 19% yield.
ES-MS m/e (%): 438.2(M+H+).
Example 256
l'-{[6-Chloro-l-(2-morpholin-4-ylethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidine]
Figure imgf000225_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 4-(2-chloro-ethyl)-morpholine gave the title compound in 50% yield. - -
ES-MS m/e (%): 480.5(M+H+).
Example 257
l'-{[6-Chloro-l-(3-morpholin-4-ylpropyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidine]
Figure imgf000226_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 4-(3-chloro-propyl)-morpholine gave the title compound in 52% yield.
ES-MS m/e (%): 494.6(M+H+).
Example 258
l'-{[6-Chloro-l-(oxiran-2-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidine]
Figure imgf000226_0002
- D -
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 2-bromomethyl-oxirane gave the title compound in 47% yield.
ES-MS m/e (%): 423.4(M+H+).
Example 259
2-[6-Chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)-lH-indol-l- yljethanol
Figure imgf000227_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available 2-chloro-ethanol gave the title compound in 47% yield.
ES-MS m/e (%): 411.4(M+H+).
Example 260
r-({6-Chloro-l-[(2-methylpyridin-4-yl)methyl]-lH-indol-3-yl)carbonyl)-3H-spiro[2- benzofuran-l,4'-piperidine] - -
Figure imgf000228_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with 4-chloromethyl-2-methyl-pyridine (described in WO 2006023707) gave the title compound in 56% yield.
ES-MS m/e (%): 472.2(M+H+).
Example 261
r-({6-Chloro-l-[(3S)-piperidin-3-ylmethyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran-l,4'-piperidine]
Figure imgf000228_0002
A solution of the r-[(6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidine] (prepared according to example 69) in dry DMF was treated with NaH (1.1 eq) and stirred for 10 min at room temperature, then treated with (S)-3- methanesulfonyloxymethyl-piperidine-l-carboxylic acid tert-butyl ester (1.1 eq) (JP 2001278872) and stirred at room temperature for 16h then 70° for 4h. Concentration and - o - treatment with excess HCl in dioxane gave after purification by preparative HPLC the desired product in 39% yield.
ES-MS m/e (%): 464.2(M+H+).
Example 262
2-[6-Chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] -N-hydroxyethan amine
Figure imgf000229_0001
A solution of the [6-chloro-3-(rH,3H-spiro[2-benzoruran-l,4'-piperidin]-l'- ylcarbonyl)-lH-indol-l-yl]acetaldehyde in MeOH was treated with KOAc (1.5 eq) and hydroxylamine hydrochloride (1.2 eq) and stirred for 1 h at room temperature, then treated with NaCNBH3 (1.1 eq) and stirred at room temperature for 5 h. Concentration and purification by preparative HPLC the desired product in 19% yield.
ES-MS m/e (%): 426.1(M+H+).
Example 263
l'-{[6-Chloro-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-indol-3-yl]carbonyl}-3H- spiro[2-benzofuran-l,4'-piperidine] - -
Figure imgf000230_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with commercially available methanesulfonic acid 2-(tetrahydro-pyran-4- yl)-ethyl ester (described in US 2004220214) gave the title compound in 55% yield.
ES-MS m/e (%): 465.2(M+H+).
Example 264
l'-({6-Chloro-l-[(l-methylpyrrolidin-3-yl)methyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidine]
Figure imgf000230_0002
A solution of l'-{[6-chloro-l-(pyrrolidin-3-ylmethyl)-lH-indol-3-yl]carbonyl}-3H- spiro[2-benzofuran-l,4'-piperidine]in MeOH was treated with aq. H2CO (1.5 eq), AcOH (1.1 eq) and stirred for 15 min at room temperature, then treated with NaCNBH3 (1.1 eq) and stirred at room temperature for Ih. Concentration and purification by preparative HPLC gave the desired product.
ES-MS m/e (%): 464.2(M+H+). Example 265
r-[(6-Chloro-l-{[(3S)-l-methylpiperidin-3-yl]methyl}-lH-indol-3-yl)carbonyl]-3H- spiro[2-benzofuran-l,4'-piperidine]
Figure imgf000231_0001
A solution of l'-({6-chloro-l-[(3S)-piperidin-3-ylmethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidine] in MeOH was treated with aq. H2CO (1.5 eq), AcOH (1.1 eq) and stirred for 15 minat room temperature, then treated with NaCNBH3 (1.1 eq) and stirred at room temperature for Ih. Concentration and purification by preparative HPLC the desired product.
ES-MS m/e (%): 478.2(M+H+).
Example 266
l'-{[6-Chloro-l-(pyrrolidin-3-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidine]
Figure imgf000231_0002
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with methanesulfonic acid pyrrolidin-3-ylmethyl ester (described in WO 9742189) gave the title compound.
ES-MS m/e (%): 450.2(M+H+).
Example 267
r-({6-Chloro-l-[(2S)-pyrrolidin-2-ylmethyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran-l,4'-piperidine
Figure imgf000232_0001
Following the general procedure III as described above, the alkylation of l'-[(6-chloro- lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] (prepared according to example 69) with methanesulfonic acid (S)-l-pyrrolidin-2-ylmethyl ester (described in Tetrahedron: Asymmetry (1997), 8(13), 2209-2213) gave the title compound.
ES-MS m/e (%): 450.2(M+H+).
Example 268
r-[(6-Chloro-l-{[(2S)-l-methylpyrrolidin-2-yl]methyl}-lH-indol-3-yl)carbonyl]-3H- spiro[2-benzofuran-l,4'-piperidine
Figure imgf000232_0002
l'-({6-Chloro-l-[(2S)-pyrrolidin-2-ylmethyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran-l,4'-piperidine was treated with a 37% aq. formaldehyde (1.05 eq.), acetic acid (1.05 eq.) and soduim cyanoborohydride (1.0 eq.) in MeOH at room temperature for 2h to give after purification by preparative HPLC the title compound.
ES-MS m/e (%): 464.2(M+H+).
Example 269
r-[(6-Chloro-l-{[(2R)-l-methylpyrrolidin-2-yl]methyl}-lH-indol-3-yl)carbonyl]-3H- spiro[2-benzofuran-l,4'-piperidine
Figure imgf000233_0001
l'-({6-Chloro-l-[(2R)-pyrrolidin-2-ylmethyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran-l,4'-piperidine (prepared according to the procedure described above for the preparation of l'-({6-chloro-l-[(2S)-pyrrolidin-2-ylmethyl]-lH-indol-3-yl}carbonyl)- 3H-spiro[2-benzofuran-l,4'-piperidine using methanesulfonic acid (R)-l-pyrrolidin-2- ylmethyl ester instead of methanesulfonic acid (S)-l-pyrrolidin-2-ylmethyl ester) was treated with a 37% aq. formaldehyde (1.05 eq.), acetic acid (1.05 eq.) and soduim cyanoborohydride (1.0 eq.) in MeOH at room temperature for 2h to give after purification by prep. HPLC the title compound.
ES-MS m/e (%): 464.2(M+H+).
Example 270
N-{2-[6-Chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-
1 -yl] ethyl Jacetamide - -
Figure imgf000234_0001
2-[6-Chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yljethanamine was treated with acetylchloride (1.05 eq) and triethylamine (1.05 eq) in dichloromethane under argon at room temperature.for 2h to give after purification by prep. HPLC the title compound.
ES-MS m/e (%): 452.2(M+H+).
Example 271
N-{2-[6-Chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol- l-yl]ethyl}methanesulfonamide
Figure imgf000234_0002
2-[6-Chloro-3-(lΗ,3H-spiro[2-benzoruran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yljethanamine was treated with mesylchloride (1.05 eq) and triethylamine (1.05 eq) in dichloromethane under argon at room temperature.to give after purification by prep. HPLC the title compound.
ES-MS m/e (%): 488.1(M+H+).
Example 272 - -
N-{2-[6-Chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol-
1 -yl] ethyl }-N-methylacetamide
Figure imgf000235_0001
N-{2-[6-Chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol- 1-yl] ethyl Jacetamide was treated with NaH (1.05 eq), MeI (1.05 eq) in dry DMF under argon at room temperature for 2h to give after purification by prep. HPLC the title compound.
ES-MS m/e (%): 466.2(M+H+).
Example 273
N-{2-[6-Chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol- l-yl]ethyl}-N-methylmethanesulfonamide
Figure imgf000235_0002
N-{2-[6-Chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol- l-yl]ethyl}methanesulfonamide was treated with NaH (1.05 eq), MeI (1.05 eq) in dry DMF under argon at room temperature for 2h to give after purification by prep. HPLC the title compound.
ES-MS m/e (%): 502.1(M+H+).
Example 274
tert-Butyl lO-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-3,4- dihydropyrazino[l,2-a]indole-2(lH)-carboxylate
a) 10-(2,2,2-Trifluoro-acetyl)-3,4-dihvdro-lH-pyrazinor 1,2- al indole- 2-carboxylic acid tert-butyl ester
Figure imgf000236_0001
To a stirred solution of 0.21 ml (1.5 mmol) triflu or o acetic anhydride in 7 ml 1,2- dichloroethane was added at 0 0C a solution of 0.37 g (1.4 mmol) 3,4-dihydro-lH- pyrazino[l,2-a]indole- 2-carboxylic acid tert-butyl ester and a solution of 0.23 ml (1.63 mmol) triethylamine in 3 ml 1,2-dichloroethane. After stirring for 30 min the reaction mixture was quenched with saturated aqueous sodium hydrogen carbonate solution and extracted with dichloromethane (2 x 100 ml). The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography (n- heptane / ethyl acetate) to give the title compound (0.288 g, 58%) as a light yellow solid.
MS m/e (%): 369 (M+H+, 27).
b) 3,4-Dihvdro-lH-pyrazinori,2-a1indole-2J0-dicarboxylic acid 2-tert-butyl ester
Figure imgf000236_0002
- -
To a solution of 0.29 g (0.77 mmol) 10-(2,2,2-trifluoro-acetyl)-3,4-dihydro-lH- pyrazino[l,2-a]indole-2-carboxylic acid tert-butyl ester in 7 ml N,N-dimethylformamide were subsequently added 0.22 g (4.6 mmol) sodium hydride (50% in oil) and a solution of 0.070 ml (3.9 mmol) water in 1 ml N,N-dimethylformamide at room temperature. The reaction mixture was diluted with tert-butyl methyl ether after 2 h and extracted with 1 M sodium hydroxide solution (2 x 30 ml). The combined aqueous layers were acidified (pH 1-2) with 2 M hydrochloric acid at 0 0C and extracted with tert-butyl methyl ether (3 x 50 ml). The combined organic layers were dried over sodium sulfate and concentrated in vacuo to give the title compound (0.21 g, 86%) as a light brown solid.
MS m/e (%): 315 (M-H+, 100).
c) tert-Butyl lO-dΗ,3H-spiror2-benzofuran-l,4'-piperidinl-r-ylcarbonyl)-3,4- dihvdropyrazinori,2-a1indole-2(lH)-carboxvlate
Figure imgf000237_0001
To a solution of 0.10 g (0.32 mmol) 3,4-dihydro-lH-pyrazino[l,2-a]indole-2,10- dicarboxylic acid 2-tert-butyl ester, 0.066 g (0.35 mmol) spiro[isobenzofuran-l(3H),4'- piperidine] and 0.051 g (0.38 mmol) 1-hydroxybenzotriazole in 3.5 ml N,N- dimethylformamide were added 0.073 g (0.38 mmol) N-(3-dimethylaminopropyl)-N'- ethylcarbodiimide hydrochloride at room temperature. After stirring for 3 h the reaction mixture was diluted with saturated aqueous ammonium chloride solution and extracted with tert-butyl methyl ether (2 x 50 ml). The combined organic layers were washed with 1 M sodium hydroxide solution (1 x 30 ml) and water (1 x 30 ml), dried over sodium sulfate, concentrated in vacuo and purified by flash-chromatography (aminopropyl- modified silica gel, n-heptane / ethyl acetate) to give the title compound (0.097 g, 63%) as a light yellow solid.
MS m/e (%): 488 (M+H+, 81). - - Example 275
l'-( 1,2,3,4- Tetrahydropyrazino[l,2-a]indol- 10- ylcarbonyl)-3H-spiro[2-benzofuran- 1,4'- piperidine] hydrochloride
Figure imgf000238_0001
Amixture of 0.095 g (0.19 mmol) tert-butyl 10-(l'H,3H-spiro[2-benzofuran-l,4'- piperidin]-r-ylcarbonyl)-3,4-dihydropyrazino[l,2-a]indole-2(lH)-carboxylate and 1.56 ml of a 1.25 M solution of hydrochloric acid (1.95 mmol) in methanol was stirred for 15 min at 50 0C. The reaction mixture was concentrated in vacuo to give the title compound (0.084 g, 100%) as a light yellow solid.
MS m/e (%): 388 (M+H+, 100).
Example 276
l'-[(2-Methyl-l,2,3,4-tetrahydropyrazino[l,2-a]indol-10-yl)carbonyl]-3H-spiro[2- benzofuran-l,4'-piperidine]
Figure imgf000238_0002
A solution of 0.05O g (0.12 mmol) l'-(l,2,3,4-tetrahydropyrazino[l,2-a]indol-10- ylcarbonyl)-3H-spiro[2-benzofuran-l,4'-piperidine] hydrochloride, 0.033 ml (0.24 mmol) triethylamine and 0.028 g (0.94 mmol) paraformaldehyde in 2 ml methanol was heated at reflux for 1 h. The reaction mixture was cooled to 0 0C on an ice- water bath and - - treated with 0.011 g (0.18 mmol) sodium cyanoborohydride. After completed addition the mixture was allowed to warm to room temperature and stirred for 2 h. Quenching with water and dilution with 2 M aqueous sodium carbonate solution was followed by extraction with dichloromethane (2 x 50 ml). The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash-chromatography (aminopropyl-modified silica gel, n-heptane / ethyl acetate) to give the title compound (0.036 g, 76%) as an off-white solid.
MS m/e (%): 402 (M+H+, 100).
Example 277
r-[(6-Chloro-2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidine]
a) (6-Chloro-lH-indol-2-yl)-methanol
Figure imgf000239_0001
To a solution of 2.00 g (8.94 mmol) 6-chlorindole-2-carboxylic acid ethyl ester in 50 ml diethyl ether were added 0.475 g (12.5 mmol) lithium aluminum hydride at 0 0C. The reaction mixture was heated at reflux for 45 min and quenched by consecutive addition of 10 ml water, 10 ml aqueous 2 M sodium hydroxide solution and 10 ml water at 0 0C.
The aqueous layer was extracted with tert-butyl methyl ether (3 x 100 ml). The combined organic layers were dried over sodium sulfate and concentrated in vacuo to give the crude title compound (1.64 g; 100%) as a white solid.
MS m/e (%): 180 (M-H+, 100).
b) 6-Chloro-2-methyl-lH-indole
Figure imgf000239_0002
A solution of 1.60 g (8.81 mmol) (6-chloro-lH-indol-2-yl)-methanol in 5 ml 1,2- dichloroethane was added to a mixture of 80.0 ml triflu or o acetic acid and 32.0 ml - - triethylsilane at 65 0C. After 5 min, the reaction mixture was cooled to room temperature and quenched with water. The pH was adjusted to 14 by the addition of aqueous sodium hydroxide solution (32 %). The aqueous layer was extracted with tert- butyl methyl ether (3 x 200 ml). The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash-chromatography (aminopropyl-modified silica gel, n-heptane / ethyl acetate) to give the title compound (0.39 g; 27%) as a white solid.
MS m/e (%): 164 (M-H+, 100).
c) l-(6-Chloro-2-methyl-lH-indol-3-yl)-2,2,2-trifluoro-ethanone
Figure imgf000240_0001
To a solution of 0.38 g (2.3 mmol) 6-chloro-2-methyl-lH-indole in 20 ml 1,2- dichloroethane at 0 0C were added 0.35 ml (2.5 mmol) triflu or o acetic anhydride. The reaction mixture was quenched with aqueous 2 M sodium carbonate solution after 30 min and extracted with dichloromethane (3 x 100 ml). The combined organic layers were dried over sodium sulfate and concentrated in vacuo to give the title compound (0.57 g; 95%) as an off- white solid.
MS m/e (%): 260 (M-H+, 100).
d) 6-Chloro-2-methyl-lH-indole-3-carboxylic acid
Figure imgf000240_0002
A solution of 0.57 g (2.2 mmol) l-(6-chloro-2-methyl-lH-indol-3-yl)-2,2,2-trifluoro- ethanone in 21.7 ml (86.8 mmol) aqueous 4 M sodium hydroxide solution was heated at reflux for 45 min. After cooling to room temperature the reaction mixture was diluted with water and extracted with tert-butyl methyl ether (2 x 50 ml). The aqueous layer was cooled to 0-5 0C, acidified (pH 1-2) with concentrated aqueous hydrochloric acid solution and extracted with ethyl acetate (3 x 100 ml). The combined ethyl acetate layers - - were dried over sodium sulfate and concentrated in vacuo to give the title compound (0.14 g, 31%) as an off-white solid.
MS m/e (%): 208 (M-H+, 100).
e) r-r(6-Chloro-2-methyl-lH-indol-3-yl)carbonyll-3H-spiror2-benzofuran-l,4'- piperidinel
Figure imgf000241_0001
To a solution of 0.040 g (0.19 mmol) 6-chloro-2-methyl-lH-indole-3-carboxylic acid, 0.069 ml (0.40 mmol) N,N-diisopropylethylamine and 0.061 g (0.19 mmol) 2-(1H- benzotriazole-l-yl)-l,l,3,3-tetramethyluronium tetraflu or ob orate in 1 ml dry N ,N- dimethylformamide were added 0.036 g (0.19 mmol) spiro[isobenzofuran-l(3H),4'- piperidine] at room temperature. After stirring for 1 h the reaction mixture was quenched with 0.5 M aqueous sodium hydroxide solution (20 ml) and extracted with ethyl acetate (2 x 30 ml). The combined organic layers were washed with water (2 x 30 ml) and brine (1 x 30 ml), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography (n-heptane / ethyl acetate) to give the title compound (0.036 g, 49%) as a white solid.
MS m/e (%): 379 (M-H+, 100).
Example 278
r-({l-[3,5-Bis(trifluoromethyl)benzyl]-6-chloro-2-methyl-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidine] - -
Figure imgf000242_0001
To a solution of 0.031 g (0.080 mmol) l'-[(6-chloro-2-methyl-lH-indol-3-yl)carbonyl]-
3H-spiro[2-benzofuran-l,4'-piperidine] (5) in 1 ml dry N,N-dimethylformamide were added 0.004 g (0.08 mmol) sodium hydride (50 % in oil). After stirring for 20 min 0.015 ml (0.08 mmol) 3,5-bis(trifluoromethyl)benzyl bromide were added. After stirring for 16 h the reaction mixture was quenched with water and extracted with ethyl acetate (2 x 50 ml). The combined organic layers were washed with water (2 x 30 ml) and brine (I x 30), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography (n-heptane / ethyl acetate) to give the title compound (0.020 g; 41%) as a white solid.
MS m/e (%): 607 (M+H+, 100).
Examples of compounds of formula (I-f)
Example 279
5-Bromo-r-(lH-indol-3-ylcarbonyl)spiro[indole-3,4'-piperidin]-2(lH)-one
a) 5-Bromo-l,2-dihydro-2-oxospiror3H-indole-3,4'-piperidinel- ^methyl
Figure imgf000242_0002
A solution of l,2-benzo-8-methyl-3,8-diazaspiro [4,5] decane-4-one (described in Organic Preparations and Procedures International (1995), 27(6), 691-4) (6.3 g, 29.1 mmol) in CH3CN (100 ml) and MeOH (5 ml) was cooled to - 5 0C and NBS (7.8 g, 44 mmol) was slowly added with stirring. The reaction mixture was stirred for 3.5 h at 00C. Solvent was removed by vacuo. The residue was purified by silica gel chromatography (2 - 20 % MeOH/dichloromethane) to give 6 g of a solid. The solid compound was dissolved in ethyl acetate (600 ml) and washed with saturated aqueous NaHCO3 solution, dried (Na2SO4). Evaporation of the solvent in vacuo gave 4.2 g (47%) of the desired product.
1HNMR (CD3OD, 400MHz) d 7.51(d, J = 1.8 Hz, IH), 7.35(dd, J = 1.9 and 8.2 Hz, IH), 6.81(d, J= 8.2 Hz, IH), 2.93(m, 2H), 2.67(m, 2H), 2.41(s, 3H), 1.86(m, 4H).
b) 5-Bromo-l,2-dihydro-2-oxospiror3H-indole-3,4/-piperidinel-r-cvano
Figure imgf000243_0001
5-Bromo-l, 2-dihydro-2-oxospiro [3H-indole-3, 4/-piperidine]-l/-methyl (4.6 g, 15.6 mmol) was dissolved in chloroform (700 ml) and treated with CNBr (22 g, 209.5 mmol) at room temperature. The mixture was heated to reflux for 24h. The reaction mixture was cooled, diluted with methylene chloride (300 ml) and washed with 10 % aqueous K2CO3 solution (2 x 100 ml). After the mixture was dried (Na2SO4) and concentrated, the residue was purified by silica gel chromatography (0 - 5% MeOH/dichloromethane) to give the desired product as a solid (3.9 g, 82%). 1HNMR (CDCl3, 400MHz) δ 7.52 (d, J = 1.8Hz, IH), 7.37(dd, J= 1.8 and 8.2 Hz, IH), 6.82 (d, J= 8.2 Hz, IH), 3.83(m, 2H), 3.41(m, 2H), 2.00(m, 2H), 1.86(m, 2H).
c) 5-Bromospirorindole-3,4'-piperidinl-2(lH)-one
Figure imgf000243_0002
- -
5-Bromo-l,2-dihydro-2-oxospiro[3H-indole-3,4/-piperidine]-l/-cyano (3.3 g, 10.8 mmol) was suspended in ethylene glycol (10 ml). The mixture was treated in NaOH (1.8 g, 45 mmol) and heated to 130° C for 15 min. It was diluted with methylene chloride (500 ml) and washed with 10% aqueous K2CO3 (2 x 100 m). The organic layer was dried (Na2SO4) and concentrated and residue purified by silica gel chromatography (30% MeOH/dichloromethane) to give the desired product as a light ceramic white solid (1.8 g, 60%).
Mp 256 - 258° C. 1HNMR (DMSO-d6, 400MHz) δ 10.6(br s, IH, NH), 7.57(d, J = 1.84Hz, IH), 7.36(d, J = 8.2Hz, IH), 6.79(d, J = 8.2 Hz, IH), 4.05 (br s, IH, NH), 3.06(m, 2H), 2.84(m, 2H), 1.64(m, 2H), 1.55(m, 2H), 13C NMR (DMSO-d6, 100MHz) δ 180.93, 140.64, 137.98, 130.42, 126.75, 113.20, 111.45, 46.24, 40.92, 32.94. Anal.Calcd for Ci2Hi3BrN2O: C, 51.26; H, 4.66; N, 9.9. Found: C, 50.87; H, 4.91; N, 9.67.
d) 5-Bromo-r-(lH-indol-3-ylcarbonyl)spirorindole-3,4'-piperidin1-2(lH)-one
Figure imgf000244_0001
Following the general procedure I as described above, the acylation of 5- bromospiro[indole-3,4'-piperidin]-2(lH)-one with lH-indole-3-carboxylic acid (commercially available), gave the title compound.
ES-MS m/e (%): 424.3(M+H+).
Example 280
5-Bromo-r-[(6-chloro-lH-indol-3-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(lH)-one - -
Figure imgf000245_0001
Following the general procedure I as described above, the acylation of 5- bromospiro[indole-3,4'-piperidin]-2(lH)-one with 6-chloro-lH-indole-3-carboxylic acid (preparation described in example 5 above), gave the title compound.
ES-MS m/e (%): 458.3(M+H+).
Example of compounds of formula (I-g)
Example 281
(lR,3'R,5'S)-r-[(l-Benzyl-2-methyl-lH-indol-3-yl)carbonyl]-3',5'-dimethyl-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one
Figure imgf000245_0002
Following the general procedure I as described above, the acylation of (lR,3'R,5'S)-l'-[(6- chloro-lH-indol-3-yl)carbonyl]-3',5'-dimethyl-3H-spiro[2-benzofuran-l,4'-piperidin]- 3-one (described in WO 9929696) with l-benzyl-2-methyl-lH-indole-3-carboxylic acid (preparation described in example 1), gave the title compound.
ES-MS m/e (%): 479.6(M+H+). Examples of compounds of formula (I-h)
Example 282
r-[(6-Chloro-lH-indol-3-yl)carbonyl]spiro[isoindole-l,4'-piperidin]-3(2H)-one
a) Bis-(2-chloro-ethyl)-carbamic acid tert-butyl ester
Figure imgf000246_0001
To a solution of 10.0 g (56.0 mmol) bis(2-chloroethyl) amine hydrochloride and 14.7 g (67.2 mmol) di-tert-butyl dicarbonate in 60 ml dichloromethane were added dropwise 9.37 ml (67.2 mmol) triethylamine at room temperature. After stirring for 4 h the solvent was evaporated. The residual oil was redissolved in 300 ml tert-butyl methyl ether and washed with saturated aqueous ammonium chloride solution (1 x 100 ml) and water (1 x 100 ml). The combined aqueous layers were extracted with tert-butyl methyl ether (1 x 200 ml). The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography (n-heptane / ethyl acetate) to give the title compound (9.6 g, 71%) as a colourless oil.
MS m/e (%): 186 (M-C4H8+H+, 100).
b) 4-(2-Bromo-phenyl)-4-cvano-piperidine-l-carboxyric acid tert-butyl ester
Figure imgf000246_0002
A mixture of 4.50 g (23.0 mmol) 3-bromophenylacetonitrile and 0.78 g (2.3 mmol) tetrabutylammonium hydrogen sulfate in 27 ml tetrahydrofuran and 45 ml of a 50 % aqueous sodium hydroxide solution was heated at reflux for 10 min. Thereafter 6.11 g
(25.3 mmol) bis-(2-chloro-ethyl)-carbamic acid tert-butyl ester were added at room - - temperature. The reaction mixture was heated at reflux for 4 h. Cooling to room temperature was followed by dilution with 60 ml water and extraction with tert-butyl methyl ether (3 x 100 ml). The combined organic layers were washed with brine (I x 100 ml), dried over sodium sulfate and concentrated in vacuo. The residual crude product was purified by flash chromatography (n-heptane / ethyl acetate) to give the title compound (6.72 g, 80%) as a pale yellow oil.
MS m/e (%): 265, 267 (M-BOC+H+, 82, 100).
c) 4-(2-Bromo-phenyl)-piperidine-l,4-dicarboχylic acid mono-tert-butyl ester
Figure imgf000247_0001
A mixture of 5.7 g (15.6 mmol) 4-(2-bromo-phenyl)-4-cyano-piperidine-l-carboxylic acid tert-butyl ester and 235 ml (936 mmol) of a 4 M aqueous hydrochloric acid solution was heated at reflux for 96 h. After cooling to room temperature the reaction mixture was basified with 93.90 ml (1014 mmol) of a 10.8 M aqueous sodium hydroxide solution and diluted with 200 ml 1,4-dioxane. A solution of 5.11 g (23.4 mmol) di-tert-butyl dicarbonate in 50 ml 1,4-dioxane was added quickly at 0 0C. After stirring for 2 h the reaction mixture was extracted with tert-butyl methyl ether (2 x 100 ml). The combined organic layers were washed with 1 M sodium hydroxide solution (I x 100 ml). The combined aqueous layers were cooled by the addition of 100 g ice, acidified (pH 1-2) with ice-cold 2 M aqueous hydrochloric acid solution and extracted with ethyl acetate (3 x 150 ml). The combined ethyl acetate layers were dried over sodium sulfate and concentrated in vacuo to give the title compound (5.51 g, 92%) as a light yellow solid.
MS m/e (%): 382, 384 (M+H+, 90, 100).
d) 4-Azidocarbonyl-4-(2-bromo-phenyl)-piperidine-l-carboxyh'c acid tert-butyl ester
Figure imgf000248_0001
To a solution of 2.00 g (5.20 mmol) 4-(2-bromo-phenyl)-piperidine-l,4-dicarboxylic acid mono-tert-butyl ester in 26 ml dichloromethane were added 0.76 ml (5.73 mmol) 1- chloro-N,N,2-trimethylpropenylamine at room temperature. After stirring for 45 min the reaction mixture was concentrated in vacuo. The residual oil was redissolved in 26 ml dry N,N-dimethylformamide and treated with 0.51 g (7.8 mmol) sodium azide. After stirring for 1 h the reaction mixture was diluted with 200 ml tert-butyl methyl ether and washed with 0.5 M aqueous sodium carbonate solution (2 x 50 ml). The combined aqueous layers were extracted with tert-butyl methyl ether (2 x 100 ml). The combined organic layers were washed with water (1 x 50 ml) and brine (1 x 50 ml), dried over sodium sulfate and concentrated in vacuo to give the crude title compound (1.76 g, 83%) as a light yellow solid.
e) tert-Butyl 3-oxo-2,3-dihydro-lΗ-spirorisoindole-l,4'-piperidinel-r-carboxvlate
Figure imgf000248_0002
A solution of 1.60 g (3.91 mmol) 4-azidocarbonyl-4-(2-bromo-phenyl)-piperidine-l- carboxylic acid tert-butyl ester in 40 ml toluene was stirred at 90 0C for 1 h. The reaction mixture was concentrated in vacuo and the residue was redissolved in 40 ml dry tetrahydrofuran. Cooling of the solution to -100 0C was followed by slow dropwise additon of 4.6 ml (7.8 mmol) of a 1.7 M solution of tert-butyl lithium in pentane. The cooling bath was removed after 10 min and the reaction mixture was allowed to warm to 0 0C. After quenching with 5 ml saturated aqueous ammonium chloride solution the - o - mixture was extracted with tert-butyl methyl ether (3 x 50 ml). The combined organic layers were washed with brine (1 x 50 ml), dried over sodium sulfate and concentrated in vacuo to give the title compound (1.15 g, 97%) as a light yellow solid.
MS m/e (%): 247 (M-C4H8+H+, 100).
f) Spirorisoindole-l,4'-piperidinl-3(2H)-one
Figure imgf000249_0001
To a solution of 0.10 g (0.33 mmol) tert-butyl 3-oxo-2,3-dihydro-l'H-spiro[isoindole- l,4'-piperidine]-l'-carboxylate in 3.3 ml dichloromethane were added 0.25 ml (3.3 mmol) triflu or o acetic acid at room temperature. After stirring for 4 h the reaction mixture was diluted with 20 ml aqueous 1 M sodium hydroxide solution (20 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layers were dried over sodium sulfate and concentrated in vacuo to give the crude title compound (0.095 g) as a light yellow solid.
MS m/e (%): 203 (M+H+, 100).
g) 1'-[(6-ChIoTO- lH-indol-3-yl)carbonvHspirorisoindole-l,4'-piperidin1-3(2H)-one
Figure imgf000249_0002
To a solution of 0.060 g (0.31 mmol) ό-chloro-lH-indole-S-carboxylic acid in 3 ml dichloromethane were added 0.045 ml (0.38 mmol) l-chloro-N,N,2-trimethyl- propenylamine at room temperature. After stirring for 1 h the reaction mixture was concentrated in vacuo. The residue was redissolved in 2 ml dry N,N-dimethylformamide. A solution of 0.062 g (0.31 mmol) spiro[isoindole-l,4'-piperidin]-3(2H)-one and 0.064 - - ml (0.46 mmol) triethylamine in 1 ml dry N,N-dimethylformamide was added at room temperature. After stirring for 2 h the reaction mixture was quenched with 1 M aqueous sodium hydroxide solution (30 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with water (2 x 30 ml), 0.5 M aqueous hydrochloric acid solution (1 x 30 ml) and brine (1 x 30 ml), dried over sodium sulfate and concentrated in vacuo. The crude product was triturated in warm diethyl ether, filtrated and dried in vacuo to give the title compound (0.031 g, 22%) as light brown solid with a purity of approx. 80 % by LC- .MS.
MS m/e (%): 378 (M-H+, 100).
Example 283
2-{6-Chloro-3-[(3-oxo-2,3-dihydro-rH-spiro[isoindole-l,4'-piperidin]-l'-yl)carbonyl]- lH-indol-l-yl}-N-methylacetamide
Figure imgf000250_0001
To a solution of 0.35 g (0.13 mmol) ό-chloro-l-methylcarbamoylmethyl-lH-indole-S- carboxylic acid, 0.025 ml (0.14 mmol) N,N-diisopropylethylamine and 0.055 g (0.14 mmol) O-(7-azabenzotriazol- l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate in 2 ml dry N,N-dimethylformamide were added 0.029 g (0.14 mmol) spiro[isoindole- l,4'-piperidin]-3(2H)-one at room temperature. After stirring for 2 h the reaction mixture was quenched with 0.5 M aqueous sodium hydroxide solution (20 ml) and extracted with ethyl acetate (2 x 30 ml). The combined organic layers were washed with water (2 x 30 ml) and brine (1 x 30 ml), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography (aminopropyl-modified silica gel, dichloromethane / methanol) to give the title compound (0.026 g, 44%) as a white solid. MS m/e (%): 451 (M+H+, 100).
Example 284
l'-tCό-Chloro-lH-indol-S-y^carbonyy-l^-dihydrospirofisoindole-l^'-piperidine]
a) tert-Butyl 2,3-dihydro- lΗ-spirorisoindole- l,4'-piperidinel - l'-carboxylate
Figure imgf000251_0001
To a solution of 0.20 g (0.66 mmol) tert-butyl 3-oxo-2,3-dihydro-l'H-spiro[isoindole- l,4'-piperidine]- l'-carboxylate in 6.6 ml toluene were added 0.33 ml (0.66 mmol) of a 2 M solution of borane dimethylsulfide complex in tetrahydrofuran. After stirring at reflux for 5 h the mixture was cooled to room temperature, treated with 1.5 ml of methanol and reheated to reflux for 15 min. The reaction mixture was then concentrated in vacuo to give the crude title compound (0.23 g, 84.%) as a light yellow solid with a purity of 70 % by LC-MS.
MS m/e (%): 289 (M+H+, 83).
b) 2,3-Dihydrospirorisoindole-l,4'-piperidinel dihvdrochloride
Figure imgf000251_0002
A solution of 0.16 g (0.56 mmol) tert-butyl 2,3-dihydro-l'H-spiro[isoindole-l,4'- piperidine]- l'-carboxylate in 4.5 ml (5.6 mmol) of a 1.25 M solution of hydrochloric acid in methanol was stirred at 50 0C for 30 min. The reaction mixture was concentrated in - - vacuo. The residue was triturated in hot tetrahydrofuran, filtrated and dried in vacuo to give the title compound (0.15 g, 100%) as a light yellow solid.
MS m/e (%): 189 (M+H+, 100).
c) r-rCό-Chloro-lH-indol-B-vDcarbonyll-l^-dihydrospirorisoindole-l^'-piperidinel
Figure imgf000252_0001
To a solution of 0.10 g (0.51 mmol) 6-chloro-lH-indole-3-carboxylic acid in 5 ml dichloromethane were added 0.074 ml (0.56 mmol) l-chloro-N,N,2-trimethyl- propenylamine at room temperature. The reaction mixture was concentrated in vacuo after 1 h. The residue was redissolved in 2 ml dry N,N-dimethylformamide. A suspension of 0.147 g (0.56 mmol) 2,3-dihydrospiro[isoindole-l,4'-piperidine] dihydrochloride and 0.285 ml (2.04 mmol) triethylamine in 2 ml dry N,N-dimethylformamide was added at room temperature. After stirring for 16 h the reaction mixture was quenched with 1 M aqueous sodium hydroxide solution (30 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with water (2 x 30 ml) and brine (1 x 30 ml), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography (dichloromethane / methanol) to give the title compound (0.045 g; 24%) as an off-white solid.
MS m/e (%): 366 (M+H+, 100).
Example 285
l'-[(6-Chloro-lH-indol-3-yl)carbonyl]-2-methyl-2,3-dihydrospiro[isoindole-l,4'- piperidine]
a) tert-Butyl 2-methyl-3-oxo-2,3-dihvdro-lΗ-spirorisoindole-l,4'-piperidinel-r- carboxvlate
Figure imgf000253_0001
To a solution of 0.310 g (1.03 mmol) spiro[isoindole-l,4'-piperidin]-3(2H)-one-l- carboxylic acid tert-butyl ester in 10 ml N,N-dimethylformamide were added 0.054 g (1.1 mmol) sodium hydride (50 % in oil) at room temperature. After stirring for 30 min 0.067 ml (1.1 mmol) iodomethane were added. The reaction mixture was quenched with water after 1 h and extracted with tert-butyl methyl ether (2 x 100). The combined organic layers were washed with water (2 x 50 ml) and brine (1 x 50 ml), dried over sodium sulfate and concentrated in vacuo to give the title compound (0.32 g, 99%) as light yellow solid. MS m/e (%): 317 (M+H+, 21).
b) tert-Butyl 2-methyl-2,3-dihvdro- lΗ-spirorisoindole- l,4'-piperidine1 - l'-carboxylate
Figure imgf000253_0002
To a solution of 0.10 g (0.32 mmol) tert-butyl 2-methyl-3-oxo-2,3-dihydro-l'H- spiro[isoindole-l,4'-piperidine]-l'-carboxylate in 3.2 ml toluene were added 0.16 ml (0.32 mmol) of a 2 M solution of borane dimethylsulfide complex in tetrahydrofuran. After heating at reflux for 4 h the reaction mixture was cooled to room temperature, quenched with 1.5 ml of methanol and reheated to reflux for 15 min. The reaction mixture was concentrated in vacuo and the residue was purified by flash chromatography (n-heptane / ethyl) to give the title compound (0.057 g, 60%) as a light yellow solid.
MS m/e (%): 303 (M+H+, 100).
c) 2-Methyl-2,3-dihvdrospirorisoindole- l,4'-piperidine1
Figure imgf000254_0001
A solution of 0.057 g (0.33 mmol) tert-butyl 2-methyl-2,3-dihydro-lΗ-spiro[isoindole- l,4'-piperidine]-l'-carboxylate in 1.32 ml (1.65 mmol) of a 1.25 M solution of hydrochloric acid in methanol was stirred at 50 0C for 15 min. The reaction mixture was concentrated in vacuo. The residue was dissolved in 2 M aqueous sodium hydroxide solution and extracted with dichloromethane (3 x 50 ml). The combined organic layers were dried over sodium sulfate and concentrated in vacuo to give the crude title compound (0.041 g) as a pale yellow amorphous solid.
MS m/e (%): 203 (M+H+, 100).
d) r-r(6-Chloro-lH-indol-3-yl)carbonyll-2-methyl-2,3-dihvdrospirorisoindole-l,4'- piperidinel
Figure imgf000254_0002
To a solution of 0.040 g (0.20 mmol) ό-chloro-lH-indole-S-carboxylic acid in 3 ml dichloromethane were added 0.03 ml (0.22 mmol) l-chloro-N,N,2-trimethyl- propenylamine at room temperature. After stirring for 1 h the reaction mixture was concentrated in vacuo. The residue was redissolved in 2 ml dry N,N-dimethylformamide. A solution of 0.041 g (0.20 mmol) 2-methyl-2,3-dihydrospiro[isoindole-l,4'-piperidine] and 0.043 ml (0.31 mmol) triethylamine in 1 ml dry N,N-dimethylformamide was added at room temperature. After stirring for 2 h the reaction mixture was quenched with 1 M aqueous sodium hydroxide solution (30 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with water (2 x 30 ml) and brine (1 x 30 ml), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography (n-heptane / ethyl acetate) to give the title compound (0.022 g, 23%) as an off- white solid with a purity of approx. 83 % by LC-MS.
MS m/e (%): 380 (M+H+, 100).

Claims

- - Claims
1. Compounds of the general formula (I)
Figure imgf000256_0001
wherein
Ais selected from the following groups (a), (b), (c), (d), (e), (f), (g) and (h):
Figure imgf000256_0002
(h)
Figure imgf000256_0003
- DΌ - wherein in (a) the dotted line is either nil or a double bond; R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl which are optionally substituted by one or more B, or is -(CH2)m-Ra wherein Ra is: CN, OR1, NR1R11, C3_6-cycloalkyl, 3 to 7 membered-heterocycloalkyl (3 from compound 261), aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb or -(CH2),,- (SO2) -Rb, wherein Rb is:
Ci_6-alkyl, Ci-6- alkoxy,
C3-6-cycloalkyl, -(CH2)m-NRmRlv, NR1R11,
C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or R1 and R3 together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which can be substituted by =0, C(O)O-C1-O- alkyl or C1-6- alkyl;
R2 is one or more of H, OH, halo, CN, nitro, C1-6- alkyl optionally substituted by - NRmRlv, Ci_6-alkoxy, -O-CH2-C2_6-alkenyl, benzyloxy, or two R2 may form an oxo or dioxo bridge together with the indole ring to which they are attached; R3 is H, or is halo, or is -(CO)-RC, wherein Rc is:
C1-6- alkyl, -(CH2VNR1R11, -(CH2)n-NRmRlv,
5 or 6 membered heterocycloalkyl optionally substituted by C1-6- alkyl, or is Ci-ό-alkyl or aryl, which are optionally substituted by halo, -O(CO)-C1_6-alkyl, or by-NH(CO)Rd, wherein Rd is C^-alky! optionally substituted by halo or nitro, or Rd is aryl or a 5 or 6 membered heteroaryl, which are optionally substituted by halo, nitro, C^-alky! or Q-ό-haloalkyl; R i4 is one or more of H, halo, Ci-ό-alkyl or Q-ό-alkoxy optionally substituted by OH, or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached; R5 is H, Ci_6- alkyl or aryl;
R6 is H or Q-β-alkyl; R7 is H or -SO2-R6 wherein Re is C1-6- alkyl or aryl;
R8 is H or Q-β-alkyl;
X is CH2 or C=O;
B is halo, CN, NR1R11, Ci_6-alkyl optionally substituted by CN, halo or Ci_6-alkoxy,
Ci_6-alkoxy, Ci-e-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1_6-alkyl, -C(O) NR1R11, - C(O)-Ci_6-alkyl, -S(O)2-Ci_6-alkyl, -S(O)2- NR1R11, (CRmRlv)n-phenyl, or
(CRmRlv)n-5 or 6 membered heteroaryl wherein the phenyl or 5 or 6 membered heteroaryl moiety is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, CN, NR1R11, Ci_6-alkyl optionally substituted by CN, halo or C1-6- alkoxy, Q-ό-alkoxy, Ci-ό-haloalkoxy, C3_6-cycloalkyl, -C(O)O-C1_6-alkyl, -
C(O)-NR1R11, -C(O)-Ci_6-alkyl, -S(O)2-Ci_6-alkyl, -S(O)2- NR1R11; R1 and R11 are H, C1-6-alkyl, Ci_6-alkyl-NRmRlv, -(CO)O-C1-6-alkyl, -C(O)-NRmRlv, -C(O)-
Ci_6-alkyl, -S(O)2-Ci_6-alkyl, -S(O)2- NRmRlv or OH; R111 and R1V are H or C1-6-alkyl; m is 1 to 6; n is O to 4; as well as pharmaceutically acceptable salts thereof.
2. Compounds of the general formula (I) according to claim 1, wherein A is selected from (a), (b), (c), (d), (e), (f), (g) or (h) and wherein R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl which are optionally substituted by one or more B, or is -(CH2)m-Ra wherein Ra is:
OR1, - DO -
CN,
NR1R11,
C3-6-cycloalkyl, 3 to 7 membered-heterocycloalkyl, aryl or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb or -(CH2),,- (SO2) -Rb, wherein Rb is:
Ci-6- alkoxy, NR1R11, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroarylwhich are optionally substituted by one or more B, or R1 and R3 together with the indole ring to which they are attached form a 5 or
6 membered heterocycloalkyl which can be substituted by =0, C(O)O-C1 6- alkyl or C1-6- alkyl; R2 is one or more of H, OH, halo, C1-6- alkyl optionally substituted by -NRmRlv, C1-6- alkoxy; R3 is H, or is halo or is -(CO)-RC, wherein Rc is: Ci-6-alkyl -(CH2VNR1R11, -(CH2)n-NRmRlv,
5 or 6 membered heterocycloalkyl optionally substituted by C1-6- alkyl, or is C1-6- alkyl or aryl, which are optionally substituted by halo,
R4 is is one or more of H, halo, or C1-6- alkoxy optionally substituted by OH, or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
R5 is H or aryl; R6 is H;
R7 is H or -SO2-R6 wherein Re is C1-6- alkyl or aryl;
R8 is H or Ci-e-alkyl; X is CH2 or C=O;
B is halo, CN, NH2, C1-6- alkyl optionally substituted by CN or C1-6- alkoxy, C1-6- alkoxy, Q-e-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, -(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, C1-6- alkyl optionally substituted by CN or halo, C1-6- alkoxy; R1 and R11 are H, C1-6-alkyl, Ci_6-alkyl-NRmRlv, -(CO)O-C1-6-alkyl, -C(O)-NRmRlv, -C(O)-
Ci_6-alkyl, -S(O)2-Ci_6-alkyl or -S(O)2- NR1UR1V or OH; R111 and R1V are H or C1-6-alkyl; m is 1 to 6;
> n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
3. Compounds of the general formula (I) according to claim 1 or 2, wherein Ais selected from the following groups (a), (b), (c), (d) and (e); and R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl which are optionally substituted by one or more B, or is -(CH2)m-Ra wherein Ra is: CN,
OR1, NR1R11, C3_6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2)n- (CO) -Rb or -(CH2)n- (SO2) -Rb, wherein Rb is:
Ci_6-alkyl, Ci-6- alkoxy, C3-6-cycloalkyl, -(CH2)m-NRmRlv, NR1R11,
C3_6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or R1 and R3 together with the indole ring to which they are attached form a 5 or
6 membered heterocycloalkyl which can be substituted by (CO); R2 is one or more of H, OH, halo, CN, nitro, C^-alky! optionally substituted by - NRmRlv, Ci_6-alkoxy, -O-CH2-C2_6-alkenyl, benzyloxy, or two R2 may form an oxo or dioxo bridge together with the indole ring to which they are attached; R3 is H, or is halo, - o - or is -(CO)-RC, wherein Rc is:
Ci_6-alkyl,
-(CH2VNR1R11,
-(CH2)n-NRmRlv,
5 5 or 6 membered heterocycloalkyl optionally substituted by Ci-ό-alkyl, or is Ci-ό-alkyl or aryl, which are optionally substituted by halo,
-O(CO)-Ci_6-alkyl, or by-NH(CO)Rd, wherein Rd is C^-alky! optionally substituted by halo 0 or nitro, or Rd is aryl or a 5 or 6 membered heteroaryl, which are optionally substituted by halo, nitro, C^-alky! or Q-ό-haloalkyl;
R is one or more of H, halo, C^-alky! or Q-ό-alkoxy or two R may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
R i5 is H, Ci_6-alkyl or aryl; 5 R6 is H or C1-6- alkyl;
R7 is H or -SO2-R6 wherein Re is Ci-ό-alkyl or aryl;
B is halo, CN, NR1R11, Ci_6-alkyl optionally substituted by CN, halo or Ci_6-alkoxy,
Ci_6-alkoxy, Ci-e-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1_6-alkyl, -C(O) NR1R11, - C(O)-Ci_6-alkyl, -S(O)2-Ci_6-alkyl, -S(O)2- NR1R11, (CRmRlv)n-phenyl, or 0 (CRmRlv)n-5 or 6 membered heteroaryl wherein the phenyl or 5 or 6 membered heteroaryl moiety is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, CN, NR1R11, Ci_6-alkyl optionally substituted by CN or Ci_6-alkoxy, Ci_6-alkoxy, Ci-e-haloalkoxy, C3_6-cycloalkyl, -C(O)O-C1_6-alkyl, -C(O)- 5 NR1R11, -C(O)-C1_6-alkyl, -S(O)2-C1_6-alkyl, -S(O)2- NR1R11;
R1 and R11 are H, Ci_6-alkyl, Ci_6-alkyl-NRmRlv, -(CO)O-Ci_6-alkyl, -C(O)-NRmRlv, -C(O)-
Ci_6-alkyl, -S(O)2-Ci_6-alkyl or -S(O)2- NR1UR1V; R111 and R1V are H or Ci_6-alkyl; m is 1 to 6; O n is O to 4; as well as pharmaceutically acceptable salts thereof.
4. Compounds of the general formula (I) of claim 1 to 3, wherein A is selected from the groups (a), (b), (c), (d) and (e); and R1 is H or, 5 Ci-ό-alkyl optionally substituted by CN or, - o -
Ci-6- alkoxy or, aryl or,
5 or 6 membered heteroaryl or, sulfonylaryl or, -(CH2)m-Ra wherein Ra is C3_6-cycloalkyl, 5 or 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more substituents selected from the group consisting of: halo, CN, C1-6- alkyl, C1-6- alkoxy, C1-6-haloalkoxy, -C(O)O-C1-6-alkyl and phenyl optionally substituted by halo, C1-6- alkyl, Ci-ό-haloalkyl or Ci-6- alkoxy,
-(CH2)m-NR'R" or,
-(CH2)n-(CO)-Rb, wherein Rb is aryl or 5 or 6 membered-heterocycloalkyl; R2 is one or more of H, halo, CN, nitro, C1-O- alkyl, C1-6- alkoxy, -O-CH2-C2_6-alkenyl, benzyloxy, or two R2 may form an oxo or dioxo bridge together with the indole ring to which they are attached;
R3 is H or, halo or,
-(CO)-RC, wherein Rc is C1-6- alkyl, 5 or 6 membered heterocycloalkyl optionally substituted by C1-6-a]kyl, or Rc is -(CH2)n-NR'R" or, C1-6- alkyl or aryl, which are optionally substituted by:
-O(CO)-C1-6-alkyl, or by -NH(CO)Rd, wherein Rd is C1-6- alkyl optionally substituted by halo or nitro, or Rd is aryl or a 5 or 6 membered heteroaryl, which are optionally substituted by halo, nitro, C1-6- alkyl or C1-6-haloalkyl; R4 is one or more of H, halo, C1-6- alkyl or C1-6- alkoxy or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached; R5 is H, C1-O- alkyl or aryl;
R6 is H or Ci-e-alkyl;
R7 is H or -SO2-R6 wherein Re is Q-e-alkyl or aryl; R' and R" are independently selected from H, Ci-e-alkyl or -(CO)O-C1-6-alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof. - - 5. The compounds of formula (I- a) according to any one of claims 1 to 4:
Figure imgf000263_0001
wherein the dotted line is either nil or a double bond and R1 to R6 are as defined in any one of claims 1 to 4.
6. The compounds of formula (I-a) according to claim 5, wherein: the dotted line is either nil or a double bond;
R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is sulfonylaryl, or is -(CH2)m-Ra wherein Ra is:
OR1, CN, NR1R11,
C3_6-cycloalkyl, 3 to 6 membered-heterocycloalkyl, aryl or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb, wherein Rb is: Ci-6- alkoxy, NR1R11,
6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B;
R2 is one or more of H, halo, C1-6- alkyl; R3 is H, or is C1-O- alkyl, or is -(CO)-RC, wherein Rc is: C1-6- alkyl - -
-(CHz)n-NR1R11,
R4 is is one or more of H, halo, or Q-ό-alkoxy optionally substituted by OH, or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached; R5 is H; R6 is H;
B is halo, CN, Q-o-alkyl optionally substituted by CN or Q-ό-alkoxy, Q-ό-alkoxy, C1- 6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, -(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, C1-6- alkyl optionally substituted by CN or halo, C1-6- alkoxy;
R1 and R11 are H, C1-6-alkyl, Ci_6-alkyl-NRmRlv, -C(O)-C1-6-alkyl, -S(O)2-Ci_6-alkyl or OH; R111 and R1V are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
7. The compounds of formula (I-a) according to claim 5 or 6, wherein: the dotted line is either nil or a double bond; R1 is H, or is -(CH2)m-Ra wherein Ra is aryl which is optionally substituted by one or more substituents selected from the group consisting of: halo, CN, Ci-β-alkyl, Ci_6-alkoxy, Ci-e-haloalkoxy, -C(O)O-C1-6-alkyl and phenyl optionally substituted by halo, C1-6- alkyl, Ci-ό-haloalkyl or Ci-6- alkoxy; R2 is H or halo;
R3 is H or Q-6-alkyl; and
R4, R5 and R6 are H; m is 1 to 6; as well as pharmaceutically acceptable salts thereof.
8. The compounds of formula (I-a) according to claims 5 to 7, wherein said compounds are selected from the group consisting of: r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl] spiro[indene-l,4'-piperidine] ; 1'- [(1-benzyl- 2-methyl-lH-indol-3-yl)carbonyl]-2,3-dihydrospiro[in dene- 1,4'- piperidine] ; !'-[( 1-benzyl- lH-indol-3-yl)carbonyl] spiro[indene-l,4'-piperidine] ; - - r-[(2-methyl-lH-indol-3-yl)carbonyl]spiro[indene-l,4'-piperidine] ; r-[(6-chloro-lH-indol-3-yl)carbonyl]spiro[indene-l,4'-piperidine] ; and l'-fCo-chloro-lH-indol-S-y^carbonyy-l^-dihydrospirofindene-l^'-piperidine].
9. The compounds of formula (I-b) according to any one of claims 1 to 4:
Figure imgf000265_0001
wherein R1, R2, R3, R4, R6 and R7 are as defined in any one of claims 1 to 4.
10. The compounds of formula (I-b) according to claim 9, wherein
R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is sulfonylaryl, or is -(CH2)m-Ra wherein Ra is: OR, CN, NR1R11, C3-6-cycloalkyl, 3 to 6 membered-heterocycloalkyl, aryl or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb, wherein Rb is: Ci-6- alkoxy, NR1R11, 5 or 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B; R2 is one or more of H, halo, C1-6- alkyl; R3 is H, or is Ci-6- alkyl, or is - (CO) -Rc, wherein Rc is: - DJ -
Ci_6-alkyl -(CHz)n-NR1R11,
R4 is is one or more of H, halo, or Q-ό-alkoxy optionally substituted by OH, or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
R6 is H;
R7 is H or -SO2-R6 wherein Re is Ci-ό-alkyl or aryl;
B is halo, CN, Q-o-alkyl optionally substituted by CN or Q-ό-alkoxy, Q-ό-alkoxy, C1- 6-haloalkoxy, C3-6-cycloalkyl, -C(0)0-C1-6-alkyl, -(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, C1-6- alkyl optionally substituted by CN or halo, C1-6- alkoxy;
R1 and R11 are H, C1-6-alkyl, C1-6-alkyl-NRmRlv, -C(O)-C1_6-alkyl, -S(O)2-C1_6-alkyl or OH; R111 and R1V are H or C1-6-alkyl; m is 1 to 6; n is O to 4; as well as pharmaceutically acceptable salts thereof.
11. The compounds of formula (I-b) according to claim 9 or 10, wherein:
R1 is H, or is -(CH2)m-Ra wherein Ra is aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more subsituents selected from the group consisting of: halo, CN, C1-6- alkyl, C1-6- alkoxy, C1-6-haloalkoxy, -C(O)O-C1-6-alkyl and phenyl optionally substituted by halo, Ci-ό-haloalkyl or C1-6- alkoxy, or is -(CH2)I11-NR1R11, or is -(CH2)n-(CO)-Rb, wherein Rb is aryl or 5 or 6 membered-heterocycloalkyl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb wherein Rb is NR1R11, R2 is H or halo; R3 is H or C1-6- alkyl;
R4 is H or halo;
R6 is H;
R7 is H or -SO2-R6 wherein Re is Ci_6-alkyl or aryl;
B is halo, NH2, C1-6- alkyl optionally substituted by CN or C1-6- alkoxy, C1-6- alkoxy, Ci-e-haloalkoxy, C3_6-cycloalkyl, -C(O)O-C1_6-alkyl, -(CRmRlv)n-phenyl, wherein - DD - the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci-ό-alkyl optionally substituted by CN or halo, Q-ό-alkoxy; R1, R11 are independently selected from H or C1-6- alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
12. The compounds of formula (I-b) according to any one of claims 9 to 11, wherein said compounds are selected from the group consisting of: r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-l-(methylsulfonyl)-l,2- dihydrospiro[indole-3,4'-piperidine] ; r-{[6-chloro-l-(3-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-l,2- dihydrospiro[indole-3,4'-piperidine] ; l'-{[6-chloro-l-(2-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-l,2- dihydrospiro[indole-3,4'-piperidine] ; r-{[6-chloro-l-(3,5-difluorobenzoyl)-lH-indol-3-yi]carbonyl}-l,2- dihydrospiro[indole-3,4'-piperidine] ; l'-{[6-chloro-l-(2,3-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-l,2- dihydrospiro[indole-3,4'-piperidine] ; l'-({6-chloro-l-[(3,5-difluorophenyl)sulfonyl]-lH-indol-3-yl}carbonyl)-l,2- dihydrospiro[indole-3,4'-piperidine] ;
2-[6-chloro-3-(l,2-dihydro-rH-spiro[indole-3,4'-piperidin]-l'-ylcarbonyl)-lH- indol- 1-yl] - l-(3,5-difluorophenyl)ethanone;
2-[6-chloro-3-(l,2-dihydro-rH-spiro[indole-3,4'-piperidin]-l'-ylcarbonyl)-lH- indol- 1-yl] - l-(3,4-difluorophenyl)ethanone;
2-[6-chloro-3-(l,2-dihydro-rH-spiro[indole-3,4'-piperidin]-l'-ylcarbonyl)-lH- indol- 1-yl] - l-(2-fluorophenyl)ethanone;
2-[6-chloro-3-(l,2-dihydro-rH-spiro[indole-3,4'-piperidin]-l'-ylcarbonyl)-lH- indol- 1-yl] -N,N-diethylethan amine; and l'-{[6-chloro-l-(pyridin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-l,2- dihydrospiro[indole-3,4'-piperidine] .
13. The compounds of formula (I-c) according to any one of claims 1 to 4: - -
Figure imgf000268_0001
wherein R1 to R4 are as defined in any one of claims 1 to 4.
14. The compounds of formula (I-c) according to claim 13, wherein
R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl which are optionally substituted by one or more B, or is -(CH2)m-Ra wherein Ra is:
OR1, CN,
NR1R11,
C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb wherein Rb is: Ci-6- alkoxy,
NR1R11, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or R1 and R3 together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which can be substituted by =0;
R2 is one or more of H, halo, Ci-ό-alkyl optionally substituted by -NRmRlv, C1-6- alkoxy; R3 is H, or is Ci-6- alkyl, or is halo, or is -(CO)-RC, wherein Rc is: - oo -
Ci_6-alkyl -(CHz)n-NR1R11, -(CH2)n-NRmRlv,
5 or 6 membered heterocycloalkyl optionally substituted by C1-6- alkyl; R4 is one or more of H, halo, or Q-ό-alkoxy optionally substituted by OH, or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached; B is halo, NH2, Q-o-alkyl optionally substituted by CN or Q-ό-alkoxy, Q-ό-alkoxy,
Ci-e-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, -(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci-ό-alkyl optionally substituted by CN or halo, Q-ό-alkoxy; R1 and R11 are H, C1-6-alkyl, Ci_6-alkyl-NRmRlv, -(CO)O-C1-6-alkyl, -C(O)-NRmRlv, -C(O)-
Ci_6-alkyl, -S(O)2-Ci_6-alkyl, -S(O)2- NRmRlv; R111 and R1V are H or C1-6-alkyl; m is 1 to 6; n is O to 4; as well as pharmaceutically acceptable salts thereof.
15. The compounds of formula (I-c) according to claim 13 or 14, wherein said compounds are selected from the group consisting of: r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-6-chloro-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one; r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-4-fluoro-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one; l'-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-6-methoxy-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; l'-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-5-methoxy-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-7-chloro-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one; r-[(6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3- one; r-[(6-chloro-lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one; r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one; - -
6-chloro-3-[(5-fluoro-3-oxo-rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'- yl)carbonyl] -N,N- dimethyl- lH-indole-2-carboxamide; tert-butyl {2-[({6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'- piperidin] - l'-yl)carbonyl] - lH-indol-2-yl}carbonyl) amino] ethyl Jmethylcarbamate; 6-chloro-N,N-diethyl-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'- piperidin] - l'-yl)carbonyl] - lH-indole-2-carboxamide; r-lfό-chloro^^piperidin-l-ylcarbony^-lH-indol-S-yllcarbonylJ-S-fluoro-SH- spiro[2-benzofuran-l,4'-piperidin]-3-one; r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-7H-spiro[furo[3,4- f] [l,3]benzodioxole-5,4'-piperidin]-7-one;
3-{6-chloro-3-[(3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-yl)carbonyl]- lH-indol-l-yl}propanenitrile;
{6-chloro-3-[(3-oxo-lΗ,3H-spiro[2-benzofuran- l,4'-piperidin]-r-yl)carbonyl]- lH-indol-l-yl}acetonitrile; l'-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-6-(2-hydroxyethoxy)-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; l'-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one; l'-{[6-chloro-l-(3,5-difluorophenyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; l'-{[6-chloro-l-(3,5-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; l'-{[6-chloro-l-(3,5-difluorobenzyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; l'-{[6-chloro-l-(3-fluorobenzyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran- l,4'-piperidin]-3-one; l'-({6-chloro-l-[2-(3-fluorophenyl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-({6-chloro-l-[2-(2,5-difluorophenyl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; r-lfo-chloro-l-CS^-difluorobenzy^-lH-indol-S-yljcarbonylJ-S-fluoro-SH- spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-{[6-chloro-l-(3-fluorobenzyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; l'-({6-chloro-l-[2-(3-fluorophenyl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; 5-bromo-l'- {[6-chloro- l-(3,5-difluorobenzyl)-lH-indol-3-yl]carbonyl}- 3H- spiro[2-benzofuran-l,4'-piperidin]-3-one;
5-bromo-l'- {[6-chloro- l-(3-fluorobenzyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; 5-bromo- 1'-( {6-chloro- 1- [2-(3-fluorophenyl)-2-oxoethyl] - lH-indol-3- yl}carbonyl)-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-({6-chloro-l-[2-(2-fluorophenyl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-({6-chloro-l-[2-(3,4-difluorophenyl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one;
1'- {[6-chloro- l-(3-fluorophenyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one;
1'- {[6-chloro- l-(2-oxo-2-piperidin-l-ylethyl)-lH-indol-3-yl]carbonyl}- 3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-{[6-chloro-l-(2-morpholin-4-yl-2-oxoethyl)-lH-indol-3-yl]carbonyl}-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one;
2-{6-chloro-3-[(3-oxo-rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)carbonyl]- lH-indol-l-yl}-N,N-dimethylacetamide;
2-{6-chloro-3-[(3-oxo-rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)carbonyl]- lH-indol- l-yl}-N,N-diethylacetamide;
1'- {[6-chloro- l-(piperidin-l-ylcarbonyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; tert-butyl {6-chloro-3-[(3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- l-yl}acetate; 1'- [(6-chloro- l-pyridin-2-yl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran- 1,4'- piperidin]-3-one;
1'- [(6-chloro- l-pyridin-2-yl-lH-indol-3-yl)carbonyl]-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; l'-( {6-chloro- l-[(2-methylpyridin-4-yl)methyl]-lH-indol-3-yl}carbonyl)-5-fluoro- 3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-( {6-chloro- l-[(6-chloropyridin-3-yl)methyl]-lH-indol-3-yl}carbonyl)-5-fluoro- 3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-( {6-chloro- 1- [(3-chloro-6-methylpyridazin-4- yl) methyl]- lH-indol-3- yl}carbonyl)-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; r-{[6-chloro-l-(pyridin-4-ylmethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-{[6-chloro-l-(2-pyridin-4-ylethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; r-lfό-chloro-l-Cpyridin-Φylmethy^-lH-indol-S-yllcarbonylJ-SH-spirofl- benzofuran-l,4'-piperidin]-3-one; l'-{[6-chloro-l-(2-oxo-2-pyridin-2-ylethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-({6-chloro-l-[2-(5-methyl-2-phenyl-l,3-oxazol-4-yl)-2-oxoethyl]-lH-indol-3- yl}carbonyl)-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; r-{[6-chloro-l-(pyridin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one;
2-{6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- l-yl}-N,N-dimethylacetamide; r-({6-chloro-l-[2-(dimethylamino)ethyl]-lH-indol-3-yl}carbonyl)-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; r-{[6-chloro-l-(pyridin-3-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; r-{[6-chloro-l-(pyrazin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; r-{[6-chloro-l-(pyrimidin-5-ylmethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one;
3-{6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- l-yl}propanenitrile; tert-butyl {6-chloro-3-[(5-fluoro-3-oxo-l'H,3H-spiro[2-benzofuran-l,4'- piperidin] - l'-yl)carbonyl] - lH-indol- l-yl}acetate; l'-{[6-chloro-l-(2-morpholin-4-yl-2-oxoethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-
3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-({l-[(4-benzylmorpholin-2-yl)methyl]-6-chloro-lH-indol-3-yl}carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-({6-chloro-l-[(5-methylisoxazol-3-yl)methyl]-lH-indol-3-yl}carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-({6-chloro-l-[2-(4-methylpiperazin-l-yl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)- 5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; r-{[6-chloro-l-(pyridin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; r-({6-chloro-l-[(5-cyclopropyl-2-methyl-l,3-oxazol-4-yl)methyl]-lH-indol-3- yl}carbonyl)-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-( {6-chloro- 1-[( 1 -methyl- lH-imidazol-5-yl)methyl] - lH-indol-3-yl}carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-( {6-chloro- l-[(3-methylisoxazol-5-yl)methyl] -lH-indol-3-yl }carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-({6-chloro-l-[(l,5-dimethyl-lH-pyrazol-3-yl)methyl]-lH-indol-3-yl}carbonyl)-
5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-( {6-chloro- l-[(3,5-dimethylisoxazol-4-yl)methyl] -lH-indol-3-yl }carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin] -3-one; l'-({6-chloro-l-[(2,5-dimethyl-l,3-oxazol-4-yl)methyl]-lH-indol-3-yl}carbonyl)- 5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin] -3-one; l'-( {6-chloro- l-[(3-fluorooxetan-3-yl)methyl]-lH-indol-3-yl}carbonyl)-5-fluoro- 3H-spiro[2-benzofuran-l,4'-piperidin] -3-one; l'-({6-chloro-l-[(3-fluorooxetan-3-yl)methyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidin] -3-one; l'-[(6-chloro-l-{[l-(methoxymethyl)-cyclopropyl]methyl}-lH-indol-3- yl)carbonyl]-5-fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one;
[l-({6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- l-yl}methyl)cyclopropyl] acetonitrile; l'-[(6-chloro-l-{[l-(methoxymethyl)-cyclopropyl]methyl}-lH-indol-3- yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one;
[l-({6-chloro-3-[(3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- l-yl}methyl)cyclopropyl] acetonitrile; l'-({6-chloro-l-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-lH-indol-3-yl}carbonyl)-5- fluoro-3H-spiro[2-benzofuran-l,4'-piperidin]-3-one hydrochloride; l'-({6-chloro-l-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; tert-butyl 2-({6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'- piperidin] - l'-yl)carbonyl] - lH-indol- l-yl}methyl)morpholine-4-carboxylate; tert-butyl 2-({6-chloro-3-[(3-oxo-rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'- yl)carbonyl] - lH-indol- l-yl}methyl)morpholine-4-carboxylate;
1'- {[6-chloro- l-(morpholin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H- spiro[2-benzofuran- l,4'-piperidin] -3-one dihydrochloride;
1'- {[6-chloro- l-(morpholin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidin] -3-one hydrochloride; 2-{6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- l-yl}acetamide; - -
2-{6-chloro-3-[(5-fluoro-3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- l-yl}-N-methylacetamide; l'-{[6-chloro-l-(2-oxo-2-piperazin-l-ylethyl)-lH-indol-3-yl]carbonyl}-5-fluoro- 3H-spiro[2-benzofuran-l,4'-piperidin]-3-one; l'-{[l-(3,5-difluorobenzyl)-lH-indol-3-yl]carbonyl}-5-fluoro-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one; l'-{[l-(3,5-difluorobenzyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2-benzofuran-l,4'- piperidin]-3-one;
N,N-diethyl-2-{3-[(3-oxo-lΗ,3H-spko[2-benzofuran-l,4'-piperidin]-l'- yl)carbonyl]-lH-indol-l-yl}acetamide; and
2-{6-chloro-5-methyl-3-[(3-oxo-lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- yl)carbonyl] - lH-indol- l-yl}-N,N-dimethylacetamide.
16. The compounds of formula (I-d) according to any one of claims 1 to 4:
Figure imgf000274_0001
wherein R1 to R5 are as defined in any one of claims 1 to 4.
17. The compounds of formula (I-d) according to claim 16, wherein
R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl which are optionally substituted by one or more B, or is -(CH2)m-Ra wherein Ra is: OR1, CN, NR1R11, C3-6-cycloalkyl, 3 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2)n- (CO) -Rb wherein Rb is:
Ci-6- alkoxy, NR1R11,
4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or R1 and R3 together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which can be substituted by C(O)O-C1_6-alkyl or C1-6- alkyl;
R2 is one or more of H, halo, C1-6- alkyl, Q-ό-alkoxy; R3 is H, or is C1-O- alkyl, or is -(CO)-RC, wherein Rc is C1-6-alkyl, or - (CH2VNR1R11; R4 is one or more of H, halo, or Q-ό-alkoxy optionally substituted by OH, or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
R5 is H or aryl;
B is halo, NH2, Q-o-alkyl optionally substituted by CN or Q-ό-alkoxy, Q-ό-alkoxy, Ci-e-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1_6-alkyl, -(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci-ό-alkyl optionally substituted by CN or halo, Q-ό-alkoxy; R1 and R11 are H, C1-6-alkyl, Ci_6-alkyl-NRmRlv, -(CO)O-C1-6-alkyl, -C(O)-NRmRlv, -C(O)- Q-6-a.kyl, -S(O)2-C1_6-alkyl, -S(O)2- NRmRlv or OH;
R111 and R1V are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
18. The compounds of formula (I-d) according to claim 16 or 17, wherein said compounds are selected from the group consisting of: r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidine] ; r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-6-chloro-3H-spiro[2-benzofuran- l,4'-piperidine] ; r-[(2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] ; r-[(l-benzoyl-2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidine] ; r-{[2-methyl-l-(phenylsulfonyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; r-{[l-(cyclohexylmethyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; l'-{[l-(3-fluorobenzyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; r-({2-methyl-l-[2-(trifluoromethoxy)benzyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran- l,4'-piperidine] ; r-{[l-(3,5-dimethylbenzyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; methyl 4- {[2-methyl-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- ylcarbonyl)-lH-indol-l-yl]methyl}benzoate;
4-{[2-methyl-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH- indol-1-yl] methyl Jbenzonitrile; l'-{[l-(3,5-difluorobenzyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; l'-{[l-(2-chlorobenzyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; l'-{[l-(2-methoxybenzyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; l'-{[l-(4-methoxybenzyl)-2-methyl-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; r-[(l-{[2-(2-methoxyphenyl)-5-methyl-l,3-oxazol-4-yl]methyl}-2-methyl-lH- indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] ; r-[(l-benzyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] ; r-[(6-chloro-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'-piperidine] ; N,N-dimethyl-2-[3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)- lH-indol-l-yl]ethan amine;
2-methyl-l-[3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)-lH- indol-2-yl]butan-l-one;
[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH-indol- l-yl]acetonitrile; - - l'-{[6-chloro-l-(3-fluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; l'-lfό-chloro-l-^-fluorobenzoy^-lH-indol-S-ylJcarbonylJ-SH-spiroP- benzofuran- l,4'-piperidine] ; l'-{[6-chloro-l-(3,5-difluorobenzoyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; r-lfo-chloro-l-Cl^-difluorobenzoy^-lH-indol-S-yllcarbonylJ-SH-spirofl- benzofuran- l,4'-piperidine] ; l'-{[6-chloro-l-(3,5-difluorobenzyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; r-lfό-chloro-l-CS-fluorobenzy^-lH-indol-S-yllcarbonylJ-SH-spirofl-benzofuran- l,4'-piperidine] ; l'-{[6-chloro-l-(2-oxo-2-piperidin-l-ylethyl)-lH-indol-3-yl]carbonyl}-3H- spiro[2-benzofuran- l,4'-piperidine] ; l'-{[6-chloro-l-(2-morpholin-4-yl-2-oxoethyl)-lH-indol-3-yl]carbonyl}-3H- spiro[2-benzofuran- l,4'-piperidine] ;
2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH- indol- 1-yl] -N,N-dimethylacetamide;
2-[6-chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)-lH- indol- 1-yl] -N,N-diethylacetamide; r-{[6-chloro-l-(piperidin-l-ylcarbonyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; tert-butyl [6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)- lH-indol- 1-yl] acetate; l'-{[6-chloro-l-(3,5-difluorophenyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; l'-{[6-chloro-l-(3-fluorophenyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ;
2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH- indol- 1-yl] - l-(2-fluorophenyl)ethanone; r-[(6-chloro-l-pyridin-2-yl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidine] ; r-{[6-chloro-l-(pyridin-4-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; 2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH- indol- 1-yl] - l-pyridin-2-ylethanone; r-{[6-chloro-l-(pyridin-3-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; r-lfό-chloro-l-Cpyridin-l-ylmethy^-lH-indol-S-yllcarbonylJ-SH-spirofl- benzofuran- l,4'-piperidine] ; 1'- {[6-chloro- l-(pyrazin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; r-{[6-chloro-l-(pyrimidin-5-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ;
2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH- indol- 1-yl] -N,N-dimethylethanamine; l'-{[6-chloro-l-(2-oxo-2-piperazin-l-ylethyl)-lH-indol-3-yl]carbonyl}-3H- spiro[2-benzofuran- l,4'-piperidine] ; l'-({l-[(4-benzylmorpholin-2-yl)methyl]-6-chloro-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran- l,4'-piperidine] ; r-dό-chloro-l-fCS-methylisoxazol-S-y^methyy-lH-indol-S-ylJcarbony^-SH- spiro[2-benzofuran- l,4'-piperidine] ; l'-({6-chloro-l-[2-(4-methylpiperazin-l-yl)-2-oxoethyl]-lH-indol-3-yl}carbonyl)- 3H-spiro[2-benzofuran-l,4'-piperidine] ;
4-( 1- {l-[(2-cyclopropyl-4-methylcyclopenta- 1,4-dien- l-yl)methyl] -6-methyl- IH- inden-3-yl}vinyl)-2',3'-dihydrospiro[cyclohexane-l,r-indene] ; l'-( {6-chloro- 1-[( 1 -methyl- lH-imidazol-5-yl)methyl] - lH-indol-3-yl}carbonyl)- 3H-spiro[2-benzofuran-l,4'-piperidine] ; l'-( {6-chloro- l-[(3-methylisoxazol-5-yl)methyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran- l,4'-piperidine] ; l'-({6-chloro-l-[(l,5-dimethyl-lH-pyrazol-3-yl)methyl]-lH-indol-3-yl}carbonyl)-
3H-spiro[2-benzofuran-l,4'-piperidine] ; l'-( {6-chloro- l-[(3,5-dimethylisoxazol-4-yl)methyl] -lH-indol-3-yl }carbonyl)-3H- spiro[2-benzofuran- l,4'-piperidine] ; l'-({6-chloro-l-[(2,5-dimethyl-l,3-oxazol-4-yl)methyl]-lH-indol-3-yl}carbonyl)- 3H-spiro[2-benzofuran-l,4'-piperidine] ; l'-( {6-chloro- l-[(3-fluorooxetan-3-yl)methyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran- l,4'-piperidine] ;
1'- [(6-chloro- l-{[l-(methoxymethyl)-cyclopropyl] methyl }-lH-indol-3- yl)carbonyl] -3H-spiro[2-benzofuran- l,4'-piperidine] ; (l-{[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH- indol-l-yljmethyljcyclopropy^acetonitrile; - /0 - l'-({6-chloro-l-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran- l,4'-piperidine] ; tert-butyl 2-{[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-l'- ylcarbonyl)-lH-indol-l-yl] methyl }morpholine-4-carboxylate; r-{[6-chloro-l-(morpholin-2-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] hydrochloride;
2-[6-chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)-lH- indol- 1-yl] -N- [2-(dimethylamino)ethyl] acetamide;
2-[6-chloro-5-methyl-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- ylcarbonyl)- lH-indol- 1-yl] -N,N-dimethylacetamide;
2-[6-chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)-lH- indol- 1-yl] acetamide;
2-[6-chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)-lH- indol- 1-yl] -N- [2-(methylamino)ethyl] acetamide; N-(2-aminoethyl)-2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r- ylcarbonyl)- lH-indol- 1-yl] acetamide;
2-[6-chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)-lH- indol- 1-yl] ethan amine;
2-[6-chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)-lH- indol- 1-yl] -N-methylethanamine;
2-[6-chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)-lH- indol- 1-yl] -N-methylacetamide; l'-{[6-chloro-l-(2-morpholin-4-ylethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; l'-{[6-chloro-l-(3-morpholin-4-ylpropyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; l'-{[6-chloro-l-(oxiran-2-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ;
2-[6-chloro-3-(rH,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-ylcarbonyl)-lH- indol- 1-yl] ethanol; l'-({6-chloro-l-[(2-methylpyridin-4-yl)methyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran- l,4'-piperidine] ; r-({6-chloro-l-[(3S)-piperidin-3-ylmethyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran- l,4'-piperidine] ; 2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH- indol- 1-yl] -N-hydroxyethan amine; l'-{[6-chloro-l-(tetrahydro-2H-pyran-4-ylmethyl)-lH-indol-3-yl]carbonyl}-3H- spiro[2-benzofuran- l,4'-piperidine] ; r-({6-chloro-l-[(l-methylpyrrolidin-3-yl)methyl]-lH-indol-3-yl}carbonyl)-3H- spiro[2-benzofuran- l,4'-piperidine] ; r-[(6-chloro-l-{[(3S)-l-methylpiperidin-3-yl]methyl}-lH-indol-3-yl)carbonyl]-
3H-spiro[2-benzofuran-l,4'-piperidine] ; r-{[6-chloro-l-(pyrrolidin-3-ylmethyl)-lH-indol-3-yl]carbonyl}-3H-spiro[2- benzofuran- l,4'-piperidine] ; l'-({6-chloro-l-[(2S)-pyrrolidin-2-ylmethyl]-lH-indol-3-yl}carbonyl)-3H-spiro[2- benzofuran- l,4'-piperidine] ; r-[(6-chloro-2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidine] ; l'-( 1,2,3,4- tetrahydropyrazino[ 1,2- a] indol- 10- ylcarbonyl)-3H-sp iro[2-benzo furan- l,4'-piperidine] hydrochloride; r-[(2-methyl-l,2,3,4-tetrahydropyrazino[l,2-a]indol-10-yl)carbonyl]-3H-spiro[2- benzofuran- l,4'-piperidine] ; l'-[(6-chloro-2-methyl-lH-indol-3-yl)carbonyl]-3H-spiro[2-benzofuran-l,4'- piperidine] ;
N-{2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH- indol-l-yl]ethyl}acetamide;
N-{2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH- indol-1-yl] ethyl Jmethanesulfonamide;
N-{2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH- indol-l-yl]ethyl}-N-methylacetamide; N-{2-[6-chloro-3-(lΗ,3H-spiro[2-benzofuran-l,4'-piperidin]-r-ylcarbonyl)-lH- indol-1-yl] ethyl }-N-methylmethanesulfonamide; r-[(6-chloro-l-{[(2S)-l-methylpyrrolidin-2-yl]methyl}-lH-indol-3-yl)carbonyl]- 3H-spiro[2-benzofuran-l,4'-piperidine] ; and r-[(6-chloro-l-{[(2R)-l-methylpyrrolidin-2-yl]methyl}-lH-indol-3-yl)carbonyl]- 3H-spiro[2-benzofuran-l,4'-piperidine].
19. The compounds of formula (I-e) according to any one of claims 1 to 4: - -
Figure imgf000281_0001
wherein R1, R2, R3, R4 and R6 are as defined in any one of claims 1 to 4.
20. The compounds of formula (I-e) according to claim 19, wherein R1 is H, or is C1-6- alkyl optionally substituted by CN, or is sulfonylaryl, or is -(CH2)m-Ra wherein Ra is: OR1, CN, NR1R11,
C3-6-cycloalkyl, 3 to 6 membered-heterocycloalkyl, aryl or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb, wherein Rb is:
Ci-6- alkoxy, NR1R11,
5 or 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B; R2 is one or more of H, halo, C1-6- alkyl; R3 is H, or is Ci-6- alkyl, or is -(CO)-RC, wherein Rc is: Ci-6-alkyl -(CHz)n-NR1R11,
R4 is is one or more of H, halo, or Q-ό-alkoxy optionally substituted by OH, or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached; R6 is H; - o -
B is halo, CN, Ci-ό-alkyl optionally substituted by CN or Q-ό-alkoxy, Q-ό-alkoxy, C1- 6-haloalkoxy, C3-6-cycloalkyl,
Figure imgf000282_0001
-(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci-ό-alkyl optionally substituted by CN or halo, Q-ό-alkoxy;
R1 and R11 are H, C1-6-alkyl, Q-e-alkyl-NR111^, -C(O)-C1_6-alkyl, -S(O)2-C1_6-alkyl or OH;
R111 and R1V are H or C1-6-alkyl; m is 1 to 6; n is O to 4; as well as pharmaceutically acceptable salts thereof.
21. The compounds of formula (I-e) according to claim 19 or 20, wherein R1 is H or,
-(CH2)m-Ra wherein Ra is 5 or 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl,
-(CH^-NR'R11 or,
-(CH2)n-(CO)-Rb, wherein Rb is 5 or 6 membered-heterocycloalkyl; R2 is one or more of H or halo;
R3 is H, or is Ci-6- alkyl;
R4 is one or more of H or halo;
R6 is H;
R1 and R11 are C1-6- alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
22. The compounds of formula (I-e) according to any one of claims 19 to 21, wherein said compounds are selected from the group consisting of: r-[(6-chloro-lH-indol-3-yl)carbonyl]spiro[l-benzofuran-3,4'-piperidine] ; r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl] spiro[l-benzofuran-3,4'- piperidine] ; r-(lH-indol-3-ylcarbonyl)spiro[l-benzofuran-3,4'-piperidine] ; r-[(6-chloro-5-fluoro-lH-indol-3-yl)carbonyl] spiro[l-benzofuran-3,4'- piperidine] ; - o -
2-[6-chloro-3-(lΗ-spiro[l-benzofuran-3,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] -N,N-dimethylethan amine; r-lfό-chloro-l-Cl-pyrrolidin-l-ylethy^-lH-indol-S-yllcarbonylJspirof l- benzofuran-3,4'-piperidine] ; 3-[6-chloro-3-(lΗ-spiro[l-benzofuran-3,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl] -N,N-dimethylpropan- 1-amine; l'-{[6-chloro-l-(2-morpholin-4-ylethyl)-lH-indol-3-yl]carbonyl}spiro[l- benzofuran-3,4'-piperidine] ;
2-[6-chloro-3-(lΗ-spiro[l-benzofuran-3,4'-piperidin]-r-ylcarbonyl)-lH-indol-l- yl]-N,N-diethylethanamine; r-({6-chloro-l-[2-(lH-pyrrol-l-yl)ethyl]-lH-indol-3-yl}carbonyl)spiro[l- benzofuran-3,4'-piperidine] ; and r-{[6-chloro-l-(2-oxo-2-piperidin-l-ylethyl)-lH-indol-3-yl]carbonyl}spiro[l- benzofuran-3,4'-piperidine] .
23. The compounds of formula (I-f) according to any one of claims 1 to 4:
Figure imgf000283_0001
wherein R1, R2, R3, and R4 are as defined in any one of claims 1 to 4.
24. The compounds of formula (I-f) according to claim 23, wherein R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is sulfonylaryl, or is -(CH2)m-Ra wherein Ra is:
OR, CN, - o -
NR1R11,
C3-6-cycloalkyl, 3 to 6 membered-heterocycloalkyl, aryl or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb, wherein Rb is: Ci-6- alkoxy,
NR1R11, 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B; R2 is one or more of H, halo, C1-6- alkyl; R3 is H, or is Ci-6- alkyl, or is -(CO)-RC, wherein Rc is: Ci-6-alkyl -(CHz)n-NR1R11, R4 is is one or more of H, halo, or Q-ό-alkoxy optionally substituted by OH, or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
B is halo, CN, Ci-ό-alkyl optionally substituted by CN or Q-ό-alkoxy, Q-ό-alkoxy, C1- 6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, -(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, Ci-ό-alkyl optionally substituted by CN or halo, Q-ό-alkoxy;
R1 and R11 are H, C1-6-alkyl, Ci-6-alkyl-NRmRlv, -C(O)-C1-6-alkyl, -S(O)2-Ci-6-alkyl or OH; R111 and R1V are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
25. The compounds of formula (I-f) according to claim 23 or 24, wherein R1 is H; R2 is one or more of H or halo; R3 is H;
R4 is one or more of H or halo; as well as pharmaceutically acceptable salts thereof.
26. The compounds of formula (I-f) according to any one of claims 23 to 25, wherein said compounds are selected from the group consisting of - -
5-bromo-r-(lH-indol-3-ylcarbonyl)spiro[indole-3,4'-piperidin]-2(lH)-one; and 5-bromo-r-[(6-chloro-lH-indol-3-yl)carbonyl]spiro[indole-3,4'-piperidin]- 2(lH)-one.
27. The compounds of formula (I-g) according to any one of claims 1 to 4:
Figure imgf000285_0001
wherein R1, R2, R3, and R4 are as defined in any one of claims 1 to 4.
28. The compounds of formula (I-g) according to claim 27, wherein R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is sulfonylaryl, or is -(CH2)m-Ra wherein Ra is: OR1, CN, NR1R11,
C3_6-cycloalkyl, 3 to 6 membered-heterocycloalkyl, aryl or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb, wherein Rb is:
Ci-6- alkoxy, NR1R11,
6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B; R2 is one or more of H, halo, C1-O- alkyl; R3 is H, or is Ci-6- alkyl, - o - or is -(CO)-RC, wherein Rc is: Ci_6-alkyl -(CHz)n-NR1R11,
R4 is is one or more of H, halo, or Q-ό-alkoxy optionally substituted by OH, or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached;
B is halo, CN, Q-o-alkyl optionally substituted by CN or Q-ό-alkoxy, Q-ό-alkoxy, C1- 6-haloalkoxy, C3-6-cycloalkyl, -C(O)O-C1-6-alkyl, -(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, C1-6- alkyl optionally substituted by CN or halo, C1-6- alkoxy;
R1 and R11 are H, C1-6-alkyl, Ci_6-alkyl-NRmRlv, -C(O)-C1-6-alkyl, -S(O)2-Ci_6-alkyl or OH; R111 and R1V are H or C1-6-alkyl; m is 1 to 6; n is 0 to 4; as well as pharmaceutically acceptable salts thereof.
29. The compounds of formula (I-g) according to claim 27 or 28, wherein R1 is H or, -(CH2)m-Ra wherein Ra is aryl;
R2 is one or more of H or halo;
R3 is H, or is Ci-6- alkyl;
R4 is H; R6 is H; as well as pharmaceutically acceptable salts thereof.
30. The compounds of formula (I-g) according to any one of claims 27 to 29, wherein said compounds are selected from the group consisting of
(SS5RR)- r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-3',5'-dimethyl- 3H- spiro[2-benzofuran-l,4'-piperidin]-3-one;
(RS5SR)- r-[(6-chloro-lH-indol-3-yl)carbonyl]-3',5'-dimethyl-3H-spiro[2- benzofuran-l,4'-piperidin]-3-one;
(RS5SR)- r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-3',5'-dimethyl- 3H- spiro[2-benzofuran-l,4'-piperidin]-3-one; and - -
(lr,3'R,5'S)-r-[(l-benzyl-2-methyl-lH-indol-3-yl)carbonyl]-3',5'-dimethyl-3H- spiro[2-benzofuran-l,4'-piperidin]-3-one.
31. The compounds of formula (I-h) according to any one of claims 1 to 4:
Figure imgf000287_0001
wherein R1, R2, R3, R4, R8 and X are as defined in any one of claims 1 to 4.
32. The compounds of formula (I-h) according to claim 31, wherein R1 is H, or is Ci-ό-alkyl optionally substituted by CN, or is sulfonylaryl, or is -(CH2)m-Ra wherein Ra is: OR1, CN, NR1R11, C3_6-cycloalkyl, 3 to 6 membered-heterocycloalkyl, aryl or 5 or 6 membered heteroaryl which are optionally substituted by one or more B, or is -(CH2V (CO) -Rb, wherein Rb is: Ci-6- alkoxy, NR1R11, 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl which are optionally substituted by one or more B; R2 is one or more of H, halo, C1-6- alkyl; R3 is H, or is Ci-6- alkyl, or is - (CO) -Rc, wherein Rc is:
Ci-6-alkyl - o -
-(CHz)n-NR1R11,
R4 is is one or more of H, halo, or Q-ό-alkoxy optionally substituted by OH, or two R4 may form an oxo or dioxo bridge together with the phenyl ring to which they are attached; R8 is H or C1-6- alkyl;
X is CH2 or C=O;
B is halo, CN, Q-o-alkyl optionally substituted by CN or Q-ό-alkoxy, Q-ό-alkoxy, C1- 6-haloalkoxy, C3-6-cycloalkyl, -C(0)0-C1-6-alkyl, -(CRmRlv)n-phenyl, wherein the phenyl is optionally substituted by one or more substituent(s) selected from the group consisting of: halo, C1-6- alkyl optionally substituted by CN or halo, C1-6- alkoxy;
R1 and R11 are H, C1-6-alkyl, Ci_6-alkyl-NRmRlv, -C(O)-C1-6-alkyl, -S(O)2-Ci_6-alkyl or OH; R111 and R1V are H or C1-6-alkyl; m is 1 to 6; n is O to 4; as well as pharmaceutically acceptable salts thereof.
33. The compounds of formula (I-h) according to claim 31 or 32, wherein R1 is H, or is -(CH2V (CO) -Rb, wherein Rb is NR1R11;
R2 is one or more of H or halo;
R3 is H;
R4 is H •>
R8 is H or Ci_6- alkyl; X is CH2 or C=O;
R1 and R11 are H or C1-O- alkyl; as well as pharmaceutically acceptable salts thereof.
34. The compounds of formula (I-h) according to any one of claims 31 to 33, wherein said compounds are selected from the group consisting of r-[(6-chloro-lH-indol-3-yl)carbonyl] spiro[isoindole-l,4'-piperidin]-3(2H)-one; l'-[(6-chloro-lH-indol-3-yl)carbonyl]-2-methyl-2,3-dihydrospiro[isoindole-l,4'- piperidine] ;
1'- [(6-chloro- lH-indol-3-yl)carbonyl] -2,3-dihydrosp iro[iso indole- 1,4'- piperidine] ; and - -
2- {6-chloro-3-[(3-oxo-2,3-dihydro-lΗ-spiro[iso indole- l,4'-piperidin]-l'- yl)carbonyl] - lH-indol- l-yl}-N-methylacetamide.
35. A process for the preparation of the compounds of formula (I), (I- a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h) according to any one of claims 1 to 34 comprising the step of reacting a compound of formula (II):
Figure imgf000289_0001
with a compound of formula A-H in order to obtain the compound of formula (I), (I- a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h) wherein A, R1, R2 and R3 are as defined in any one of claims 1 to 34.
36. A process for the preparation of the compounds of formula (I), (I- a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h) according to any one of claims 1 to 34 comprising the step of reacting a compound of formula (III):
Figure imgf000289_0002
with an electrophile compound of formula R1- Y in order to obtain the compound of formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h), wherein R1, R2 and R3 are as defined in any one of claims 1 to 34 and Yis halo.
37. A process for the preparation of the compounds of formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h) according to any one of claims 1 to 34 comprising the step of reacting a compound of formula (IV) :
Figure imgf000290_0001
with an amine of formula HNR1R11 in order to obtain the compound of formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h), wherein R1, R2, R3, R1 and R11 are as defined in any one of claims 1 to 34.
38. A compound formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h) obtainable by a process according to any one of claims 35 to 37.
39. A compound of formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h) according to any one of claims 1 to 34 for a use in the prevention or treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.
40. A pharmaceutical composition comprising one or more compounds of formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h) according to any one of claims 1 to 34 and a pharmaceutically acceptable carrier.
41. A pharmaceutical composition according to claim 40, wherein it is useful against dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.
42. Use of a compound of formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h) according to any one of claims 1 to 34 for the preparation of a medicament.
43. Use according to claim 42, wherein the medicament is useful against dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.
44. The invention as described hereinabove.
***
PCT/EP2006/063846 2005-07-14 2006-07-04 Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists WO2007006688A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP2008520842A JP4927079B2 (en) 2005-07-14 2006-07-04 Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1A receptor antagonists
CA2615726A CA2615726C (en) 2005-07-14 2006-07-04 Indol-3-yl-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
BRPI0612988-9A BRPI0612988A2 (en) 2005-07-14 2006-07-04 indol-3-ylcarbonyl-spiro-piperidine derivatives as v1a receptor antagonists
DK06764048T DK1904477T3 (en) 2005-07-14 2006-07-04 Indole-3-carbonyl-spiro-piperodome derivatives as V1A receptor antagonists
MX2008000585A MX2008000585A (en) 2005-07-14 2006-07-04 Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists.
DE602006004997T DE602006004997D1 (en) 2005-07-14 2006-07-04 INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE V1A RECEPTOR
CN2006800321491A CN101253164B (en) 2005-07-14 2006-07-04 Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
AU2006268724A AU2006268724B2 (en) 2005-07-14 2006-07-04 Indol-3-carbonyl-spiro-piperidine derivatives as V1A receptor antagonists
PL06764048T PL1904477T3 (en) 2005-07-14 2006-07-04 Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
EP06764048A EP1904477B1 (en) 2005-07-14 2006-07-04 Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
IL188478A IL188478A (en) 2005-07-14 2007-12-27 Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
NO20080059A NO20080059L (en) 2005-07-14 2008-01-04 Indole-3-carbonyl-spiro-piperidine derivatives as V1A receptor antagonists
HK09101245.2A HK1123554A1 (en) 2005-07-14 2009-02-11 Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05106443 2005-07-14
EP05106443.4 2005-07-14
EP05109364.9 2005-10-07
EP05109364 2005-10-07

Publications (1)

Publication Number Publication Date
WO2007006688A1 true WO2007006688A1 (en) 2007-01-18

Family

ID=37001896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/063846 WO2007006688A1 (en) 2005-07-14 2006-07-04 Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists

Country Status (26)

Country Link
US (2) US7332501B2 (en)
EP (1) EP1904477B1 (en)
JP (1) JP4927079B2 (en)
KR (1) KR100974967B1 (en)
CN (1) CN101253164B (en)
AR (1) AR054830A1 (en)
AT (1) ATE421511T1 (en)
AU (1) AU2006268724B2 (en)
BR (1) BRPI0612988A2 (en)
CA (1) CA2615726C (en)
CY (1) CY1108996T1 (en)
DE (1) DE602006004997D1 (en)
DK (1) DK1904477T3 (en)
ES (1) ES2317558T3 (en)
HK (1) HK1123554A1 (en)
IL (1) IL188478A (en)
MX (1) MX2008000585A (en)
MY (1) MY144684A (en)
NO (1) NO20080059L (en)
PL (1) PL1904477T3 (en)
PT (1) PT1904477E (en)
RU (1) RU2414466C2 (en)
SI (1) SI1904477T1 (en)
TW (1) TWI312780B (en)
WO (1) WO2007006688A1 (en)
ZA (1) ZA200800320B (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007077122A1 (en) * 2006-01-05 2007-07-12 F. Hoffmann-La Roche Ag Indol-3-yl-carbonyl-spiro-piperidine derivatives
WO2008068185A1 (en) 2006-12-07 2008-06-12 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives as via receptor antagonists
WO2008068184A1 (en) 2006-12-08 2008-06-12 F. Hoffmann-La Roche Ag Indoles which act as via receptor antagonists
WO2008084005A1 (en) * 2007-01-12 2008-07-17 F. Hoffmann-La Roche Ag Spiropiperidine glycinamide derivatives
WO2009074674A3 (en) * 2007-12-13 2009-07-30 Novartis Ag Trisubstituted piperidines as renin inhibitors
WO2012120399A1 (en) 2011-03-10 2012-09-13 Pfizer Inc. Spirocyclic isoxazoline derivatives as antiparasitic agents
US9006244B2 (en) 2012-03-16 2015-04-14 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
US9073931B2 (en) 2012-03-16 2015-07-07 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
KR20190049884A (en) * 2016-09-21 2019-05-09 벡투스 바이오시스템즈 리미티드 Composition for treating hypertension and / or pulmonary fibrosis
WO2019116324A1 (en) 2017-12-15 2019-06-20 Richter Gedeon Nyrt. Triazolobenzazepines as vasopressin v1a receptor antagonists
WO2019116325A1 (en) 2017-12-15 2019-06-20 Richter Gedeon Nyrt. Tricyclic compounds as vasopressin v1a receptor antagonists
US10654867B2 (en) 2016-06-16 2020-05-19 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1904477T1 (en) * 2005-07-14 2009-06-30 Hoffmann La Roche Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
RU2418801C2 (en) * 2005-09-28 2011-05-20 Ф. Хоффманн-Ля Рош Аг Indol-3-yl-carbonyl-asaspiro derivatives as vasopressin receptor antagonists
RU2009123133A (en) * 2006-12-22 2011-01-27 Ф.Хоффманн-Ля Рош Аг (Ch) SPIRO-PIPERIDINE DERIVATIVES
WO2011137024A1 (en) * 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
RU2475489C1 (en) * 2011-10-07 2013-02-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Чувашский государственный университет имени И.Н. Ульянова" Method of producing 8-amino-1-imino-6-morpholin-4-yl-2-oxa-7-azaspiro[4,4]nona-3,6,8-triene-9-carbonitriles
JO3109B1 (en) * 2012-05-10 2017-09-20 Ferring Bv V1a receptor agonists
KR101698124B1 (en) * 2015-05-29 2017-01-19 한국외국어대학교 연구산학협력단 Process for preparing 3-(methylamino)-3-((R)-pyrrolidin-3-yl)propanenitrile or its salt
WO2017137334A1 (en) * 2016-02-08 2017-08-17 F. Hoffmann-La Roche Ag Spiroindolinones as ddr1 inhibitors
CN113563255B (en) * 2020-04-29 2023-08-18 成都倍特药业股份有限公司 Preparation method of remifloxacin intermediate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1410437A2 (en) * 2001-01-22 2004-04-21 Morgan Chemical Products, Inc. Cvd diamond enhanced microprocessor cooling system
SI1904477T1 (en) * 2005-07-14 2009-06-30 Hoffmann La Roche Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007077122A1 (en) * 2006-01-05 2007-07-12 F. Hoffmann-La Roche Ag Indol-3-yl-carbonyl-spiro-piperidine derivatives
US7351706B2 (en) 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives
WO2008068185A1 (en) 2006-12-07 2008-06-12 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives as via receptor antagonists
US8202993B2 (en) 2006-12-07 2012-06-19 Hoffmann-La Roche Inc. Spiro-piperidine derivatives
AU2007328995B2 (en) * 2006-12-07 2012-04-26 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives as VIa receptor antagonists
US8071622B2 (en) 2006-12-08 2011-12-06 Hoffman-La Roche Inc. Indoles
CN101541786A (en) * 2006-12-08 2009-09-23 弗·哈夫曼-拉罗切有限公司 Indoles which act as V1a receptor antagonists
US7799923B2 (en) 2006-12-08 2010-09-21 Hoffmann-La Roche Inc. Indoles
WO2008068184A1 (en) 2006-12-08 2008-06-12 F. Hoffmann-La Roche Ag Indoles which act as via receptor antagonists
US7498339B2 (en) 2007-01-12 2009-03-03 Hoffman-La Roche Inc. Spiropiperidine glycinamide derivatives
WO2008084005A1 (en) * 2007-01-12 2008-07-17 F. Hoffmann-La Roche Ag Spiropiperidine glycinamide derivatives
AU2008204491B2 (en) * 2007-01-12 2012-05-03 F. Hoffmann-La Roche Ag Spiropiperidine glycinamide derivatives
WO2009074674A3 (en) * 2007-12-13 2009-07-30 Novartis Ag Trisubstituted piperidines as renin inhibitors
WO2012120399A1 (en) 2011-03-10 2012-09-13 Pfizer Inc. Spirocyclic isoxazoline derivatives as antiparasitic agents
US9006244B2 (en) 2012-03-16 2015-04-14 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
US9073931B2 (en) 2012-03-16 2015-07-07 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
US9388190B2 (en) 2012-03-16 2016-07-12 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
US9416135B2 (en) 2012-03-16 2016-08-16 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
US9707232B2 (en) 2012-03-16 2017-07-18 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
US9814715B2 (en) 2012-03-16 2017-11-14 Vitae Pharamceuticals, Inc. Liver X receptor modulators
US9006245B2 (en) 2012-03-16 2015-04-14 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
US10654867B2 (en) 2016-06-16 2020-05-19 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
KR20190049884A (en) * 2016-09-21 2019-05-09 벡투스 바이오시스템즈 리미티드 Composition for treating hypertension and / or pulmonary fibrosis
EP3640243A1 (en) * 2016-09-21 2020-04-22 Vectus Biosystems Limited Piperazine derivatives for the treatment of hypertension and/or fibrosis
US11053202B2 (en) 2016-09-21 2021-07-06 Vectus Biosystems Limited Compositions for the treatment of hypertension and/or fibrosis
US11834417B2 (en) 2016-09-21 2023-12-05 Vectus Biosystems Limited Compositions for the treatment of hypertension and/or fibrosis
KR102640385B1 (en) 2016-09-21 2024-02-23 벡투스 바이오시스템즈 리미티드 Composition for treating hypertension and/or pulmonary fibrosis
WO2019116325A1 (en) 2017-12-15 2019-06-20 Richter Gedeon Nyrt. Tricyclic compounds as vasopressin v1a receptor antagonists
WO2019116324A1 (en) 2017-12-15 2019-06-20 Richter Gedeon Nyrt. Triazolobenzazepines as vasopressin v1a receptor antagonists
US11298363B2 (en) 2017-12-15 2022-04-12 Richter Gedeon Nyrt. Triazolobenzazepines as vasopressin V1a receptor antagonists

Also Published As

Publication number Publication date
HK1123554A1 (en) 2009-06-19
CN101253164A (en) 2008-08-27
US7332501B2 (en) 2008-02-19
PL1904477T3 (en) 2009-07-31
RU2414466C2 (en) 2011-03-20
TW200726469A (en) 2007-07-16
TWI312780B (en) 2009-08-01
US20070027173A1 (en) 2007-02-01
NO20080059L (en) 2008-04-02
SI1904477T1 (en) 2009-06-30
CA2615726C (en) 2014-05-27
AR054830A1 (en) 2007-07-18
ES2317558T3 (en) 2009-04-16
KR20080024231A (en) 2008-03-17
ATE421511T1 (en) 2009-02-15
US7629353B2 (en) 2009-12-08
CA2615726A1 (en) 2007-01-18
ZA200800320B (en) 2009-02-25
EP1904477A1 (en) 2008-04-02
IL188478A (en) 2012-01-31
CN101253164B (en) 2012-05-16
KR100974967B1 (en) 2010-08-09
MX2008000585A (en) 2008-03-14
MY144684A (en) 2011-10-31
PT1904477E (en) 2009-03-12
RU2008100082A (en) 2009-08-20
JP4927079B2 (en) 2012-05-09
BRPI0612988A2 (en) 2010-12-14
EP1904477B1 (en) 2009-01-21
US20080146557A1 (en) 2008-06-19
AU2006268724A1 (en) 2007-01-18
IL188478A0 (en) 2008-04-13
CY1108996T1 (en) 2014-07-02
DK1904477T3 (en) 2009-03-16
JP2009501185A (en) 2009-01-15
DE602006004997D1 (en) 2009-03-12
AU2006268724B2 (en) 2011-06-02

Similar Documents

Publication Publication Date Title
CA2615726C (en) Indol-3-yl-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
AU2006334423B2 (en) Indol-3-yl-carbonyl-spiro-piperidine derivatives
EP2125827A1 (en) Azaspiro derivatives
EP2392571A2 (en) Indol-3-yl-carbonyl-piperidin and piperazin derivatives
MX2008000886A (en) Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives as v1a receptor antagonists.
EP1931680B1 (en) Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
AU2007328994B2 (en) Indoles which act as V1a receptor antagonists
AU2007338115A1 (en) Spiro-piperidine derivatives
AU2007328995B2 (en) Spiro-piperidine derivatives as VIa receptor antagonists
AU2007341377B2 (en) Indoles
MX2008008661A (en) Indol-3-yl-carbonyl-spiro-piperidine derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006764048

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 188478

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008520842

Country of ref document: JP

Ref document number: MX/a/2008/000585

Country of ref document: MX

Ref document number: 203/CHENP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12008500101

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006268724

Country of ref document: AU

Ref document number: 2615726

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020087002692

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006268724

Country of ref document: AU

Date of ref document: 20060704

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006268724

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008100082

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200680032149.1

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006764048

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0612988

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080114